PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 35496500-4 2022 In tumor cell line models, AmB induced ICD with its typical hallmarks of calreticulin (CALR) expression and release of high mobility group box 1 (HMGB1) as well as Adenosine 5"-triphosphate (ATP). Amphotericin B 27-30 calreticulin Homo sapiens 73-85 35496500-7 2022 Even at sub-toxic concentrations, AmB was able to enhance CALR on leukemic blasts, particularly on phagocytic monoblastic THP-1 cells, which also showed features of "M1-like" differentiation after AmB exposure. Amphotericin B 34-37 calreticulin Homo sapiens 58-62 35496500-4 2022 In tumor cell line models, AmB induced ICD with its typical hallmarks of calreticulin (CALR) expression and release of high mobility group box 1 (HMGB1) as well as Adenosine 5"-triphosphate (ATP). Amphotericin B 27-30 calreticulin Homo sapiens 87-91 35496500-4 2022 In tumor cell line models, AmB induced ICD with its typical hallmarks of calreticulin (CALR) expression and release of high mobility group box 1 (HMGB1) as well as Adenosine 5"-triphosphate (ATP). Amphotericin B 27-30 high mobility group box 1 Homo sapiens 119-144 35496500-9 2022 In conclusion, we demonstrate that AmB can promote antitumor immune responses in a dose-dependent manner by ICD induction, surface translocation of CALR on leukemic blasts even at sub-toxic concentrations, and "M1-like" polarization of phagocytic cells, making it noteworthy as potential booster for cancer immunotherapy. Amphotericin B 35-38 calreticulin Mus musculus 148-152 35496500-4 2022 In tumor cell line models, AmB induced ICD with its typical hallmarks of calreticulin (CALR) expression and release of high mobility group box 1 (HMGB1) as well as Adenosine 5"-triphosphate (ATP). Amphotericin B 27-30 high mobility group box 1 Homo sapiens 146-151 35350119-4 2022 The addition of insulin or glucose at physiologic levels in RPMI medium alone altered the MIC in either a positive or negative fashion, depending on the organisms and drug tested, with C. glabrata most significantly altered with a 40, >32- and 46-fold increase in MIC for amphotericin B, itraconazole and miconazole, respectively. Amphotericin B 272-286 insulin Homo sapiens 16-23 35396335-4 2022 These defects can be relieved upon incubation with Amphotericin B, compound known to relieve IFITM-driven membrane fusion defects, as well as by v-SNARE overexpression, suggesting that IFITM3 interferes with membrane fusion processes important for Golgi functionalities. Amphotericin B 51-65 interferon induced transmembrane protein 3 Homo sapiens 185-191 35519907-7 2022 She also developed methotrexate and amphotericin B-induced pancytopenia for which injection folinic acid, granulocyte-colony stimulating factor (G-CSF), and erythropoietin were given and was switched over to liposomal amphotericin B. Amphotericin B 36-50 colony stimulating factor 3 Homo sapiens 145-150 35519907-7 2022 She also developed methotrexate and amphotericin B-induced pancytopenia for which injection folinic acid, granulocyte-colony stimulating factor (G-CSF), and erythropoietin were given and was switched over to liposomal amphotericin B. Amphotericin B 36-50 erythropoietin Homo sapiens 157-171 35099003-0 2022 Paeonol enhances treatment of fluconazole and amphotericin B against oropharyngeal candidiasis (OPC) through HIF-1alpha related IL-17 signaling. Amphotericin B 46-60 hypoxia inducible factor 1 subunit alpha Homo sapiens 109-119 35099003-0 2022 Paeonol enhances treatment of fluconazole and amphotericin B against oropharyngeal candidiasis (OPC) through HIF-1alpha related IL-17 signaling. Amphotericin B 46-60 interleukin 17A Homo sapiens 128-133 35099003-10 2022 Meanwhile, compared with the infected EC109 cells treated with a single drug, PAE plus FLU or AmB significantly inhibited the mRNA and protein expression of HIF-1alpha, IL-17A, and IL-23. Amphotericin B 94-97 hypoxia inducible factor 1 subunit alpha Homo sapiens 157-167 35099003-10 2022 Meanwhile, compared with the infected EC109 cells treated with a single drug, PAE plus FLU or AmB significantly inhibited the mRNA and protein expression of HIF-1alpha, IL-17A, and IL-23. Amphotericin B 94-97 interleukin 17A Homo sapiens 169-175 35099003-10 2022 Meanwhile, compared with the infected EC109 cells treated with a single drug, PAE plus FLU or AmB significantly inhibited the mRNA and protein expression of HIF-1alpha, IL-17A, and IL-23. Amphotericin B 94-97 interleukin 23 subunit alpha Homo sapiens 181-186 35099003-11 2022 Taken together, the possible mechanism of PAE plus FLU or AmB can be attributed to the regulation of hypoxia-associated IL-17 signaling in OPC treatment. Amphotericin B 58-61 interleukin 17A Homo sapiens 120-125 35436397-3 2022 We observed that low doses with short duration of Amph B as a therapy regime significantly enhanced the induction of Th1 cytokine (INF-gamma), but suppressed Th2 cytokine (IL-10) production. Amphotericin B 50-56 interleukin 10 Mus musculus 172-177 35436397-4 2022 Groups of mice infected with L. donovani and treated with Amph B showed clearly increasing in INF-gamma level and reduction in IL-10 level in concentration (3, 4, 5 mg/ml/kg) with best result in 5 mg/ml/kg (accumulation dose 25 mg/ml) than concentrations (6, 7 mg/ml/kg). Amphotericin B 58-64 interleukin 10 Mus musculus 127-132 35420884-9 2022 RESULTS: Serum ALT, ALP, AST, LDH, TNF-alpha and IL-1beta values were lower in the H-IR+AMB group compared to the H-IR group. Amphotericin B 88-91 PDZ and LIM domain 3 Rattus norvegicus 20-23 35420884-9 2022 RESULTS: Serum ALT, ALP, AST, LDH, TNF-alpha and IL-1beta values were lower in the H-IR+AMB group compared to the H-IR group. Amphotericin B 88-91 tumor necrosis factor Rattus norvegicus 35-44 35420884-9 2022 RESULTS: Serum ALT, ALP, AST, LDH, TNF-alpha and IL-1beta values were lower in the H-IR+AMB group compared to the H-IR group. Amphotericin B 88-91 interleukin 1 alpha Rattus norvegicus 49-57 35100643-7 2022 THERAPY AND COURSE: After initiation of liposomal amphotericin B haematopoiesis recovered and CRP decreased. Amphotericin B 51-65 C-reactive protein Homo sapiens 95-98 2903479-4 1988 Evidence for increased excretion of the renal enzymes N-acetyl-beta-D-glucosaminidase and alanine aminopeptidase during amphotericin B therapy suggested that damage to proximal tubular cells may contribute to the renal impairment that has been associated with this drug. Amphotericin B 120-134 O-GlcNAcase Homo sapiens 54-85 2730221-3 1989 min and n = 450 and 800 min-1 were respectively the lower and the upper levels of the optimal conditions by oxygen mass transfer during amphotericin B biosynthesis. Amphotericin B 136-150 CD59 molecule (CD59 blood group) Homo sapiens 24-29 2497796-1 1989 From permeability experiments carried out with series of amphotericin B derivatives in both biological and model membranes, it was concluded that derivatives, whose carboxyl group at the C18 position is blocked by substitution, are much more efficient at inducing permeability in ergosterol-containing than in cholesterol-containing membranes, whereas derivatives whose carboxyl group is free and ionizable are equally efficient in both membranes types. Amphotericin B 57-71 Bardet-Biedl syndrome 9 Homo sapiens 187-190 2567225-0 1989 The effect of T-2 toxin on active sodium transport across frog skin in the presence of ADH and amphotericin B. Amphotericin B 95-109 solute carrier family 25 member 5 Homo sapiens 14-17 2694950-1 1989 Polyclonal antibodies elicited by injection into rabbits of a nystatin-bovine serum albumin conjugate were reactive with both nystatin and amphotericin B. Amphotericin B 139-153 albumin Oryctolagus cuniculus 78-91 2903479-4 1988 Evidence for increased excretion of the renal enzymes N-acetyl-beta-D-glucosaminidase and alanine aminopeptidase during amphotericin B therapy suggested that damage to proximal tubular cells may contribute to the renal impairment that has been associated with this drug. Amphotericin B 120-134 carboxypeptidase Q Homo sapiens 98-112 3219129-2 1988 Synthesis of methyl-2,4,6-trideoxy-2,4-dimethyl-alpha-altro- hexopyranoside, the C33-C38 fragment of amphotericin B]. Amphotericin B 101-115 CD82 molecule Homo sapiens 81-84 3693251-0 1987 Deleterious effects of fungizone on growth hormone and prolactin secretion by cultured GH3 cells. Amphotericin B 23-32 gonadotropin releasing hormone receptor Rattus norvegicus 36-50 3219129-3 1988 The synthesis of methyl 2,4,6-trideoxy-2,4-dimethyl-alpha-L-altro-hexopyranoside, having the configuration of the C33-C38 fragment of amphotericin B, is described. Amphotericin B 134-148 CD82 molecule Homo sapiens 114-117 3245698-7 1988 Miconazole and AmB lowered the binding affinity of FMLP receptors on PMN and decreased the membrane fluidity in a similar manner. Amphotericin B 15-18 formyl peptide receptor 1 Homo sapiens 51-55 3693251-0 1987 Deleterious effects of fungizone on growth hormone and prolactin secretion by cultured GH3 cells. Amphotericin B 23-32 prolactin Rattus norvegicus 55-64 3693251-1 1987 The rates at which growth hormone (GH) and prolactin (PRL) are spontaneously secreted from a rat pituitary tumor cell line (GH3) were significantly reduced when these cells were maintained in medium containing 2.5 micrograms/ml Fungizone (Fz). Amphotericin B 228-237 gonadotropin releasing hormone receptor Rattus norvegicus 19-33 3693251-1 1987 The rates at which growth hormone (GH) and prolactin (PRL) are spontaneously secreted from a rat pituitary tumor cell line (GH3) were significantly reduced when these cells were maintained in medium containing 2.5 micrograms/ml Fungizone (Fz). Amphotericin B 228-237 gonadotropin releasing hormone receptor Rattus norvegicus 35-37 3693251-1 1987 The rates at which growth hormone (GH) and prolactin (PRL) are spontaneously secreted from a rat pituitary tumor cell line (GH3) were significantly reduced when these cells were maintained in medium containing 2.5 micrograms/ml Fungizone (Fz). Amphotericin B 228-237 prolactin Rattus norvegicus 43-52 3693251-1 1987 The rates at which growth hormone (GH) and prolactin (PRL) are spontaneously secreted from a rat pituitary tumor cell line (GH3) were significantly reduced when these cells were maintained in medium containing 2.5 micrograms/ml Fungizone (Fz). Amphotericin B 228-237 prolactin Rattus norvegicus 54-57 3888283-7 1985 An activation energy of 20 kJ X mol-1 was determined for uptake of amphotericin B by unmodified cells. Amphotericin B 67-81 thiamine thiazole synthase Saccharomyces cerevisiae S288C 32-37 3770945-6 1986 These findings suggest that (i) the low catalase levels in C57BL/6 and F1 hybrid mice may limit the protection of cells from the oxidant damage involved in AmB action, and (ii) the toxicity which occurs at low concentrations of AmB in the mouse strains with low intracellular catalase levels may interfere with or ablate the AmB-induced increases in mouse resistance to L. monocytogenes infection. Amphotericin B 156-159 catalase Mus musculus 40-48 3770945-6 1986 These findings suggest that (i) the low catalase levels in C57BL/6 and F1 hybrid mice may limit the protection of cells from the oxidant damage involved in AmB action, and (ii) the toxicity which occurs at low concentrations of AmB in the mouse strains with low intracellular catalase levels may interfere with or ablate the AmB-induced increases in mouse resistance to L. monocytogenes infection. Amphotericin B 228-231 catalase Mus musculus 40-48 3770945-6 1986 These findings suggest that (i) the low catalase levels in C57BL/6 and F1 hybrid mice may limit the protection of cells from the oxidant damage involved in AmB action, and (ii) the toxicity which occurs at low concentrations of AmB in the mouse strains with low intracellular catalase levels may interfere with or ablate the AmB-induced increases in mouse resistance to L. monocytogenes infection. Amphotericin B 228-231 catalase Mus musculus 276-284 3996489-2 1985 At low doses the polyene antibiotic AmB has been shown to increase cell permeability to Na+ and K+ and we found that it potentiated erythropoietin (epo)-stimulated erythroid-colony (CFU-E) and burst (BFU-E) growth at concentrations ranging from 0.5-1.0 micrograms/ml. Amphotericin B 36-39 erythropoietin Mus musculus 132-146 3996489-2 1985 At low doses the polyene antibiotic AmB has been shown to increase cell permeability to Na+ and K+ and we found that it potentiated erythropoietin (epo)-stimulated erythroid-colony (CFU-E) and burst (BFU-E) growth at concentrations ranging from 0.5-1.0 micrograms/ml. Amphotericin B 36-39 erythropoietin Mus musculus 148-151 2871108-0 1986 Amphotericin B inhibits the serum-induced expression of tissue transglutaminase in murine peritoneal macrophages. Amphotericin B 0-14 transglutaminase 2, C polypeptide Mus musculus 56-79 6722201-1 1984 The permeability coefficient of BLM to amphotericin B decreases as cholesterol content of the membrane and KCl concentration of the aqueous medium increases. Amphotericin B 39-53 BLM RecQ like helicase Homo sapiens 32-35 3985601-1 1985 Lysis of human erythrocytes induced by amphotericin B was retarded when the oxygen tension of the incubation mixture was reduced or when the antioxidant catalase was added; lysis was accelerated when cells were preincubated with the prooxidant ascorbate. Amphotericin B 39-53 catalase Homo sapiens 153-161 4004186-5 1985 For attaining the therapeutic concentrations of the antibiotic in the CSF, daily endolumbar administration of amphotericin B in a dose more than 10 units in addition to its intravenous drip infusions was required. Amphotericin B 110-124 colony stimulating factor 2 Homo sapiens 70-73 3862608-6 1985 The results indicate that: NAC and AMB, administered both before and after placebo, produce a significant increase in MCT, NAC showed a slightly greater efficacy than AMB, but the differences are not statistically significant. Amphotericin B 35-38 synuclein alpha Homo sapiens 123-126 4086422-1 1985 Amphotericin B inhibits hydroxymethylglutarylcoenzyme A (HMGCoA) reductase activity and incorporation of [3H]acetate into sterols and fatty acids of human skin fibroblasts. Amphotericin B 0-14 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 24-74 3859476-6 1985 It was also found that although the administration of AMB results in an increase in tumor-associated transferrin, this does not necessarily result in a concomitant increase in radiogallium uptake. Amphotericin B 54-57 transferrin Mus musculus 101-112 6367080-3 1984 After a brief course of intrathecal amphotericin B therapy, the patient improved clinically and the CSF returned to normal. Amphotericin B 36-50 colony stimulating factor 2 Homo sapiens 100-103 7055571-1 1982 In this study amphotericin B released the divalent trace metals Zn2+, Co2+, Cu2+, Ni2+, Mn2+, Fe2+, Cd2+ and Pb2+ from multilamellar liposomes containing cholesterol. Amphotericin B 14-28 CD2 molecule Homo sapiens 100-103 6679334-1 1983 The polyene cholesterol-binding antibiotics filipin and amphotericin B inhibited the binding of cholesterol to steroid-free, soluble adrenocortical cytochrome P-450SCC. Amphotericin B 56-70 cholesterol side-chain cleavage enzyme, mitochondrial Bos taurus 148-167 6773661-10 1980 These findings indicate that amphotericin B induces de novo synthesis of tyrosinase rather than activation of pre-existing tyrosinase. Amphotericin B 29-43 tyrosinase Gallus gallus 73-83 7299128-4 1981 Sterol binding polyene antibiotics such as amphotericine B or filipin inhibit the expression of FcR gamma during the differentiation of M1- cells by the CM obtained from the culture of mouse embryonic fibroblasts, suggesting the possible involvement of cholesterol molecules in the induction mechanism of FcR gamma. Amphotericin B 43-58 Fc receptor, IgE, high affinity I, gamma polypeptide Mus musculus 96-105 7299128-4 1981 Sterol binding polyene antibiotics such as amphotericine B or filipin inhibit the expression of FcR gamma during the differentiation of M1- cells by the CM obtained from the culture of mouse embryonic fibroblasts, suggesting the possible involvement of cholesterol molecules in the induction mechanism of FcR gamma. Amphotericin B 43-58 Fc receptor, IgE, high affinity I, gamma polypeptide Mus musculus 305-314 975049-1 1976 This paper reports the potentiation of the therapeutic effect of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) by amphotericin B (AMB) in s.c. transplanted murine ependymoblastoma 01B111. Amphotericin B 120-134 cyclin O Mus musculus 111-115 727219-3 1978 The most resistant isolate (R-2) lacked cell membrane ergosterol, the usual attachment site for amphotericin B, and was not inhibited by greater than 500 micrograms/ml of the drug. Amphotericin B 96-110 CD1e molecule Homo sapiens 28-31 407299-7 1977 Two single paraprotein-producing varients (IgG2b or IgA) were derived when cells were cultured in the presence of Fungizone. Amphotericin B 114-123 immunoglobulin heavy constant gamma 2B Mus musculus 43-48 975049-1 1976 This paper reports the potentiation of the therapeutic effect of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) by amphotericin B (AMB) in s.c. transplanted murine ependymoblastoma 01B111. Amphotericin B 136-139 cyclin O Mus musculus 111-115 975049-11 1976 Thus, the potentiation of CCNU by AMB does not seem attributable to an increased permeability of the tumor to CCNU or to an enhancement of the inhibition of DNA synthesis, at least in murine ependymoblastoma. Amphotericin B 34-37 cyclin O Mus musculus 26-30 1259412-0 1976 Enhancement of rIn:rCn-induced interferon production by amphotericin B. Amphotericin B 56-70 Ras-like without CAAX 2 Rattus norvegicus 15-18 33534106-5 2021 AmB-DVL were characterized in terms of incorporation parameters, stability, and elasticity, and evaluated in vitro for their permeation properties, cytotoxicity, and anti-leishmanial activity. Amphotericin B 0-3 dishevelled segment polarity protein 1 pseudogene 1 Homo sapiens 4-7 13521864-0 1957 Properdin levels in mice and man with coccidioidomycosis during soluble amphotericin B administration. Amphotericin B 72-86 complement factor properdin Mus musculus 0-9 697352-0 1978 Erythropoietin concentration in amphotericin B-induced anemia. Amphotericin B 32-46 erythropoietin Homo sapiens 0-14 697352-4 1978 Thus, amphotericin appears to cause anemia by inhibiting erythropoietin production rather than by suppressing bone marrow activity directly. Amphotericin B 6-18 erythropoietin Homo sapiens 57-71 169201-5 1975 Melittin from bee venom and the polyene antibiotics filipin and amphotericin B in low concentrations induced a strikingly greater release of AIB than of nucleotide label. Amphotericin B 64-78 ANIB1 Homo sapiens 141-144 1122313-1 1975 The inhibition of the lecithin-cholesterol acyltransferase reaction in human plasma by the polyene antibiotics, levorine and amphotericin B, has been demonstrated by in vitro experiments. Amphotericin B 125-139 lecithin-cholesterol acyltransferase Homo sapiens 22-58 4151862-0 1974 Alteration of tyrosine aminotransferase activity in hepatoma cells in tissue culture by amphotericin B. Amphotericin B 88-102 tyrosine aminotransferase Rattus norvegicus 14-39 4151862-1 1974 Two clonal lines of rat hepatoma cells, in tissue culture, that have steroid-inducible tyrosine aminotransferase (TAT) activities were shown to have different responses to amphotericin B. Amphotericin B 172-186 tyrosine aminotransferase Rattus norvegicus 87-112 4151862-1 1974 Two clonal lines of rat hepatoma cells, in tissue culture, that have steroid-inducible tyrosine aminotransferase (TAT) activities were shown to have different responses to amphotericin B. Amphotericin B 172-186 tyrosine aminotransferase Rattus norvegicus 114-117 4151862-4 1974 During the first few hours after the exposure of MHC cells to amphotericin B, both basal and dexamethasone-induced TAT activity were reduced; with continued exposure, enzyme activity increased over that of untreated cells and was superinduced in the presence of maximal, stimulating amounts of steroid. Amphotericin B 62-76 tyrosine aminotransferase Rattus norvegicus 115-118 33534106-6 2021 The AmB-DVL exhibited a translucent fluid gel-like aspect and a yellow color, a mean size of 132 nm (PdI <= 0.1), zeta potential values around zero (mV), and an AmB incorporation efficiency of 95%. Amphotericin B 4-7 dishevelled segment polarity protein 1 pseudogene 1 Homo sapiens 8-11 33534106-6 2021 The AmB-DVL exhibited a translucent fluid gel-like aspect and a yellow color, a mean size of 132 nm (PdI <= 0.1), zeta potential values around zero (mV), and an AmB incorporation efficiency of 95%. Amphotericin B 161-164 dishevelled segment polarity protein 1 pseudogene 1 Homo sapiens 8-11 33534106-8 2021 AmB-DVL was able to reduce promastigote viability in a dose-dependent manner, as well as the number of intracellular amastigotes in THP-1 macrophages. Amphotericin B 0-3 dishevelled segment polarity protein 1 pseudogene 1 Homo sapiens 4-7 33534106-8 2021 AmB-DVL was able to reduce promastigote viability in a dose-dependent manner, as well as the number of intracellular amastigotes in THP-1 macrophages. Amphotericin B 0-3 GLI family zinc finger 2 Homo sapiens 132-137 33606865-0 2021 pH-Dependent ion permeability control of a modified amphotericin B channel through metal complexation. Amphotericin B 52-66 phenylalanine hydroxylase Homo sapiens 0-2 33606865-1 2021 Amphotericin B incorporating 2,2"-bipyridine (bpy-AmB) forms a membrane channel exhibiting pH-dependent Ca2+ ion permeability with a selective response to Cu2+ ions. Amphotericin B 0-14 phenylalanine hydroxylase Homo sapiens 91-93 33745428-6 2021 RESULTS: Hydroxypropyl beta cyclodextrin (HP-beta-CD) better solubilized AMB than both alpha-CD and beta-CD e.g, the concentration of water-soluble AMB/HP-beta-CD IC could reach 465 microg/mL. Amphotericin B 73-76 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 45-52 33740284-5 2021 The effect of FZ on the PTCs uptake (OAT1 and OCT2) and efflux (P-gp and MRP2) transporters was evaluated. Amphotericin B 14-16 solute carrier family 22 member 6 Rattus norvegicus 37-41 33745428-6 2021 RESULTS: Hydroxypropyl beta cyclodextrin (HP-beta-CD) better solubilized AMB than both alpha-CD and beta-CD e.g, the concentration of water-soluble AMB/HP-beta-CD IC could reach 465 microg/mL. Amphotericin B 148-151 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 45-52 33745428-7 2021 Both DSC and SEM data illustrated that the drug no longer existed in its crystalline form, a in AMB/HP-beta-CD IC. Amphotericin B 96-99 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 103-110 33313322-9 2020 Molecular docking, balance dialysis, and ultrafiltration analysis showed that AMPB and POS had potential binding properties to serum albumin. Amphotericin B 78-82 albumin Mus musculus 133-140 33622715-6 2021 We have previously shown that coating AmB-LLs with the extracellular oligomannan-binding domain of the C-type lectin receptor Dectin-2 (DEC2-AmB-LLs) effectively targets DEC2-AmB-LLs to cell walls, exopolysaccharide matrices, and biofilms of fungal pathogens in vitro In vitro, DEC2-AmB-LLs reduce the effective dose of AmB for 95% inhibition and killing of A. fumigatus 10-fold compared to that of untargeted AmB-LLs. Amphotericin B 38-41 C-type lectin domain family 4, member n Mus musculus 126-134 33622715-6 2021 We have previously shown that coating AmB-LLs with the extracellular oligomannan-binding domain of the C-type lectin receptor Dectin-2 (DEC2-AmB-LLs) effectively targets DEC2-AmB-LLs to cell walls, exopolysaccharide matrices, and biofilms of fungal pathogens in vitro In vitro, DEC2-AmB-LLs reduce the effective dose of AmB for 95% inhibition and killing of A. fumigatus 10-fold compared to that of untargeted AmB-LLs. Amphotericin B 141-144 C-type lectin domain family 4, member n Mus musculus 126-134 33622715-6 2021 We have previously shown that coating AmB-LLs with the extracellular oligomannan-binding domain of the C-type lectin receptor Dectin-2 (DEC2-AmB-LLs) effectively targets DEC2-AmB-LLs to cell walls, exopolysaccharide matrices, and biofilms of fungal pathogens in vitro In vitro, DEC2-AmB-LLs reduce the effective dose of AmB for 95% inhibition and killing of A. fumigatus 10-fold compared to that of untargeted AmB-LLs. Amphotericin B 141-144 C-type lectin domain family 4, member n Mus musculus 126-134 33622715-9 2021 Furthermore, Dectin-2-targeted liposomes delivering AmB at a dose of 0.2 mg/kg of body weight significantly reduced the fungal burden in lungs compared to results with untargeted AmB-LLs at 0.2 mg/kg and micellar voriconazole at 20 mg/kg and prolonged mouse survival. Amphotericin B 52-55 C-type lectin domain family 4, member n Mus musculus 13-21 33622715-14 2021 Herein, we employed liposomal amphotericin B coated with the innate immune receptor Dectin-2 to direct antifungals specifically to the fungal pathogen. Amphotericin B 30-44 C-type lectin domain containing 6A Homo sapiens 84-92 33622715-15 2021 Using two mouse models of pulmonary aspergillosis, we demonstrate that Dectin-2-targeted delivery of amphotericin B to A. fumigatus resulted in remarkably higher efficacy than that of the untargeted antifungal formulations. Amphotericin B 101-115 C-type lectin domain family 4, member n Mus musculus 71-79 33360084-7 2021 Furthermore, eugenol oleate and amphotericin B significantly (p < 0.01) enhanced the nitrite generation, and pro-inflammatory cytokines (IL-12, IFN-gamma and TNF-alpha) in infected macrophages in vitro and in BALB/c mice in vivo. Amphotericin B 32-46 interferon gamma Mus musculus 144-153 33360084-7 2021 Furthermore, eugenol oleate and amphotericin B significantly (p < 0.01) enhanced the nitrite generation, and pro-inflammatory cytokines (IL-12, IFN-gamma and TNF-alpha) in infected macrophages in vitro and in BALB/c mice in vivo. Amphotericin B 32-46 tumor necrosis factor Mus musculus 158-167 33493169-8 2021 Two major effect QTL for amphotericin B resistance map to the genes SSK1 and SSK2, which encode key components of the HOG pathway, a fungal-specific signal transduction network that orchestrates cellular responses to osmotic and other stresses. Amphotericin B 25-39 BUB1 mitotic checkpoint serine/threonine kinase B Homo sapiens 68-72 33309058-3 2021 Further, AmB increased ASL pH in CFTR-null pigs, suggesting an alternative CFTR-independent approach to achieve gain-of-function. Amphotericin B 9-12 CF transmembrane conductance regulator Sus scrofa 33-37 33309058-8 2021 In eight people with CF not on CFTR modulators, intranasal Fungizone treatment caused a statistically significant change in NPD. Amphotericin B 59-68 CF transmembrane conductance regulator Homo sapiens 31-35 32602823-9 2020 Interestingly, we also found that amphotericin B could enhance the infectious entry of SARS-CoVs and SL-CoVs by evading IFITM3-mediated restriction. Amphotericin B 34-48 interferon induced transmembrane protein 3 Homo sapiens 120-126 32875362-3 2020 Moreover, the emergence of strains resistant to conventional drugs, co-infections such as HIV/Leishmania spp., the small therapeutic arsenal (pentavalent antimonials, amphotericin B and formulations, and miltefosine), and the low investment for the discovery/development of new drugs force researchers and world health agencies to seek new strategies to combat and control this important neglected disease. Amphotericin B 167-181 histocompatibility minor 13 Homo sapiens 105-108 33313322-14 2020 Meanwhile, POS could enhance the efficacy of AMPB in the treatment of CNM, which may be independent of P-gp and BCRP proteins. Amphotericin B 45-49 phosphoglycolate phosphatase Mus musculus 103-107 33096778-7 2020 Consequently, we identified amphotericin B and celastrol as new non-substrate-based XT-I protein inhibitors. Amphotericin B 28-42 xylosyltransferase 1 Homo sapiens 84-88 32390849-8 2020 Key Results: AmB treatment showed a stronger cytotoxic impact on HK-2 viability and gene expression of cell death markers (Kim-1/HAVcr-1, CASP3) compared with SM21 and SM21 analogue in vitro (P < 0.01). Amphotericin B 13-16 hepatitis A virus cellular receptor 1 Rattus norvegicus 123-128 32641482-7 2020 Interestingly, overexpression of serine protease TMPRSS2 or amphotericin treatment significantly neutralized the IFN-inducible transmembrane 3 (IFITM3) restriction of human coronavirus (CoV) entry, but did not compromise the effect of LY6E on the entry of human coronaviruses. Amphotericin B 60-72 interferon induced transmembrane protein 3 Homo sapiens 144-150 32641482-7 2020 Interestingly, overexpression of serine protease TMPRSS2 or amphotericin treatment significantly neutralized the IFN-inducible transmembrane 3 (IFITM3) restriction of human coronavirus (CoV) entry, but did not compromise the effect of LY6E on the entry of human coronaviruses. Amphotericin B 60-72 lymphocyte antigen 6 family member E Homo sapiens 235-239 32661494-5 2020 Ergotamine, amphotericin b, and vancomycin are most promising to block the interaction of the SARS-CoV-2 S-protein with human ACE-2. Amphotericin B 12-26 vitronectin Homo sapiens 105-114 32661494-5 2020 Ergotamine, amphotericin b, and vancomycin are most promising to block the interaction of the SARS-CoV-2 S-protein with human ACE-2. Amphotericin B 12-26 angiotensin converting enzyme 2 Homo sapiens 126-131 33112230-7 2020 Furthermore, a compound which counteracts virus inhibition by IFITM3, amphotericin B, prevented the IFITM3-mediated rigidification of membranes. Amphotericin B 70-84 interferon induced transmembrane protein 3 Homo sapiens 62-68 33112230-7 2020 Furthermore, a compound which counteracts virus inhibition by IFITM3, amphotericin B, prevented the IFITM3-mediated rigidification of membranes. Amphotericin B 70-84 interferon induced transmembrane protein 3 Homo sapiens 100-106 32514920-8 2020 AmB significantly increased serum level of creatinine, urea, uric acid, ALP, TOS, MDA, and kidney and renal tissue damage (p < 0.05). Amphotericin B 0-3 PDZ and LIM domain 3 Rattus norvegicus 72-75 32030555-12 2020 Short-pulsed CO2 9.3 mum laser irradiation followed by additional application of AmF/NaF/SnCl2 solution significantly reduces the progression of dental enamel erosion in vitro. Amphotericin B 81-84 C-X-C motif chemokine ligand 8 Homo sapiens 85-88 32390849-8 2020 Key Results: AmB treatment showed a stronger cytotoxic impact on HK-2 viability and gene expression of cell death markers (Kim-1/HAVcr-1, CASP3) compared with SM21 and SM21 analogue in vitro (P < 0.01). Amphotericin B 13-16 hepatitis A virus cellular receptor 1 Rattus norvegicus 129-136 32390849-8 2020 Key Results: AmB treatment showed a stronger cytotoxic impact on HK-2 viability and gene expression of cell death markers (Kim-1/HAVcr-1, CASP3) compared with SM21 and SM21 analogue in vitro (P < 0.01). Amphotericin B 13-16 caspase 3 Rattus norvegicus 138-143 32390849-11 2020 Kim-1 and CLU were the most sensitive biomarkers for detection of AmB-induced kidney damage. Amphotericin B 66-69 hepatitis A virus cellular receptor 1 Rattus norvegicus 0-5 32390849-11 2020 Kim-1 and CLU were the most sensitive biomarkers for detection of AmB-induced kidney damage. Amphotericin B 66-69 clusterin Rattus norvegicus 10-13 32132181-5 2020 Our results highlight that antileishmanial drugs have an impact on monocytes by altering the expression of IL-12 induced by LPS, whereas only AmB induced IL-10 secretion; both cytokines are essential in regulating Th1 cell-mediated immunity. Amphotericin B 142-145 interleukin 10 Homo sapiens 154-159 32295440-0 2020 BSC2 enhances cell resistance to AmB by inhibiting oxidative damage in Saccharomyces cerevisiae. Amphotericin B 33-36 Bsc2p Saccharomyces cerevisiae S288C 0-4 32295440-3 2020 Previous study has shown that Saccharomyces cerevisiae strain lack of BSC2 was sensitive significantly to Amphotericin B. Amphotericin B 106-120 Bsc2p Saccharomyces cerevisiae S288C 70-74 32295440-4 2020 In the present study, the role of BSC2 on Amphotericin B resistance were investigated. Amphotericin B 42-56 Bsc2p Saccharomyces cerevisiae S288C 34-38 32295440-5 2020 We found that BSC2 enhanced the resistance of yeast cells to Amphotericin B, which was not related to cellular ergosterol content. Amphotericin B 61-75 Bsc2p Saccharomyces cerevisiae S288C 14-18 32295440-8 2020 Taken together, BSC2 inhibits oxidative damage induced by Amphotericin B through increasing activities of antioxidant enzymes and levels of GSH to alleviate the accumulation of reactive oxygen species, lipid peroxidation and superoxide radical, resulting in the maintenance of mitochondrial membrane potential and cell membrane integrity. Amphotericin B 58-72 Bsc2p Saccharomyces cerevisiae S288C 16-20 32295440-9 2020 However, Amphotericin B resistance mediated by BSC2 is independent of Yap1p, GSH1 and Hog1p. Amphotericin B 9-23 Bsc2p Saccharomyces cerevisiae S288C 47-51 32295440-10 2020 The results demonstrate for the first time that BSC2 enhances cell resistance to Amphotericin B by inhibiting oxidative damage in yeast. Amphotericin B 81-95 Bsc2p Saccharomyces cerevisiae S288C 48-52 32132181-6 2020 Interestingly, IL-12 and anti-IL-10 Abs improved T cell proliferation inhibited by AmB. Amphotericin B 83-86 interleukin 10 Homo sapiens 30-35 32132181-8 2020 Thus, AmB induced IL-1beta and IL-18 secretions, which are reduced by specific inhibitors of caspase activation (Q-VD) and NLRP3 activation (MCC950). Amphotericin B 6-9 interleukin 1 alpha Homo sapiens 18-26 32132181-8 2020 Thus, AmB induced IL-1beta and IL-18 secretions, which are reduced by specific inhibitors of caspase activation (Q-VD) and NLRP3 activation (MCC950). Amphotericin B 6-9 interleukin 18 Homo sapiens 31-36 32132181-8 2020 Thus, AmB induced IL-1beta and IL-18 secretions, which are reduced by specific inhibitors of caspase activation (Q-VD) and NLRP3 activation (MCC950). Amphotericin B 6-9 NLR family pyrin domain containing 3 Homo sapiens 123-128 31134303-0 2019 ABCA1 transporter reduces amphotericin B cytotoxicity in mammalian cells. Amphotericin B 26-40 ATP binding cassette subfamily A member 1 Homo sapiens 0-5 31372914-6 2020 While conventional amphotericin B further increased IL-6 and to a smaller extent IL-8 levels, this was not the case for its liposomal formulation. Amphotericin B 19-33 interleukin 6 Homo sapiens 52-56 31372914-6 2020 While conventional amphotericin B further increased IL-6 and to a smaller extent IL-8 levels, this was not the case for its liposomal formulation. Amphotericin B 19-33 C-X-C motif chemokine ligand 8 Homo sapiens 81-85 31791946-9 2020 In the survival study, NT-a9 significantly prolonged the survival times of mice compared with the survival times of the control group or the isavuconazole-, fluconazole-, or amphotericin B-treated groups. Amphotericin B 174-188 nuclear encoded tRNA alanine 9 (anticodon AGC) Mus musculus 23-28 31757822-5 2020 Most notably, we identified cobalamin (vitamin B12) biosynthesis genes within the AmII and AmIII phylogroups. Amphotericin B 91-96 NADH:ubiquinone oxidoreductase subunit B3 Homo sapiens 47-50 31968633-5 2020 The urinary biomarker kidney injury molecule-1 (Kim-1) showed significant increases in both gentamicin (20 fold increase) and amphotericin-B-treated (9.2 fold increase) animals. Amphotericin B 126-140 hepatitis A virus cellular receptor 1 Rattus norvegicus 22-46 31968633-5 2020 The urinary biomarker kidney injury molecule-1 (Kim-1) showed significant increases in both gentamicin (20 fold increase) and amphotericin-B-treated (9.2 fold increase) animals. Amphotericin B 126-140 hepatitis A virus cellular receptor 1 Rattus norvegicus 48-53 31968633-6 2020 Urinary alpha glutathione-S-transferase (GST) showed significant increases for gentamicin (6.2 fold increase) only and mu GST for amphotericin-B-treated (19.1 fold increase) animals only. Amphotericin B 130-144 hematopoietic prostaglandin D synthase Rattus norvegicus 41-44 31968633-6 2020 Urinary alpha glutathione-S-transferase (GST) showed significant increases for gentamicin (6.2 fold increase) only and mu GST for amphotericin-B-treated (19.1 fold increase) animals only. Amphotericin B 130-144 hematopoietic prostaglandin D synthase Rattus norvegicus 122-125 32065126-9 2020 Specifically, we show that the TRPM4 channel blocker 9-phenanthrol reduces voltage-step evoked cation currents recorded with the amphotericin-B perforated patch-clamp approach. Amphotericin B 129-143 transient receptor potential cation channel subfamily M member 4 Homo sapiens 31-36 31597765-7 2019 In accord with these findings, counteraction of IFITM3-mediated restriction by amphotericin B and reduction of endosomal pH by moderate acidification of the extracellular medium, enhanced infectivity of viruses with stable HA for HULEC without significant effect on infectivity for MDCK cells. Amphotericin B 79-93 interferon-induced transmembrane protein 3 Canis lupus familiaris 48-54 31134303-6 2019 Here, we demonstrate that cells expressing ABCA1 are more resistant to AmB treatment, while cells lacking ABCA1 expression or expressing non-active ABCA1MM mutant display increased sensitivity. Amphotericin B 71-74 ATP binding cassette subfamily A member 1 Homo sapiens 43-48 31134303-7 2019 Further, a FLIM analysis of AmB-treated cells reveals a fraction of the antibiotic molecules, characterized by relatively high fluorescence lifetimes (> 6 ns), involved in formation of bulk cholesterol-AmB structures at the surface of ABCA1-expressing cells. Amphotericin B 28-31 ATP binding cassette subfamily A member 1 Homo sapiens 238-243 31134303-7 2019 Further, a FLIM analysis of AmB-treated cells reveals a fraction of the antibiotic molecules, characterized by relatively high fluorescence lifetimes (> 6 ns), involved in formation of bulk cholesterol-AmB structures at the surface of ABCA1-expressing cells. Amphotericin B 205-208 ATP binding cassette subfamily A member 1 Homo sapiens 238-243 31134303-8 2019 Finally, lowering the cellular cholesterol content abolishes resistance of ABCA1-expressing cells to AmB. Amphotericin B 101-104 ATP binding cassette subfamily A member 1 Homo sapiens 75-80 31134303-9 2019 Therefore, we propose that ABCA1-mediated cholesterol efflux from cells induces formation of bulk cholesterol-AmB structures at the cell surface, preventing AmB cytotoxicity. Amphotericin B 110-113 ATP binding cassette subfamily A member 1 Homo sapiens 27-32 31134303-9 2019 Therefore, we propose that ABCA1-mediated cholesterol efflux from cells induces formation of bulk cholesterol-AmB structures at the cell surface, preventing AmB cytotoxicity. Amphotericin B 157-160 ATP binding cassette subfamily A member 1 Homo sapiens 27-32 31511938-9 2019 Multivariate analysis revealed that the risk factors of VCM-induced AKI were an initial VCM trough concentration of > 15 mg/L and concomitant use of tazobactam/piperacillin (TAZ/PIPC) and liposomal amphotericin B (L-AMB). Amphotericin B 201-215 tafazzin, phospholipid-lysophospholipid transacylase Homo sapiens 177-180 31717352-1 2019 Here, we aimed to prepare and optimize liposomal amphotericin B (AmB) while using the supercritical fluid of carbon dioxide (SCF-CO2) method and investigate the characteristics and pharmacokinetics of the SCF-CO2-processed liposomal AmB. Amphotericin B 233-236 KIT ligand Rattus norvegicus 205-208 31717352-6 2019 The stability study of the liposomes showed that liposomal AmB that was prepared by the SCF method was stable over time. Amphotericin B 59-62 KIT ligand Rattus norvegicus 88-91 31062385-8 2019 Perturbation studies with the IFITM antagonist amphotericin B revealed that modulation of membrane properties by IFITM proteins is responsible for the IFITM-mediated blockade of viral entry and enhancement of antibody-mediated neutralization. Amphotericin B 47-61 ifitm None 30-35 31666315-12 2019 Dectin-2-coated amphotericin B-loaded liposomes reduced the growth and viability of all three species more than an order of magnitude more efficiently than untargeted control liposomes and dramatically decreased the effective dose. Amphotericin B 16-30 C-type lectin domain containing 6A Homo sapiens 0-8 31666315-19 2019 Dectin-2-coated liposomes loaded with amphotericin B bound 50- to 150-fold more strongly to C. albicans, C. neoformans, and A. fumigatus than untargeted liposomes and killed these fungi more than an order of magnitude more efficiently. Amphotericin B 38-52 C-type lectin domain containing 6A Homo sapiens 0-8 31209012-2 2019 In this study, we performed a high-copy-number genomic DNA (gDNA) library screening to find and characterize genes that reduce susceptibility to amphotericin B, caspofungin, and voriconazole in Saccharomyces cerevisiae We identified the PDR16 and PMP3 genes for amphotericin B, the RMD9 and SWH1 genes for caspofungin, and the MRS3 and TRI1 genes for voriconazole. Amphotericin B 145-159 phosphatidylinositol transporter Saccharomyces cerevisiae S288C 237-242 31513380-3 2019 AMB-FUBINACA is a member of this class of drugs and is responsible for a large proportion of SCRA-related toxicity both in New Zealand and internationally. Amphotericin B 0-3 anillin, actin binding protein Homo sapiens 93-97 31542189-6 2019 Furthermore, VMA4 and VMA10 deletion strains showed hypersensitivity to fluconazole, terbinafine, and amphotericin B. Amphotericin B 102-116 H(+)-transporting V1 sector ATPase subunit E Saccharomyces cerevisiae S288C 13-17 31542189-6 2019 Furthermore, VMA4 and VMA10 deletion strains showed hypersensitivity to fluconazole, terbinafine, and amphotericin B. Amphotericin B 102-116 H(+)-transporting V1 sector ATPase subunit G Saccharomyces cerevisiae S288C 22-27 31209012-2 2019 In this study, we performed a high-copy-number genomic DNA (gDNA) library screening to find and characterize genes that reduce susceptibility to amphotericin B, caspofungin, and voriconazole in Saccharomyces cerevisiae We identified the PDR16 and PMP3 genes for amphotericin B, the RMD9 and SWH1 genes for caspofungin, and the MRS3 and TRI1 genes for voriconazole. Amphotericin B 145-159 Pmp3p Saccharomyces cerevisiae S288C 247-251 31209012-2 2019 In this study, we performed a high-copy-number genomic DNA (gDNA) library screening to find and characterize genes that reduce susceptibility to amphotericin B, caspofungin, and voriconazole in Saccharomyces cerevisiae We identified the PDR16 and PMP3 genes for amphotericin B, the RMD9 and SWH1 genes for caspofungin, and the MRS3 and TRI1 genes for voriconazole. Amphotericin B 145-159 Rmd9p Saccharomyces cerevisiae S288C 282-286 31209012-2 2019 In this study, we performed a high-copy-number genomic DNA (gDNA) library screening to find and characterize genes that reduce susceptibility to amphotericin B, caspofungin, and voriconazole in Saccharomyces cerevisiae We identified the PDR16 and PMP3 genes for amphotericin B, the RMD9 and SWH1 genes for caspofungin, and the MRS3 and TRI1 genes for voriconazole. Amphotericin B 145-159 oxysterol-binding protein related protein SWH1 Saccharomyces cerevisiae S288C 291-295 31209012-2 2019 In this study, we performed a high-copy-number genomic DNA (gDNA) library screening to find and characterize genes that reduce susceptibility to amphotericin B, caspofungin, and voriconazole in Saccharomyces cerevisiae We identified the PDR16 and PMP3 genes for amphotericin B, the RMD9 and SWH1 genes for caspofungin, and the MRS3 and TRI1 genes for voriconazole. Amphotericin B 145-159 Fe(2+) transporter Saccharomyces cerevisiae S288C 327-331 31209012-2 2019 In this study, we performed a high-copy-number genomic DNA (gDNA) library screening to find and characterize genes that reduce susceptibility to amphotericin B, caspofungin, and voriconazole in Saccharomyces cerevisiae We identified the PDR16 and PMP3 genes for amphotericin B, the RMD9 and SWH1 genes for caspofungin, and the MRS3 and TRI1 genes for voriconazole. Amphotericin B 145-159 Tri1p Saccharomyces cerevisiae S288C 336-340 31140972-5 2019 CONCLUSION: Our study illustrated varying degrees of synergism between caspofungin or terbinafine and itraconazole, voriconazole, posaconazole or amphotericin B towards Chaetomium spp., which could be a reference for the clinical treatment of Chaetomium spp. Amphotericin B 146-160 histocompatibility minor 13 Homo sapiens 180-183 31239178-7 2019 Compounds 10c, 11b, 11d and 11f displayed remarkable antimicrobial activity relating to their standard drugs Gentamycin, Amphotericin B and Ampicillin. Amphotericin B 121-135 Rho GTPase activating protein 9 Homo sapiens 10-13 31295336-8 2019 Association of AmB/LE and vitamin D deficiency led to diminished glomerular filtration rate and increased tubular injury, evidenced by reduced renal protein expression of NaPi-IIa and TRPM6 leading to hyperphosphaturia / hypermagnesuria. Amphotericin B 15-18 solute carrier family 34 member 1 Rattus norvegicus 171-179 31295336-8 2019 Association of AmB/LE and vitamin D deficiency led to diminished glomerular filtration rate and increased tubular injury, evidenced by reduced renal protein expression of NaPi-IIa and TRPM6 leading to hyperphosphaturia / hypermagnesuria. Amphotericin B 15-18 transient receptor potential cation channel, subfamily M, member 6 Rattus norvegicus 184-189 31140972-5 2019 CONCLUSION: Our study illustrated varying degrees of synergism between caspofungin or terbinafine and itraconazole, voriconazole, posaconazole or amphotericin B towards Chaetomium spp., which could be a reference for the clinical treatment of Chaetomium spp. Amphotericin B 146-160 histocompatibility minor 13 Homo sapiens 254-257 30867598-4 2019 Amphotericin B also restored airway surface liquid pH, viscosity, and antibacterial activity in primary cultures of airway epithelia from people with cystic fibrosis caused by different mutations, including ones that do not yield CFTR, and increased airway surface liquid pH in CFTR-null pigs in vivo. Amphotericin B 0-14 CF transmembrane conductance regulator Homo sapiens 230-234 31971247-3 2019 Cryptic species often demonstrate elevated MICs to drugs recommended for IA therapy such as voriconazole or amphotericin B. Amphotericin B 108-122 cripto, FRL-1, cryptic family 1 Homo sapiens 0-7 30954529-4 2019 Our results showed that both amphotericin B and its liposomal form at various doses induced obvious depression-like behaviors in naive mice, likely owing to increased serum interleukin-6 (IL-6) and IL-1beta levels. Amphotericin B 29-43 interleukin 6 Mus musculus 173-186 30954529-4 2019 Our results showed that both amphotericin B and its liposomal form at various doses induced obvious depression-like behaviors in naive mice, likely owing to increased serum interleukin-6 (IL-6) and IL-1beta levels. Amphotericin B 29-43 interleukin 6 Mus musculus 188-192 30954529-4 2019 Our results showed that both amphotericin B and its liposomal form at various doses induced obvious depression-like behaviors in naive mice, likely owing to increased serum interleukin-6 (IL-6) and IL-1beta levels. Amphotericin B 29-43 interleukin 1 beta Mus musculus 198-206 31138748-3 2019 The present studies describe a new nanoparticle crystal encapsulated formulation of amphotericin B known as encochleated amphotericin B (CAmB) that seeks to provide an oral formulation that is low in toxicity and cost. Amphotericin B 84-98 annexin A6 Mus musculus 137-141 31138748-3 2019 The present studies describe a new nanoparticle crystal encapsulated formulation of amphotericin B known as encochleated amphotericin B (CAmB) that seeks to provide an oral formulation that is low in toxicity and cost. Amphotericin B 121-135 annexin A6 Mus musculus 137-141 31138748-5 2019 Transport of fluorescent CAmB particles to brain as well as significant brain levels of amphotericin drug was demonstrated in treated mice, and immunological profiles were similar to those of mice treated with conventional amphotericin B. Amphotericin B 223-237 annexin A6 Mus musculus 25-29 31138748-11 2019 Toward this end, the present work describes the development of a new formulation of amphotericin B (CAmB) that encapsulates the drug as a crystal lipid nanoparticle that facilitates oral absorption and prevents toxicity. Amphotericin B 84-98 annexin A6 Mus musculus 100-104 30632399-11 2019 These results indicate that SLN and NLC stabilized by P407 and/or phospholipid as the colloidal carrier for AmB were successfully developed. Amphotericin B 108-111 sarcolipin Homo sapiens 28-31 30368648-9 2019 The strain exhibited in vitro sensitive to voriconazole (MIC = 0.016 mug/mL) and resistance to amphotericin B (MIC = 4 mug/mL); therefore, the amphotericin B was replaced with voriconazole. Amphotericin B 95-109 CD44 molecule (Indian blood group) Homo sapiens 111-118 31024507-13 2019 Amphotericin B had activity against most isolates although MICs ranged from 0.5 to 32 mug mL-1. Amphotericin B 0-14 2'-5' oligoadenylate synthetase 1B Mus musculus 90-94 29846682-10 2019 The MIC90 of amphotericin B and nystatins were 2 and 4 mug/ml, respectively, against either C. albicans or non-albicans Candida spp. Amphotericin B 13-27 histocompatibility minor 13 Homo sapiens 128-131 30867598-4 2019 Amphotericin B also restored airway surface liquid pH, viscosity, and antibacterial activity in primary cultures of airway epithelia from people with cystic fibrosis caused by different mutations, including ones that do not yield CFTR, and increased airway surface liquid pH in CFTR-null pigs in vivo. Amphotericin B 0-14 CF transmembrane conductance regulator Homo sapiens 278-282 30915146-7 2019 The test compounds showed lower activity (IC50 = 6.7 to 12.1 muM for promastigotes and IC50 = 3.6 to 10.2 muM for axenic amastigotes) than the reference drug amphotericin B (IC50 = 1.3 to 2.7 muM). Amphotericin B 158-172 latexin Homo sapiens 106-109 30915146-7 2019 The test compounds showed lower activity (IC50 = 6.7 to 12.1 muM for promastigotes and IC50 = 3.6 to 10.2 muM for axenic amastigotes) than the reference drug amphotericin B (IC50 = 1.3 to 2.7 muM). Amphotericin B 158-172 latexin Homo sapiens 106-109 30915146-8 2019 However, amphotericin B (LC50 = 11.1 muM) was much more toxic than the test compounds (LC50 = 369.2 - 611.6 muM) towards human monocytic cell line (THP-1) despite its efficiency. Amphotericin B 9-23 latexin Homo sapiens 37-40 29451812-0 2019 Efficacy of nebulized liposomal amphotericin B in the treatment of ABPA in an HIV/HBV co-infected man: Case report and literature review. Amphotericin B 32-46 filamin C Homo sapiens 67-71 30640957-7 2019 IAV fusion with IFITM3-containing compartments could be rescued by amphotericin B treatment, which has been previously shown to antagonize the antiviral activity of this protein. Amphotericin B 67-81 interferon induced transmembrane protein 3 Homo sapiens 16-22 30055454-1 2018 In this work, we investigated the interaction of amphotericin B (AmB) nanomicelles on the binding affinity and conformational change of human serum albumin (HSA) in comparison with bovine serum albumin (BSA) under physiological conditions by conducting several spectroscopic techniques further confirmed through molecular docking approaches. Amphotericin B 49-63 albumin Homo sapiens 142-155 30481559-0 2019 Development of a flow-through USP 4 apparatus drug release assay for the evaluation of amphotericin B liposome. Amphotericin B 87-101 ubiquitin specific peptidase 4 Homo sapiens 30-35 30481559-4 2019 In this study, we describe the development of a USP-4 apparatus-based IVR assay capable of discriminating liposomal Amp B formulations based on the drug release profile. Amphotericin B 116-121 ubiquitin specific peptidase 4 Homo sapiens 48-53 30481559-11 2019 Taken together, the developed USP-4 IVR assay can be a useful tool for drug release profile characterization in generic liposomal Amp B formulation development. Amphotericin B 130-135 ubiquitin specific peptidase 4 Homo sapiens 30-35 30055454-1 2018 In this work, we investigated the interaction of amphotericin B (AmB) nanomicelles on the binding affinity and conformational change of human serum albumin (HSA) in comparison with bovine serum albumin (BSA) under physiological conditions by conducting several spectroscopic techniques further confirmed through molecular docking approaches. Amphotericin B 65-68 albumin Homo sapiens 142-155 29575146-9 2018 The highest concentration of amphotericin B (500 mug ml-1 ) that inhibited the growth of the fungus also inhibited the bacteria and most of serovars of Leptospira spp. Amphotericin B 29-43 histocompatibility minor 13 Homo sapiens 163-166 30126959-6 2018 Overexpression of LDM or Ncp1 modified the ergosterol content of yeast and affected growth inhibition by the polyene antibiotic amphotericin B. Amphotericin B 128-142 cytochrome P450 family 51 subfamily A member 1 Homo sapiens 18-21 30126959-6 2018 Overexpression of LDM or Ncp1 modified the ergosterol content of yeast and affected growth inhibition by the polyene antibiotic amphotericin B. Amphotericin B 128-142 NADPH--hemoprotein reductase Saccharomyces cerevisiae S288C 25-29 29907984-7 2018 Importantly, deletion of RAD30 sensitized the strain to amphotericin B; but its presence resulted in azole drug tolerance only in DNA damaging conditions. Amphotericin B 56-70 DNA-directed DNA polymerase eta Saccharomyces cerevisiae S288C 25-30 29500853-6 2018 For voriconazole and amphotericin B the GM-MIC values were acceptably low for the yeast phase (0.39 and 0.72 mug mL-1 ), while the mycelial phase showed values >=2-fold higher (8.76 and 1.88 mug mL-1 ), P < .05. Amphotericin B 21-35 L1 cell adhesion molecule Mus musculus 113-117 29500853-6 2018 For voriconazole and amphotericin B the GM-MIC values were acceptably low for the yeast phase (0.39 and 0.72 mug mL-1 ), while the mycelial phase showed values >=2-fold higher (8.76 and 1.88 mug mL-1 ), P < .05. Amphotericin B 21-35 L1 cell adhesion molecule Mus musculus 198-202 29965517-3 2018 Results showed that the ambient areal rate of total NO3--N uptake Uamb varied from 11.40 to 69.13 mug (m2 s)-1 with an average of 34.45 mug (m2 s)-1, and the ambient uptake velocity Vf-amb averaged 0.24 mm s-1 and varied from 0.07 to 0.43 mm s-1 across three well-mixed sub-reaches in the study. Amphotericin B 24-27 NBL1, DAN family BMP antagonist Homo sapiens 52-55 29468746-11 2018 The most troubling observation was that the minimum inhibitory concentration for amphotericin B was elevated (>=2 mg L-1 ) in 87% of patients with A. flavus isolates and 43% with Aspergillus fumigatus isolates. Amphotericin B 81-95 immunoglobulin kappa variable 1-16 Homo sapiens 120-123 29695237-14 2018 Interestingly, antifungal agent amphotericin B not only inhibited STAT6 phosphorylation to suppress the M2 polarization of macrophages, but also promoted CD3+ T cell proliferation by regulating B7-H1 protein expression in macrophages. Amphotericin B 32-46 signal transducer and activator of transcription 6 Homo sapiens 66-71 29695237-14 2018 Interestingly, antifungal agent amphotericin B not only inhibited STAT6 phosphorylation to suppress the M2 polarization of macrophages, but also promoted CD3+ T cell proliferation by regulating B7-H1 protein expression in macrophages. Amphotericin B 32-46 CD274 molecule Homo sapiens 194-199 28566496-9 2017 A small molecule inhibitor of Pho84, a Food and Drug Administration-approved drug, inhibits TORC1 signaling and potentiates the activity of the antifungals amphotericin B and micafungin. Amphotericin B 156-170 phosphate transporter PHO84 Saccharomyces cerevisiae S288C 30-35 29636843-7 2018 Surprisingly, exposure of parasite to amphotericin B and sodium antimony gluconate upregulates the expression of UNG. Amphotericin B 38-52 uracil DNA glycosylase Homo sapiens 113-116 28662432-8 2017 Results suggested positive induction of VDR-dependent cathelicidin in PKDL macrophages by Amphotericin B treatment, which could be due to indirect effect of drug-induced IL12 upregulation. Amphotericin B 90-104 vitamin D receptor Homo sapiens 40-43 28662432-10 2017 Cathelicidin also augmented the anti-leishmanial effect and macrophage activating potential of Amphotericin B, attributable to regulation of VDR-dependent enhancement of CD40, p-STAT-I and MHC-II expression leading to regulation of IL10/IL12 balance in PKDL-BT patient macrophages. Amphotericin B 95-109 vitamin D receptor Homo sapiens 141-144 28662432-10 2017 Cathelicidin also augmented the anti-leishmanial effect and macrophage activating potential of Amphotericin B, attributable to regulation of VDR-dependent enhancement of CD40, p-STAT-I and MHC-II expression leading to regulation of IL10/IL12 balance in PKDL-BT patient macrophages. Amphotericin B 95-109 CD40 molecule Homo sapiens 170-174 28662432-10 2017 Cathelicidin also augmented the anti-leishmanial effect and macrophage activating potential of Amphotericin B, attributable to regulation of VDR-dependent enhancement of CD40, p-STAT-I and MHC-II expression leading to regulation of IL10/IL12 balance in PKDL-BT patient macrophages. Amphotericin B 95-109 interleukin 10 Homo sapiens 232-236 28662432-11 2017 CONCLUSIONS: This study indicates that cathelicidin augments anti-leishmanial macrophage activating property of Amphotericin B in a TLR2/VDR dependent mechanism, and advocate the development of novel adjunct treatment modality of cathelicidin with conventional Amphotericin B in PKDL patients. Amphotericin B 112-126 toll like receptor 2 Homo sapiens 132-136 28662432-11 2017 CONCLUSIONS: This study indicates that cathelicidin augments anti-leishmanial macrophage activating property of Amphotericin B in a TLR2/VDR dependent mechanism, and advocate the development of novel adjunct treatment modality of cathelicidin with conventional Amphotericin B in PKDL patients. Amphotericin B 112-126 vitamin D receptor Homo sapiens 137-140 28764751-6 2017 Short term exposure (3 h) to a combination of amphotericin B (1 microg/ml) and IFN-gamma (32 pg/ml) increased the effectiveness of amphotericin B against A. fumigatus and S. cerevisiae but not Candida albicans. Amphotericin B 131-145 interferon gamma Homo sapiens 79-88 28764751-7 2017 These data suggest that IFN-gamma does not possess strong antifungal activity but can enhance the effect of amphotericin B under some testing conditions against Aspergillus species. Amphotericin B 108-122 interferon gamma Homo sapiens 24-33 29325755-1 2018 Amphotericin B (AmB), a hydrophobic drug with negligible aqueous solubility was conjugated to bovine serum albumin (BSA) via amide bond coupling to give 6 to 8 wt% drug payload. Amphotericin B 0-14 albumin Homo sapiens 101-114 29325755-1 2018 Amphotericin B (AmB), a hydrophobic drug with negligible aqueous solubility was conjugated to bovine serum albumin (BSA) via amide bond coupling to give 6 to 8 wt% drug payload. Amphotericin B 16-19 albumin Homo sapiens 101-114 29128814-0 2017 Amphotericin B-copper (II) complex alters transcriptional activity of genes encoding transforming growth factor-beta family members and related proteins in renal cells. Amphotericin B 0-14 transforming growth factor beta 1 Homo sapiens 85-116 28765172-1 2017 In visceral leishmaniasis, we found that the antileishmanial drug Amp B produces a higher level of IL-1beta over the infected control. Amphotericin B 66-71 interleukin 1 beta Mus musculus 99-107 28765172-2 2017 Moreover, administering anti-IL-1beta antibody to infected Amp B-treated mice showed significantly less parasite clearance. Amphotericin B 59-64 interleukin 1 beta Mus musculus 29-37 27755992-0 2017 A new form of amphotericin B - the complex with copper (II) ions - downregulates sTNFR1 shedding and changes the activity of genes involved in TNF-induced pathways: AmB-Cu2+ downregulates sTNFR1 shedding and changes the activity of genes involved in TNF-induced pathways. Amphotericin B 14-28 tumor necrosis factor Homo sapiens 82-85 28575880-0 2017 Urinary Neutrophil Gelatinase-associated Lipocalin as a Biomarker of Kidney Injury in Hematologic-Oncologic Patients Receiving Amphotericin B. Amphotericin B 127-141 lipocalin 2 Homo sapiens 8-50 28575880-1 2017 INTRODUCTION: The aim of the present study was to compare the changing pattern of urine neutrophil gelatinase-associated lipocalin (NGAL) with serum as well as urine creatinine during amphotericin B treatment and determine its accuracy in the early detection of amphotericin B nephrotoxicity. Amphotericin B 184-198 lipocalin 2 Homo sapiens 88-130 28575880-1 2017 INTRODUCTION: The aim of the present study was to compare the changing pattern of urine neutrophil gelatinase-associated lipocalin (NGAL) with serum as well as urine creatinine during amphotericin B treatment and determine its accuracy in the early detection of amphotericin B nephrotoxicity. Amphotericin B 184-198 lipocalin 2 Homo sapiens 132-136 28575880-1 2017 INTRODUCTION: The aim of the present study was to compare the changing pattern of urine neutrophil gelatinase-associated lipocalin (NGAL) with serum as well as urine creatinine during amphotericin B treatment and determine its accuracy in the early detection of amphotericin B nephrotoxicity. Amphotericin B 262-276 lipocalin 2 Homo sapiens 88-130 28575880-1 2017 INTRODUCTION: The aim of the present study was to compare the changing pattern of urine neutrophil gelatinase-associated lipocalin (NGAL) with serum as well as urine creatinine during amphotericin B treatment and determine its accuracy in the early detection of amphotericin B nephrotoxicity. Amphotericin B 262-276 lipocalin 2 Homo sapiens 132-136 28575880-8 2017 The area under the curve of urine NGAL (0.765; 95% confidence interval, 0.588 to 0.962) on day zero was significantly higher than that of serum creatinine (0.464; 95% confidence interval, 0.268 to 0.660; P = .01) for predicting amphotericin nephrotoxicity. Amphotericin B 228-240 lipocalin 2 Homo sapiens 34-38 28575880-9 2017 CONCLUSIONS: The incremental pattern of urine NGAL during amphotericin B treatment was not significant compared to baseline values. Amphotericin B 58-72 lipocalin 2 Homo sapiens 46-50 28575880-10 2017 The urine level of NGAL on the first day of amphotericin B administration was more accurate than serum creatinine in predicting acute kidney injury caused by this agent. Amphotericin B 44-58 lipocalin 2 Homo sapiens 19-23 28364684-0 2017 Biophysical and molecular docking approaches for the investigation of biomolecular interactions between amphotericin B and bovine serum albumin. Amphotericin B 104-118 albumin Homo sapiens 130-143 28364684-3 2017 In this contribution, we describe the possible interactions between an antifungal drug Amphotericin B (AmB) and Bovine Serum Albumin (BSA) using multi-spectroscopic techniques and further confirmed through in-silico approaches. Amphotericin B 87-101 albumin Homo sapiens 119-132 28364684-3 2017 In this contribution, we describe the possible interactions between an antifungal drug Amphotericin B (AmB) and Bovine Serum Albumin (BSA) using multi-spectroscopic techniques and further confirmed through in-silico approaches. Amphotericin B 103-106 albumin Homo sapiens 119-132 28224343-0 2017 Amphotericin B Increases Transglutaminase 2 Expression Associated with Upregulation of Endocytotic Activity in Mouse Microglial Cell Line BV-2. Amphotericin B 0-14 transglutaminase 2, C polypeptide Mus musculus 25-43 27755992-0 2017 A new form of amphotericin B - the complex with copper (II) ions - downregulates sTNFR1 shedding and changes the activity of genes involved in TNF-induced pathways: AmB-Cu2+ downregulates sTNFR1 shedding and changes the activity of genes involved in TNF-induced pathways. Amphotericin B 14-28 tumor necrosis factor Homo sapiens 143-146 27755992-2 2017 Cytokines, including Tumor Necrosis Factor (TNF), are responsible for nephrotoxicity observed in patients treated with AmB. Amphotericin B 119-122 tumor necrosis factor Homo sapiens 21-42 27755992-2 2017 Cytokines, including Tumor Necrosis Factor (TNF), are responsible for nephrotoxicity observed in patients treated with AmB. Amphotericin B 119-122 tumor necrosis factor Homo sapiens 44-47 27755992-4 2017 To elucidate the molecular mechanism responsible for the reduction of the toxicity of AmB-Cu2+, we evaluated the expression of genes encoding TNF and its receptors alongside encoding proteins involved in TNF-induced signalization. Amphotericin B 86-89 tumor necrosis factor Homo sapiens 142-145 27755992-4 2017 To elucidate the molecular mechanism responsible for the reduction of the toxicity of AmB-Cu2+, we evaluated the expression of genes encoding TNF and its receptors alongside encoding proteins involved in TNF-induced signalization. Amphotericin B 86-89 tumor necrosis factor Homo sapiens 204-207 26733258-4 2016 Exogenous FH inhibited complement activation induced by the antifungal liposomal Amphotericin-B (AmBisome), the widely used solvent of anticancer drugs Cremophor EL, and the anticancer monoclonal antibody rituximab in vitro. Amphotericin B 81-95 complement factor H Homo sapiens 10-12 27683660-0 2016 Filamentation protects Candida albicans from amphotericin B-induced programmed cell death via a mechanism involving the yeast metacaspase, MCA1. Amphotericin B 45-59 Ca(2+)-dependent cysteine protease MCA1 Saccharomyces cerevisiae S288C 139-143 26919709-3 2016 A multiplexed, reporter gene-based high-throughput assay capable of detecting agonists of TLR2, TLR3, TLR4, TLR5, TLR7, TLR8, TLR9, NOD1 and NOD2 was utilized in screening 123,943 compounds, in which amphotericin B (AmpB) and nystatin were identified as prominent hits. Amphotericin B 200-214 toll like receptor 2 Homo sapiens 90-94 26919709-3 2016 A multiplexed, reporter gene-based high-throughput assay capable of detecting agonists of TLR2, TLR3, TLR4, TLR5, TLR7, TLR8, TLR9, NOD1 and NOD2 was utilized in screening 123,943 compounds, in which amphotericin B (AmpB) and nystatin were identified as prominent hits. Amphotericin B 200-214 toll like receptor 8 Homo sapiens 120-124 26919709-3 2016 A multiplexed, reporter gene-based high-throughput assay capable of detecting agonists of TLR2, TLR3, TLR4, TLR5, TLR7, TLR8, TLR9, NOD1 and NOD2 was utilized in screening 123,943 compounds, in which amphotericin B (AmpB) and nystatin were identified as prominent hits. Amphotericin B 216-220 toll like receptor 2 Homo sapiens 90-94 26919709-3 2016 A multiplexed, reporter gene-based high-throughput assay capable of detecting agonists of TLR2, TLR3, TLR4, TLR5, TLR7, TLR8, TLR9, NOD1 and NOD2 was utilized in screening 123,943 compounds, in which amphotericin B (AmpB) and nystatin were identified as prominent hits. Amphotericin B 216-220 toll like receptor 8 Homo sapiens 120-124 26919709-5 2016 The TLR4-stimulatory activity of AmpB was similar to that of monophosphoryl lipid A, suggestive of TRIF-biased signaling. Amphotericin B 33-37 toll like receptor 4 Homo sapiens 4-8 26919709-5 2016 The TLR4-stimulatory activity of AmpB was similar to that of monophosphoryl lipid A, suggestive of TRIF-biased signaling. Amphotericin B 33-37 tripartite motif containing 69 Homo sapiens 99-103 27826143-11 2016 Combined therapy with AMB and PAF-which are synergistic in vitro-was found to be more effective than either AMB or PAF treatment alone. Amphotericin B 108-111 patchy fur Mus musculus 30-33 27267989-9 2016 Our results suggested that the Gentian Cys C-based GFR equation correlated significantly with the Cockcroft-Gault formula at least at the early time period of treatment with amphotericin B. Amphotericin B 174-188 cystatin C Homo sapiens 39-44 27267989-10 2016 Graphical abstract Comparison between a serum creatinine-and a cystatin C-based glomerular filtration rate equation in patients receiving amphotericin B. Amphotericin B 138-152 cystatin C Homo sapiens 63-73 27001813-9 2016 Amphotericin B only weakly inhibited BCRP-mediated transport (127 muM). Amphotericin B 0-14 BCR pseudogene 1 Homo sapiens 37-41 27001813-9 2016 Amphotericin B only weakly inhibited BCRP-mediated transport (127 muM). Amphotericin B 0-14 latexin Homo sapiens 66-69 26816333-4 2016 Here, we report the preparation and evaluation of two novel PEG amide conjugates of amphotericin B (AMB (1)): AB1 (4) and AM2 (5). Amphotericin B 84-98 adrenomedullin 2 Mus musculus 122-125 27774409-6 2016 The treatment of Fungizone also significantly (p < 0.05) increased levels of urinary enzymes, N-acetyl-beta-D-glucosaminidase (NAG) and kidney injury molecule-1 (KIM-1) by 3.1- and 3.0 fold, respectively, whereas levels of NAG and KIM-1 were unchanged for mAmB, consistent with hematoxylin and eosin (H&E) staining of excised kidneys. Amphotericin B 17-26 O-GlcNAcase Rattus norvegicus 98-129 27774409-6 2016 The treatment of Fungizone also significantly (p < 0.05) increased levels of urinary enzymes, N-acetyl-beta-D-glucosaminidase (NAG) and kidney injury molecule-1 (KIM-1) by 3.1- and 3.0 fold, respectively, whereas levels of NAG and KIM-1 were unchanged for mAmB, consistent with hematoxylin and eosin (H&E) staining of excised kidneys. Amphotericin B 17-26 O-GlcNAcase Rattus norvegicus 131-134 27774409-6 2016 The treatment of Fungizone also significantly (p < 0.05) increased levels of urinary enzymes, N-acetyl-beta-D-glucosaminidase (NAG) and kidney injury molecule-1 (KIM-1) by 3.1- and 3.0 fold, respectively, whereas levels of NAG and KIM-1 were unchanged for mAmB, consistent with hematoxylin and eosin (H&E) staining of excised kidneys. Amphotericin B 17-26 hepatitis A virus cellular receptor 1 Rattus norvegicus 140-164 27774409-6 2016 The treatment of Fungizone also significantly (p < 0.05) increased levels of urinary enzymes, N-acetyl-beta-D-glucosaminidase (NAG) and kidney injury molecule-1 (KIM-1) by 3.1- and 3.0 fold, respectively, whereas levels of NAG and KIM-1 were unchanged for mAmB, consistent with hematoxylin and eosin (H&E) staining of excised kidneys. Amphotericin B 17-26 hepatitis A virus cellular receptor 1 Rattus norvegicus 166-171 27774409-6 2016 The treatment of Fungizone also significantly (p < 0.05) increased levels of urinary enzymes, N-acetyl-beta-D-glucosaminidase (NAG) and kidney injury molecule-1 (KIM-1) by 3.1- and 3.0 fold, respectively, whereas levels of NAG and KIM-1 were unchanged for mAmB, consistent with hematoxylin and eosin (H&E) staining of excised kidneys. Amphotericin B 17-26 O-GlcNAcase Rattus norvegicus 227-230 27774409-6 2016 The treatment of Fungizone also significantly (p < 0.05) increased levels of urinary enzymes, N-acetyl-beta-D-glucosaminidase (NAG) and kidney injury molecule-1 (KIM-1) by 3.1- and 3.0 fold, respectively, whereas levels of NAG and KIM-1 were unchanged for mAmB, consistent with hematoxylin and eosin (H&E) staining of excised kidneys. Amphotericin B 17-26 hepatitis A virus cellular receptor 1 Rattus norvegicus 235-240 25911243-9 2015 Amphotericin B was more cytotoxic against THP1 cells, with an IC50 of 0.15 microM (95% C.I. Amphotericin B 0-14 GLI family zinc finger 2 Homo sapiens 42-46 26410457-6 2016 FXYD1 but not FXYD3 overexpression inhibited amphotericin B-sensitive equivalent short-circuit current in Ussing chamber studies. Amphotericin B 45-59 FXYD domain containing ion transport regulator 1 Homo sapiens 0-5 26303800-0 2015 Role of urine neutrophil gelatinase-associated lipocalin in the early diagnosis of amphotericin B-induced acute kidney injury. Amphotericin B 83-97 lipocalin 2 Homo sapiens 14-56 26259607-10 2015 The increases of HSPA8 and ENO1 levels were also detected in CM of HK-2 cells treated with other nephrotoxic agents, such as HgCl2, NaAsO2, cisplatin, amphotericin B, and cyclosporine A. Amphotericin B 151-165 heat shock protein family A (Hsp70) member 8 Homo sapiens 17-22 26259607-10 2015 The increases of HSPA8 and ENO1 levels were also detected in CM of HK-2 cells treated with other nephrotoxic agents, such as HgCl2, NaAsO2, cisplatin, amphotericin B, and cyclosporine A. Amphotericin B 151-165 enolase 1 Homo sapiens 27-31 26491294-0 2015 Anti-transferrin receptor-modified amphotericin B-loaded PLA-PEG nanoparticles cure Candidal meningitis and reduce drug toxicity. Amphotericin B 35-49 transferrin Mus musculus 5-16 26491294-5 2015 In order to enhance the receptor-mediated delivery of AMB into CNS with therapeutic level, an anti-TfR antibody (OX26)-modified AMB-loaded PLA (poly[lactic acid])-PEG (polyethylene glycol)-based micellar drug delivery system was constructed. Amphotericin B 54-57 transferrin receptor Mus musculus 99-102 26364309-9 2015 To not disrupt TRPV1 carried-Ca(2+) activation of ANO1 in DRG neurons, ANO1 modulation of capsaicin-induced action potentials was measured by perforated-patch (Amphotericin-B) current-clamp technique. Amphotericin B 160-174 anoctamin 1, calcium activated chloride channel Mus musculus 71-75 26710539-6 2015 Amphotericin B, itraconazole and voriconazole were the most potent antifungal drugs against Paracoccidioides spp (CMI: 0.03-1 microg/mL). Amphotericin B 0-14 histocompatibility minor 13 Homo sapiens 109-112 25609628-4 2015 Here, we describe that amphotericin B activates these cells through engaging MyD88/TRIF signaling. Amphotericin B 23-37 myeloid differentiation primary response gene 88 Mus musculus 77-82 26001273-4 2015 The activity of Ysp2p, reflected in amphotericin-sensitivity assays, requires its second StART-like domain to be positioned so that it can reach across ER-PM contacts. Amphotericin B 36-48 Ysp2p Saccharomyces cerevisiae S288C 16-21 25802233-4 2015 Furthermore, in C. albicans, null mutation of CPH1 increased the expression of MDR1 as well as decreased susceptibility to fluconazole and voriconazole but not to amphotericin B. Amphotericin B 163-177 peptidylprolyl isomerase CPR1 Saccharomyces cerevisiae S288C 46-50 26034750-12 2015 Organ transplant recipients received amphotericin B formulation as initial therapy less often than other groups (22% vs 57% HIV vs 55% TNF-alpha; P = .006). Amphotericin B 37-51 tumor necrosis factor Homo sapiens 135-144 25609628-6 2015 Treatment with amphotericin B, particularly in combination with MCSF, increased the number of oligodendrocyte precursor cells and promoted remyelination within lesions; these pro-regenerative effects were mitigated in mice treated with clodronate liposomes to reduce circulating monocytes and tissue-infiltrated macrophages. Amphotericin B 15-29 colony stimulating factor 1 (macrophage) Mus musculus 64-68 24963546-0 2015 Does P-glycoprotein contribute to amphotericin B epithelial transport in Caco-2 cells? Amphotericin B 34-48 ATP binding cassette subfamily B member 1 Homo sapiens 5-19 24963546-10 2015 Non-toxic concentrations of AmB were 1 mug/mL-5 mug/mL; these were used in subsequent experiments. Amphotericin B 28-31 kinocilin Mus musculus 43-47 25609628-4 2015 Here, we describe that amphotericin B activates these cells through engaging MyD88/TRIF signaling. Amphotericin B 23-37 toll-like receptor adaptor molecule 2 Mus musculus 83-87 25609628-5 2015 When mice were subjected to lysolecithin-induced demyelination of the spinal cord, systemic injections of nontoxic doses of amphotericin B and another activator, macrophage colony-stimulating factor (MCSF), further elevated the representation of microglia/macrophages at the site of injury. Amphotericin B 124-138 colony stimulating factor 1 (macrophage) Mus musculus 162-198 24957831-10 2014 AmB did not interact with hOAT1 but strongly inhibited hOCT2. Amphotericin B 0-3 POU class 2 homeobox 2 Homo sapiens 55-60 25485894-5 2014 ABCG1 increased detergent-soluble pools of PM and LE cholesterol, generated detergent-resistant, non-SM-associated PM cholesterol, and increased resistance to both amphotericin B-induced (cholesterol-mediated) and lysenin-induced (SM-mediated) cytolysis, consistent with altered organization of both PM cholesterol and SM. Amphotericin B 164-178 ATP binding cassette subfamily G member 1 Homo sapiens 0-5 25477079-0 2015 Th-1 biased immunomodulation and synergistic antileishmanial activity of stable cationic lipid-polymer hybrid nanoparticle: biodistribution and toxicity assessment of encapsulated amphotericin B. Amphotericin B 180-194 negative elongation factor complex member C/D Homo sapiens 0-4 24105867-0 2014 Alteration in cellular viability, pro-inflammatory cytokines and nitric oxide production in nephrotoxicity generation by Amphotericin B: involvement of PKA pathway signaling. Amphotericin B 121-135 protein kinase cAMP-activated catalytic subunit alpha Sus scrofa 152-155 24105867-2 2014 The purpose of this study was to evaluate the effect of inhibiting the PKA signaling pathway in nephrotoxicity using Amphotericin B from the assessment of cell viability, pro-inflammatory cytokines and nitric oxide (NO) production in LLC-PK1 and MDCK cell lines. Amphotericin B 117-131 protein kinase cAMP-activated catalytic subunit alpha Sus scrofa 71-74 24105867-3 2014 Amphotericin B proved to be cytotoxic for both cell lines, as assessed by the mitochondrial enzyme activity (MTT) assay; caused DNA fragmentation, determined by flow cytometry using the propidium iodide (PI) dye; and activated the PKA pathway (western blot assay). Amphotericin B 0-14 protein kinase cAMP-activated catalytic subunit alpha Sus scrofa 231-234 24105867-6 2014 The NO production was increased when cells were pre-incubated with H89 followed by Amphotericin B, and this production produced a dependent PKA pathway in LLC-PK1 and MDCK cells lines. Amphotericin B 83-97 protein kinase cAMP-activated catalytic subunit alpha Sus scrofa 140-143 24105867-7 2014 Therefore, considering the present study"s results as a whole, it can be concluded that the inhibition of the PKA signaling pathway can aid in reducing the degree of nephrotoxicity caused by Amphotericin B. Amphotericin B 191-205 protein kinase cAMP-activated catalytic subunit alpha Sus scrofa 110-113 25352847-11 2014 Our results provide the first evidence that EPO improved the outcome of mice presenting with disseminated aspergillosis when combined with amphotericin B. Amphotericin B 139-153 erythropoietin Mus musculus 44-47 24867970-8 2014 In conclusion, we demonstrated that P-gp inhibitors can enhance the uptake of AMB through the BBB, suggesting that AMB is a P-gp substrate. Amphotericin B 115-118 phosphoglycolate phosphatase Mus musculus 36-40 24891430-0 2014 Amphotericin B transfer to CSF following intravenous administration of liposomal amphotericin B. Amphotericin B 0-14 colony stimulating factor 2 Homo sapiens 27-30 24891430-0 2014 Amphotericin B transfer to CSF following intravenous administration of liposomal amphotericin B. Amphotericin B 81-95 colony stimulating factor 2 Homo sapiens 27-30 24891430-1 2014 OBJECTIVES: Although amphotericin B (AmB) and its lipid formulations are used for the treatment of fungal infections of the CNS, the kinetics of AmB in the CSF after intravenous administration of liposomal amphotericin B (LAmB) are not well characterized. Amphotericin B 21-35 colony stimulating factor 2 Homo sapiens 156-159 24867970-0 2014 In vitro and in vivo evidence for amphotericin B as a P-glycoprotein substrate on the blood-brain barrier. Amphotericin B 34-48 phosphoglycolate phosphatase Mus musculus 54-68 24867970-8 2014 In conclusion, we demonstrated that P-gp inhibitors can enhance the uptake of AMB through the BBB, suggesting that AMB is a P-gp substrate. Amphotericin B 115-118 phosphoglycolate phosphatase Mus musculus 124-128 24867970-3 2014 The uptake of AMB by primary brain capillary endothelial cells in vitro was significantly enhanced after inhibition of P-gp by verapamil. Amphotericin B 14-17 phosphoglycolate phosphatase Mus musculus 119-123 24867970-8 2014 In conclusion, we demonstrated that P-gp inhibitors can enhance the uptake of AMB through the BBB, suggesting that AMB is a P-gp substrate. Amphotericin B 78-81 phosphoglycolate phosphatase Mus musculus 36-40 25064453-0 2014 Amphotericin B down-regulates Aggregatibacter actinomycetemcomitans-induced production of IL-8 and IL-6 in human gingival epithelial cells. Amphotericin B 0-14 interleukin 6 Homo sapiens 99-103 24867970-8 2014 In conclusion, we demonstrated that P-gp inhibitors can enhance the uptake of AMB through the BBB, suggesting that AMB is a P-gp substrate. Amphotericin B 78-81 phosphoglycolate phosphatase Mus musculus 124-128 25064453-5 2014 Amphotericin B and the p38 MAP kinase inhibitor down-regulated the A. actinomycetemcomitans-induced increase in the expression of IL-8 and IL-6 at the mRNA. Amphotericin B 0-14 interleukin 6 Homo sapiens 139-143 24968833-0 2014 [Amphotericin B suppresses migration and invasion of esophageal carcinoma Eca109 cells in hypoxic microenvironment by down-regulating hypoxia-inducible factor-1alpha activity]. Amphotericin B 1-15 hypoxia inducible factor 1 subunit alpha Homo sapiens 134-165 24968833-5 2014 AmB treatment resulted in significantly lowered mRNA and protein expressions of MMP-2 (P<0.05) and increased expressions of E-cadherin (P<0.05); the protein expression of HIF-1alpha decreased significantly in cells after AmB treatment (P<0.05) but its mRNA levels showed no significant changes (P>0.05). Amphotericin B 0-3 matrix metallopeptidase 2 Homo sapiens 80-85 24968833-5 2014 AmB treatment resulted in significantly lowered mRNA and protein expressions of MMP-2 (P<0.05) and increased expressions of E-cadherin (P<0.05); the protein expression of HIF-1alpha decreased significantly in cells after AmB treatment (P<0.05) but its mRNA levels showed no significant changes (P>0.05). Amphotericin B 0-3 cadherin 1 Homo sapiens 127-137 24968833-5 2014 AmB treatment resulted in significantly lowered mRNA and protein expressions of MMP-2 (P<0.05) and increased expressions of E-cadherin (P<0.05); the protein expression of HIF-1alpha decreased significantly in cells after AmB treatment (P<0.05) but its mRNA levels showed no significant changes (P>0.05). Amphotericin B 0-3 hypoxia inducible factor 1 subunit alpha Homo sapiens 177-187 24968833-5 2014 AmB treatment resulted in significantly lowered mRNA and protein expressions of MMP-2 (P<0.05) and increased expressions of E-cadherin (P<0.05); the protein expression of HIF-1alpha decreased significantly in cells after AmB treatment (P<0.05) but its mRNA levels showed no significant changes (P>0.05). Amphotericin B 227-230 hypoxia inducible factor 1 subunit alpha Homo sapiens 177-187 23786573-3 2014 The aim of this analysis was to evaluate the efficacy of micafungin, caspofungin and liposomal amphotericin B in patients with invasive candidiasis and candidaemia caused by different Candida spp. Amphotericin B 95-109 histocompatibility minor 13 Homo sapiens 192-195 24402241-5 2014 Our results show that AmB can create cytotoxic (long open) channels in cholesterol membrane with C14-C16 tail PCs and nontoxic (short open) channels with C17-C18 tail PCs as the lifetime of one-sided AmB channel depends on ~2-5 A difference in the thickness of sterol-containing C16 and C18 tail PC membranes. Amphotericin B 22-25 cytokine like 1 Homo sapiens 154-157 24402241-5 2014 Our results show that AmB can create cytotoxic (long open) channels in cholesterol membrane with C14-C16 tail PCs and nontoxic (short open) channels with C17-C18 tail PCs as the lifetime of one-sided AmB channel depends on ~2-5 A difference in the thickness of sterol-containing C16 and C18 tail PC membranes. Amphotericin B 22-25 Bardet-Biedl syndrome 9 Homo sapiens 158-161 24402241-5 2014 Our results show that AmB can create cytotoxic (long open) channels in cholesterol membrane with C14-C16 tail PCs and nontoxic (short open) channels with C17-C18 tail PCs as the lifetime of one-sided AmB channel depends on ~2-5 A difference in the thickness of sterol-containing C16 and C18 tail PC membranes. Amphotericin B 22-25 Bardet-Biedl syndrome 9 Homo sapiens 287-290 23786573-10 2014 Micafungin, caspofungin and liposomal amphotericin B exhibit favourable treatment response rates that are comparable for patients infected with different Candida spp. Amphotericin B 38-52 histocompatibility minor 13 Homo sapiens 162-165 23677844-4 2013 Amphotericin B was the only other antifungal that demonstrated a 2D SDR with CHF-related events. Amphotericin B 0-14 caveolae associated protein 2 Homo sapiens 68-71 25032223-8 2014 The activity of SOD, MDA, and NO levels increased and catalase activity decreased in the amphotericin B group compared to the control group (P = 0.0001, P = 0.003, P = 0.0001, and P = 0.0001, resp.). Amphotericin B 89-103 catalase Rattus norvegicus 54-62 25032223-9 2014 Amphotericin B plus CAPE treatment caused a significant decrease in MDA, NO levels, and SOD activity (P = 0.04, P = 0.02, and P = 0.0001, resp.) and caused an increase in CAT activity compared with amphotericin B treatment alone (P = 0.005). Amphotericin B 0-14 catalase Rattus norvegicus 171-174 24187506-1 2013 BACKGROUND: Lipid-based formulations of amphotericin B (LF-AMB) are indicated for treatment of invasive fungal infections in patients intolerant to conventional amphotericin B (CAB) or with refractory infections. Amphotericin B 40-54 neural proliferation, differentiation and control 1 Homo sapiens 177-180 24187506-13 2013 CONCLUSION: Among patients at risk for amphotericin B toxicity, differences between CAB and LF-AMB seen in crude outcomes analyses relate to channeling of sicker patients to initiate treatment with LF-AMB. Amphotericin B 39-53 neural proliferation, differentiation and control 1 Homo sapiens 84-87 23988732-1 2013 In this study we investigate whether Amphotericin B (AmB), a widely used antifungal agent, could decrease the proliferation of a myofibroblast cell line - GRX, a model of activated hepatic stellate cells (HSC). Amphotericin B 37-51 glutaredoxin Homo sapiens 155-158 23988732-1 2013 In this study we investigate whether Amphotericin B (AmB), a widely used antifungal agent, could decrease the proliferation of a myofibroblast cell line - GRX, a model of activated hepatic stellate cells (HSC). Amphotericin B 53-56 glutaredoxin Homo sapiens 155-158 23988732-9 2013 GRX cells treated with 1.25 mug/mL AmB were unable to close the wound after 96 h. Cell cycle analysis showed an increase in sub-G1 population and a decrease in G2/M population in AmB-treated cells. Amphotericin B 35-38 glutaredoxin Homo sapiens 0-3 23988732-10 2013 In addition, AmB-treated GRX cells showed increased expression of LC-3 and Caspase-3 by immunohistochemistry, suggesting an increase in both autophagy and apoptosis. Amphotericin B 13-16 glutaredoxin Homo sapiens 25-28 23988732-10 2013 In addition, AmB-treated GRX cells showed increased expression of LC-3 and Caspase-3 by immunohistochemistry, suggesting an increase in both autophagy and apoptosis. Amphotericin B 13-16 microtubule associated protein 1 light chain 3 alpha Homo sapiens 66-70 23988732-10 2013 In addition, AmB-treated GRX cells showed increased expression of LC-3 and Caspase-3 by immunohistochemistry, suggesting an increase in both autophagy and apoptosis. Amphotericin B 13-16 caspase 3 Homo sapiens 75-84 24395234-0 2014 Sphingolipid biosynthetic pathway genes FEN1 and SUR4 modulate amphotericin B resistance. Amphotericin B 63-77 multifunctional nuclease RAD27 Saccharomyces cerevisiae S288C 40-44 24395234-0 2014 Sphingolipid biosynthetic pathway genes FEN1 and SUR4 modulate amphotericin B resistance. Amphotericin B 63-77 fatty acid elongase ELO3 Saccharomyces cerevisiae S288C 49-53 24038187-0 2013 Search for highly efficient, stereoselective, and practical synthesis of complex organic compounds of medicinal importance as exemplified by the synthesis of the C21-C37 fragment of amphotericin B. Amphotericin B 182-196 TBL1X/Y related 1 Homo sapiens 162-165 24038187-1 2013 Highly stereoselective: A highly efficient, stereoselective and practical synthesis of the C21-C37 fragment of amphotericin B was realized in 25 % overall yield in eight longest linear steps from commercially available ethyl (S)-3-hydroxybutyrate by using Frater-Seebach alkylation, Brown crotylboration, Negishi coupling, Heck reaction, and Horner-Wadsworth-Emmons (HWE) olefination as key steps (see diagram). Amphotericin B 111-125 TBL1X/Y related 1 Homo sapiens 91-94 23345219-4 2013 Using simultaneous fura-2 Ca(2+) imaging and amphotericin B perforated patch-clamp electrophysiology, we find that bradykinin raises [Ca(2+)](i) and induces a biphasic voltage response. Amphotericin B 45-59 kininogen 1 Homo sapiens 115-125 23673538-6 2013 Liposomal amphotericin B was administered for 6 days, but the patient"s temperature reached 39.6 C and his white blood cell (WBC) count reached 52,300/muL. Amphotericin B 10-24 tripartite motif containing 37 Homo sapiens 152-155 23946621-11 2013 Compared with the LF-AMB group, the CAB/LF-AMB patients had a longer post-amphotericin B LOS (24.1 days vs. 15.7 days, respectively; P < 0.001), with a marginal effect of 4.5 days longer for those receiving CAB/LF-AMB (P = 0.016). Amphotericin B 74-88 neural proliferation, differentiation and control 1 Homo sapiens 36-39 23303813-3 2013 bFGF and VEGF monotherapy significantly increased survival rates and potentiated the activity of amphotericin B. Amphotericin B 97-111 fibroblast growth factor 2 Mus musculus 0-4 23303813-3 2013 bFGF and VEGF monotherapy significantly increased survival rates and potentiated the activity of amphotericin B. Amphotericin B 97-111 vascular endothelial growth factor A Mus musculus 9-13 23416056-6 2013 With amphotericin B, we discovered the highly conserved membrane protein Pmp3 as a potent resistance factor and a possible target. Amphotericin B 5-19 peroxisomal biogenesis factor 2 Homo sapiens 73-77 23878583-5 2013 Mycograb is a human recombinant monoclonal antibody against heat shock protein 90 (Hsp90) that was revealed to have synergy when combined with fluconazole, caspofungin, and amphotericin B against a broad spectrum of Candida species. Amphotericin B 173-187 heat shock protein 90 alpha family class A member 1 Homo sapiens 60-81 23878583-5 2013 Mycograb is a human recombinant monoclonal antibody against heat shock protein 90 (Hsp90) that was revealed to have synergy when combined with fluconazole, caspofungin, and amphotericin B against a broad spectrum of Candida species. Amphotericin B 173-187 heat shock protein 90 alpha family class A member 1 Homo sapiens 83-88 23027188-0 2012 Two clinical isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B both harbor mutations in ERG2. Amphotericin B 76-90 C-8 sterol isomerase ERG2 Saccharomyces cerevisiae S288C 116-120 23027188-1 2012 Two novel isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B (MIC, 8 mug ml(-1)) were found to be ERG2 mutants, wherein Delta(8)-sterol intermediates comprised >90% of the total cellular sterol fraction. Amphotericin B 73-87 C-8 sterol isomerase ERG2 Saccharomyces cerevisiae S288C 125-129 23027188-3 2012 This constitutes the first report of C. glabrata harboring mutations in ERG2 and exhibiting reduced sensitivity to amphotericin B. Amphotericin B 115-129 C-8 sterol isomerase ERG2 Saccharomyces cerevisiae S288C 72-76 22797606-12 2012 Differences could be observed by comparing animals treated with AbM to those treated with AmpB, as indicated by a significant reduction in tissue parasitism, higher levels of IFN-gamma and NO, and lower levels of IL-4 and IL-10, as well as by a decreased hepatic toxicity. Amphotericin B 90-94 interferon gamma Mus musculus 175-184 23089469-11 2012 In conclusion, high therapeutic concentration of prazosin can up-regulate angiogenic IL6 and CCL2 genes in human HCC cells susceptible to amphotericin B-induced oxidative stress. Amphotericin B 138-152 interleukin 6 Homo sapiens 85-88 23089469-11 2012 In conclusion, high therapeutic concentration of prazosin can up-regulate angiogenic IL6 and CCL2 genes in human HCC cells susceptible to amphotericin B-induced oxidative stress. Amphotericin B 138-152 C-C motif chemokine ligand 2 Homo sapiens 93-97 23781666-10 2012 If facility for fungal culture is not available and if CSF smear shows evidence of fungal infection then standard therapy with Amphotericin may be instituted earlier to reduce mortality. Amphotericin B 127-139 colony stimulating factor 2 Homo sapiens 55-58 22908154-5 2012 AMB treatment of a kidney cell line modulated the trafficking of three receptors (C-X-C chemokine receptor type 4 [CXCR4], M1 receptor, and human transferrin receptor [hTfnR]) due to an increase in endosomal pH. Amphotericin B 0-3 C-X-C motif chemokine receptor 4 Homo sapiens 82-113 22908154-5 2012 AMB treatment of a kidney cell line modulated the trafficking of three receptors (C-X-C chemokine receptor type 4 [CXCR4], M1 receptor, and human transferrin receptor [hTfnR]) due to an increase in endosomal pH. Amphotericin B 0-3 C-X-C motif chemokine receptor 4 Homo sapiens 115-120 22908154-5 2012 AMB treatment of a kidney cell line modulated the trafficking of three receptors (C-X-C chemokine receptor type 4 [CXCR4], M1 receptor, and human transferrin receptor [hTfnR]) due to an increase in endosomal pH. Amphotericin B 0-3 transferrin receptor Homo sapiens 146-166 22797606-12 2012 Differences could be observed by comparing animals treated with AbM to those treated with AmpB, as indicated by a significant reduction in tissue parasitism, higher levels of IFN-gamma and NO, and lower levels of IL-4 and IL-10, as well as by a decreased hepatic toxicity. Amphotericin B 90-94 interleukin 4 Mus musculus 213-217 22797606-12 2012 Differences could be observed by comparing animals treated with AbM to those treated with AmpB, as indicated by a significant reduction in tissue parasitism, higher levels of IFN-gamma and NO, and lower levels of IL-4 and IL-10, as well as by a decreased hepatic toxicity. Amphotericin B 90-94 interleukin 10 Mus musculus 222-227 22547734-0 2012 Efficacy of nebulised liposomal amphotericin B in the attack and maintenance treatment of ABPA. Amphotericin B 32-46 filamin C Homo sapiens 90-94 22694788-6 2012 As determined by microcalorimetry, amphotericin B was the most active agent against Mucorales (MHIC 0.06-0.125 mug/mL) and Fusarium spp. Amphotericin B 35-49 histocompatibility minor 13 Homo sapiens 132-135 22538414-0 2012 Amphotericin B up-regulates lipid A-induced IL-6 production via caspase-8. Amphotericin B 0-14 interleukin 6 Homo sapiens 44-48 22538414-0 2012 Amphotericin B up-regulates lipid A-induced IL-6 production via caspase-8. Amphotericin B 0-14 caspase 8 Homo sapiens 64-73 22538414-3 2012 Amphotericin B alone elicited a slight increase in interleukin (IL)-6 and IL-8 production by human gingival fibroblasts. Amphotericin B 0-14 interleukin 6 Homo sapiens 51-69 22538414-3 2012 Amphotericin B alone elicited a slight increase in interleukin (IL)-6 and IL-8 production by human gingival fibroblasts. Amphotericin B 0-14 C-X-C motif chemokine ligand 8 Homo sapiens 74-78 22538414-4 2012 However, amphotericin B synergistically up-regulated lipid A-induced production of IL-6 and IL-8. Amphotericin B 9-23 interleukin 6 Homo sapiens 83-87 22538414-4 2012 However, amphotericin B synergistically up-regulated lipid A-induced production of IL-6 and IL-8. Amphotericin B 9-23 C-X-C motif chemokine ligand 8 Homo sapiens 92-96 22538414-5 2012 While amphotericin B minimally activated nuclear factor (NF)-kappaB, it synergistically increased lipid A-induced NF-kappaB activation. Amphotericin B 6-20 nuclear factor kappa B subunit 1 Homo sapiens 41-67 22538414-8 2012 Amphotericin B activated caspase-8. Amphotericin B 0-14 caspase 8 Homo sapiens 25-34 22538414-9 2012 In addition, a caspase-8 inhibitor inhibited IL-6 production by amphotericin B and lipid A. Amphotericin B 64-78 caspase 8 Homo sapiens 15-24 22538414-9 2012 In addition, a caspase-8 inhibitor inhibited IL-6 production by amphotericin B and lipid A. Amphotericin B 64-78 interleukin 6 Homo sapiens 45-49 22538414-10 2012 This suggests that caspase-8 is required for the synergistic production of IL-6 by amphotericin B and lipid A. Amphotericin B 83-97 caspase 8 Homo sapiens 19-28 22538414-10 2012 This suggests that caspase-8 is required for the synergistic production of IL-6 by amphotericin B and lipid A. Amphotericin B 83-97 interleukin 6 Homo sapiens 75-79 22860418-0 2012 [Application of recording SK2 current in human atrial myocytes by perforated patch clamp techniques with the mix of beta-escin and amphotericin B]. Amphotericin B 131-145 potassium calcium-activated channel subfamily N member 2 Homo sapiens 26-29 22860418-1 2012 OBJECTIVE: To establish a perforated patch-clamp technology with amphotericin B and beta-escin and to research the regulation of small conductance calcium-activated potassium channel SK2 currents by calcium ions. Amphotericin B 65-79 potassium calcium-activated channel subfamily N member 2 Homo sapiens 183-186 22860418-6 2012 RESULTS: Mixed perforated electrode liquid compared with 150 microg/ml amphotericin B or 6.88 microg/ml beta-escin alone, it was easy to seal cells and activate SK2 current by the former method. Amphotericin B 71-85 potassium calcium-activated channel subfamily N member 2 Homo sapiens 161-164 22860418-9 2012 CONCLUSION: The appropriate concentration of amphotericin B mixed with beta-escin can form a stable whole-cell patch recording technology that is appropriate for the research of SK2 current regulation by intracellular calcium. Amphotericin B 45-59 potassium calcium-activated channel subfamily N member 2 Homo sapiens 178-181 21787882-5 2012 By comparison with a nonfunctional mutant, we demonstrated that ABCA1 elicits specific phenotypes in response to compounds known to interact with membrane lipids, such as papuamide B, amphotericin B and pimaricin. Amphotericin B 184-198 ATP-binding cassette, sub-family A (ABC1), member 1 Mus musculus 64-69 21739321-0 2012 Encapsulation and release of Amphotericin B from an ABC triblock fluorous copolymer. Amphotericin B 29-43 ATP binding cassette subfamily B member 6 (Langereis blood group) Homo sapiens 52-55 21739321-3 2012 METHODS: Novel ABC fluorous copolymers were synthesized, characterized, and used for encapsulation release of amphotericin B. Amphotericin B 110-124 ATP binding cassette subfamily B member 6 (Langereis blood group) Homo sapiens 15-18 21840673-0 2011 In vitro synergisms obtained by amphotericin B and voriconazole associated with non-antifungal agents against Fusarium spp. Amphotericin B 32-46 histocompatibility minor 13 Homo sapiens 119-122 22863853-5 2012 Expression of genes encoding kidney injury molecule 1, lipocalin 2, tissue inhibitor of metalloproteinase 1, and secreted phosphoprotein 1 was highly upregulated by Fungizone, nystatin, natamycin, amphotericin B methyl ester, and liposomal amphotericin B, and their area under the ROC curve values were more than 0.95. Amphotericin B 165-174 hepatitis A virus cellular receptor 1 Mus musculus 29-53 22863853-5 2012 Expression of genes encoding kidney injury molecule 1, lipocalin 2, tissue inhibitor of metalloproteinase 1, and secreted phosphoprotein 1 was highly upregulated by Fungizone, nystatin, natamycin, amphotericin B methyl ester, and liposomal amphotericin B, and their area under the ROC curve values were more than 0.95. Amphotericin B 165-174 lipocalin 2 Mus musculus 55-66 22863853-5 2012 Expression of genes encoding kidney injury molecule 1, lipocalin 2, tissue inhibitor of metalloproteinase 1, and secreted phosphoprotein 1 was highly upregulated by Fungizone, nystatin, natamycin, amphotericin B methyl ester, and liposomal amphotericin B, and their area under the ROC curve values were more than 0.95. Amphotericin B 165-174 tissue inhibitor of metalloproteinase 1 Mus musculus 68-107 22863853-5 2012 Expression of genes encoding kidney injury molecule 1, lipocalin 2, tissue inhibitor of metalloproteinase 1, and secreted phosphoprotein 1 was highly upregulated by Fungizone, nystatin, natamycin, amphotericin B methyl ester, and liposomal amphotericin B, and their area under the ROC curve values were more than 0.95. Amphotericin B 165-174 secreted phosphoprotein 1 Mus musculus 113-138 21855134-8 2011 KS1 was used to monitor K(+) efflux stimulated by adenosine-5"-triphosphate (ATP), amphotericin, and a mixture of nigericin, bumetanide and ouabain, demonstrating application of this material as an intracellular potassium ion sensor. Amphotericin B 83-95 zinc finger protein 382 Homo sapiens 0-3 22863853-5 2012 Expression of genes encoding kidney injury molecule 1, lipocalin 2, tissue inhibitor of metalloproteinase 1, and secreted phosphoprotein 1 was highly upregulated by Fungizone, nystatin, natamycin, amphotericin B methyl ester, and liposomal amphotericin B, and their area under the ROC curve values were more than 0.95. Amphotericin B 197-211 hepatitis A virus cellular receptor 1 Mus musculus 29-53 22863853-5 2012 Expression of genes encoding kidney injury molecule 1, lipocalin 2, tissue inhibitor of metalloproteinase 1, and secreted phosphoprotein 1 was highly upregulated by Fungizone, nystatin, natamycin, amphotericin B methyl ester, and liposomal amphotericin B, and their area under the ROC curve values were more than 0.95. Amphotericin B 197-211 lipocalin 2 Mus musculus 55-66 22863853-5 2012 Expression of genes encoding kidney injury molecule 1, lipocalin 2, tissue inhibitor of metalloproteinase 1, and secreted phosphoprotein 1 was highly upregulated by Fungizone, nystatin, natamycin, amphotericin B methyl ester, and liposomal amphotericin B, and their area under the ROC curve values were more than 0.95. Amphotericin B 197-211 tissue inhibitor of metalloproteinase 1 Mus musculus 68-107 22863853-5 2012 Expression of genes encoding kidney injury molecule 1, lipocalin 2, tissue inhibitor of metalloproteinase 1, and secreted phosphoprotein 1 was highly upregulated by Fungizone, nystatin, natamycin, amphotericin B methyl ester, and liposomal amphotericin B, and their area under the ROC curve values were more than 0.95. Amphotericin B 197-211 secreted phosphoprotein 1 Mus musculus 113-138 21189055-8 2011 Of the Amb a IgE-positive patients, 38% were positive for Amb a 1. Amphotericin B 7-10 immunoglobulin heavy constant epsilon Homo sapiens 13-16 22090300-27 2011 MIC value of amphotericin B for all of the Candida spp. Amphotericin B 13-27 histocompatibility minor 13 Homo sapiens 51-54 21854638-11 2011 Cytotoxicity in THP1 cells was observed for Fungizone and Ambisome , but not with the novel AmpB formulations. Amphotericin B 44-53 GLI family zinc finger 2 Homo sapiens 16-20 21616148-5 2011 The inhibitory activity of AmB in all liquid crystal formulations (cholesteryl palmityl carbonate: CPC, dicholesteryl carbonate: DCC and sodium cholesteryl carbonate: SCC) on fungi was significantly enhanced when compared to that of the same amount of pure AmB. Amphotericin B 27-30 serpin family B member 3 Homo sapiens 167-170 21491436-6 2011 However, urine levels of N-acetyl-beta-glucosaminidase and gamma-glutamyltransferase were significantly lower for AmB/PEG-b-PHSA relative to AmB for injection, USP. Amphotericin B 114-117 O-GlcNAcase Rattus norvegicus 25-54 21625424-3 2011 Here we report that only the polyene macrolides amphotericin B, nystatin, and natamycin but none of the tested azole antimycotic drugs induce significant IL-1beta secretion in-vitro in dendritic cells isolated from C57BL/6 mouse bone marrow. Amphotericin B 48-62 interleukin 1 beta Mus musculus 154-162 21625424-2 2011 However, amphotericin and nystatin have been reported to also trigger interleukin-1beta (IL-1beta) secretion in monocytes but the molecular mechanism is unknown. Amphotericin B 9-21 interleukin 1 beta Mus musculus 70-87 21625424-2 2011 However, amphotericin and nystatin have been reported to also trigger interleukin-1beta (IL-1beta) secretion in monocytes but the molecular mechanism is unknown. Amphotericin B 9-21 interleukin 1 beta Mus musculus 89-97 27186104-2 2011 In-silico analysis shows that amphotericin B and curcumin have separate binding regions on human serum albumin and bovine serum albumin. Amphotericin B 30-44 albumin Homo sapiens 97-110 27186104-2 2011 In-silico analysis shows that amphotericin B and curcumin have separate binding regions on human serum albumin and bovine serum albumin. Amphotericin B 30-44 albumin Homo sapiens 122-135 21406958-6 2011 In addition, we find that PKCdelta inhibition diminishes TRPM4-dependent currents in smooth muscle cells patch clamped in the amphotericin B perforated patch configuration. Amphotericin B 126-140 protein kinase C delta Homo sapiens 26-34 21406958-6 2011 In addition, we find that PKCdelta inhibition diminishes TRPM4-dependent currents in smooth muscle cells patch clamped in the amphotericin B perforated patch configuration. Amphotericin B 126-140 transient receptor potential cation channel subfamily M member 4 Homo sapiens 57-62 21789447-7 2011 In this context, ATR"s nephrotoxicity and the synergic adverse effect by the use of nephrotoxic antifungal agents were discussed, particularly amphotericin B, as well as the importance of differential diagnosis between ATRA syndrome and infectious diseases. Amphotericin B 143-157 ATR serine/threonine kinase Homo sapiens 17-20 19780977-0 2011 In vitro interactions between amphotericin B and other antifungal agents and rifampin against Fusarium spp. Amphotericin B 30-44 histocompatibility minor 13 Homo sapiens 103-106 19780977-3 2011 In this study, we evaluated the in vitro interactions of amphotericin B with caspofungin, ketoconazole, 5-flucytosine, itraconazole, miconazole, rifampin, fluconazole, terbinafine and voriconazole against isolates of Fusarium spp. Amphotericin B 57-71 histocompatibility minor 13 Homo sapiens 226-229 20649491-4 2011 Treating bovine CAs for 20 min with potassium chloride (KCl; 30 mM), amphotericin B (50 muM), or U46619 (100 nM) significantly (p < 0.05) increased both G6PD activity and glucose flux through the pentose phosphate pathway. Amphotericin B 69-83 glucose-6-phosphate dehydrogenase Bos taurus 156-160 21625424-7 2011 Together, the polyene macrolides amphotericin B, nystatin, and natamycin trigger IL-1beta secretion by causing potassium efflux from which activates the NLRP3-ASC-caspase-1. Amphotericin B 33-47 interleukin 1 beta Mus musculus 81-89 21625424-7 2011 Together, the polyene macrolides amphotericin B, nystatin, and natamycin trigger IL-1beta secretion by causing potassium efflux from which activates the NLRP3-ASC-caspase-1. Amphotericin B 33-47 NLR family, pyrin domain containing 3 Mus musculus 153-158 21625424-7 2011 Together, the polyene macrolides amphotericin B, nystatin, and natamycin trigger IL-1beta secretion by causing potassium efflux from which activates the NLRP3-ASC-caspase-1. Amphotericin B 33-47 steroid sulfatase Mus musculus 159-162 21625424-7 2011 Together, the polyene macrolides amphotericin B, nystatin, and natamycin trigger IL-1beta secretion by causing potassium efflux from which activates the NLRP3-ASC-caspase-1. Amphotericin B 33-47 caspase 1 Mus musculus 163-172 19733103-3 2010 Some studies have shown a reduction of circulating CD4+ T cells and of the CD4+/CD8+ ratio in dogs with CL and these changes normalised following treatment with meglumine antimoniate or amphotericin B. Amphotericin B 186-200 T-cell surface glycoprotein CD4 Canis lupus familiaris 51-54 19733103-3 2010 Some studies have shown a reduction of circulating CD4+ T cells and of the CD4+/CD8+ ratio in dogs with CL and these changes normalised following treatment with meglumine antimoniate or amphotericin B. Amphotericin B 186-200 T-cell surface glycoprotein CD4 Canis lupus familiaris 75-78 20412849-2 2010 Herein we reveal that co-administration with AmB enhances the immunogenicity of oral Lip-JENS1 vaccine which derived from liposomes functionalized with DSPC (distearoylphosphatidylcholine) and cholesterol (2:1, molar ratio)-bearing JE virus NS1 protein (600 microg ml(-1)). Amphotericin B 45-48 influenza virus NS1A binding protein Mus musculus 91-94 20696226-0 2010 A phospholipid-apolipoprotein A-I nanoparticle containing amphotericin B as a drug delivery platform with cell membrane protective properties. Amphotericin B 58-72 apolipoprotein A1 Homo sapiens 15-33 20639350-5 2010 The functional activity of ENaC was measured in the IPT after short-circuiting the Na(+)-K(+) pump with basolateral amphotericin B (7.5 muM). Amphotericin B 116-130 amiloride-sensitive sodium channel subunit alpha Cavia porcellus 27-31 20966584-3 2010 The patient responded well initially to the treatment with Amphotericin B followed by itraconazole; however, lesions recurred after three months with the further deterioration of immune status of the patient indicated by decline in CD4 counts. Amphotericin B 59-73 CD4 molecule Homo sapiens 232-235 20602334-4 2010 The minimal inhibitory concentration (MIC) of caspofungin and amphotericin B was two-fold lower for sec59-1 and dpm1-6 than for the respective wild-type strains. Amphotericin B 62-76 dolichol kinase Saccharomyces cerevisiae S288C 100-105 20602334-4 2010 The minimal inhibitory concentration (MIC) of caspofungin and amphotericin B was two-fold lower for sec59-1 and dpm1-6 than for the respective wild-type strains. Amphotericin B 62-76 dolichyl-phosphate beta-D-mannosyltransferase Saccharomyces cerevisiae S288C 112-116 20345749-0 2010 Amphotericin B, identified from a natural product screen, antagonizes CNS inhibitors to promote axon growth via activation of an Akt pathway in neurons. Amphotericin B 0-14 AKT serine/threonine kinase 1 Homo sapiens 129-132 20345749-6 2010 AmB was found to activate Akt and thereby suppress the activity of glycogen synthase kinase 3 beta. Amphotericin B 0-3 AKT serine/threonine kinase 1 Homo sapiens 26-29 20345749-6 2010 AmB was found to activate Akt and thereby suppress the activity of glycogen synthase kinase 3 beta. Amphotericin B 0-3 glycogen synthase kinase 3 beta Homo sapiens 67-98 20054151-11 2010 24h treatment with terbutaline increased the capacity of Na(+)/K(+)-ATPase and ENaC as measured after permeabilization with amphotericin. Amphotericin B 124-136 sodium channel epithelial 1 subunit gamma Rattus norvegicus 79-83 20516724-0 2010 Correlation of proteinase production with amphotericin B resistance in fungi from mycotic keratitis. Amphotericin B 42-56 endogenous retrovirus group K member 25 Homo sapiens 15-25 19839798-1 2009 The pharmacokinetics of Amphotericin B (AmB) from polyethylene glycol 2000 (PEG 2000) entrapped cross-linked bovine serum albumin (BSA) microsphere formulations were investigated and compared with solution formulation. Amphotericin B 24-38 albumin Homo sapiens 116-129 20516724-7 2010 Proteinase seems to be an important virulence marker of filamentous fungi in mycotic keratitis, correlating significantly with amphotericin B resistance. Amphotericin B 127-141 endogenous retrovirus group K member 25 Homo sapiens 0-10 19381990-1 2009 AIM: To investigate how different formulations of Amphotericin-B (Amp-B) affect the activity of phospholipid transfer protein (PLTP) when incubated with hyperlipidemic and normolipidemic plasma at physiological temperature (37 degrees C). Amphotericin B 50-64 phospholipid transfer protein Homo sapiens 127-131 19381990-1 2009 AIM: To investigate how different formulations of Amphotericin-B (Amp-B) affect the activity of phospholipid transfer protein (PLTP) when incubated with hyperlipidemic and normolipidemic plasma at physiological temperature (37 degrees C). Amphotericin B 66-71 phospholipid transfer protein Homo sapiens 127-131 19381990-6 2009 RESULTS: In normolipidemic plasma, PLTP activity was found to be increased by Abelcet and AmBisome but inhibited by Fungizone. Amphotericin B 116-125 phospholipid transfer protein Homo sapiens 35-39 19198012-5 2009 RESULTS: Incubation of the prototype polyene amphotericin B (AMB) with phospholipid vesicles and apolipoprotein A-I results in the formation of nanoscale complexes, termed nanodisks (NDs), capable of solubilizing significant quantities of AMB. Amphotericin B 61-64 apolipoprotein A1 Homo sapiens 97-115 19460378-6 2009 Amphotericin B reduced Leishmania infection by 50% at concentrations of 0.1 microM in THP-1 and murine macrophages at 72 h.p.i. Amphotericin B 0-14 GLI family zinc finger 2 Homo sapiens 86-91 19451289-1 2009 Granulocyte-macrophage colony-stimulating factor enhanced the efficacy of liposomal amphotericin B (LAMB) in a murine model of disseminated infection by Rhizopus oryzae, significantly prolonging survival and reducing tissue burden. Amphotericin B 84-98 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 0-48 20838546-2 2009 We describe case of 10 year old boy (CALLA - VE B cell ALL) who received conventional Amphotericin-B, but he persisted with hypokalemia. Amphotericin B 86-100 membrane metalloendopeptidase Homo sapiens 37-42 19198012-5 2009 RESULTS: Incubation of the prototype polyene amphotericin B (AMB) with phospholipid vesicles and apolipoprotein A-I results in the formation of nanoscale complexes, termed nanodisks (NDs), capable of solubilizing significant quantities of AMB. Amphotericin B 239-242 apolipoprotein A1 Homo sapiens 97-115 18271034-2 2008 We report that incubation of ABLC with recombinant human apolipoprotein A-I (apoA-I) induces solubilization of ABLC by transforming the micron sized phospholipid/AMB assemblies into discrete nanoscale disk-shaped complexes termed nanodisks (ND). Amphotericin B 162-165 apolipoprotein A1 Homo sapiens 57-75 18819017-2 2009 In this study, the susceptibility to amphotericin B of Candida spp. Amphotericin B 37-51 histocompatibility minor 13 Homo sapiens 63-66 19710541-7 2009 Exposure to amphotericin B (0.1-1 microg/ml) within 48 hours significantly increased annexin V-binding, decreased forward scatter, increased cytosolic Ca2+ activity and decreased cytosolic ATP content. Amphotericin B 12-26 annexin A5 Homo sapiens 85-94 18271034-2 2008 We report that incubation of ABLC with recombinant human apolipoprotein A-I (apoA-I) induces solubilization of ABLC by transforming the micron sized phospholipid/AMB assemblies into discrete nanoscale disk-shaped complexes termed nanodisks (ND). Amphotericin B 162-165 apolipoprotein A1 Homo sapiens 77-83 18606588-0 2008 Microarray analysis of amphotericin B-treated THP-1 monocytic cells identifies unique gene expression profiles among lipid and non-lipid drug formulations. Amphotericin B 23-37 GLI family zinc finger 2 Homo sapiens 46-51 18606693-0 2008 Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses. Amphotericin B 58-72 interleukin 10 Mus musculus 144-149 18606693-9 2008 This IL-10-deficient environment of IFN-gamma-secreting T cells probably up-regulated the enhanced IL-12 and NO production observed in splenic culture supernatants of these mice, correlating with prolonged disease suppression better than free AmB and AmBisome. Amphotericin B 243-246 interleukin 10 Mus musculus 5-10 18606693-9 2008 This IL-10-deficient environment of IFN-gamma-secreting T cells probably up-regulated the enhanced IL-12 and NO production observed in splenic culture supernatants of these mice, correlating with prolonged disease suppression better than free AmB and AmBisome. Amphotericin B 243-246 interferon gamma Mus musculus 36-45 18095759-0 2007 [In vitro activity of amphotericin B and anidulafungin against Candida spp. Amphotericin B 22-36 histocompatibility minor 13 Homo sapiens 71-74 18378789-0 2008 Nebulised corticosteroid and amphotericin B: an alternative treatment for ABPA? Amphotericin B 29-43 filamin C Homo sapiens 74-78 18385888-0 2008 Kinetic analysis of the interaction between amphotericin B and human serum albumin using surface plasmon resonance and fluorescence spectroscopy. Amphotericin B 44-58 albumin Homo sapiens 69-82 18385888-1 2008 The binding interaction between amphotericin B and human serum albumin (HSA) has been studied using surface plasmon resonance (SPR) spectroscopy combined with a fluorescence quenching method to confirm the binding kinetic results. Amphotericin B 32-46 albumin Homo sapiens 57-70 17999396-11 2008 A conformational search of the AmB-ergosterol conjugate by using distance constraints derived from the RDX results suggested that ergosterol molecules possibly surround the AmB assembly, which is in contrast with the conventional image in which ergosterol is inserted into AmB molecules. Amphotericin B 31-34 radixin Homo sapiens 103-106 17999396-11 2008 A conformational search of the AmB-ergosterol conjugate by using distance constraints derived from the RDX results suggested that ergosterol molecules possibly surround the AmB assembly, which is in contrast with the conventional image in which ergosterol is inserted into AmB molecules. Amphotericin B 173-176 radixin Homo sapiens 103-106 17999396-11 2008 A conformational search of the AmB-ergosterol conjugate by using distance constraints derived from the RDX results suggested that ergosterol molecules possibly surround the AmB assembly, which is in contrast with the conventional image in which ergosterol is inserted into AmB molecules. Amphotericin B 173-176 radixin Homo sapiens 103-106 18159926-2 2008 AmB release from PEG-DSPE micelles is slow in buffer but remarkably rapid in the presence of bovine serum albumin (BSA). Amphotericin B 0-3 albumin Homo sapiens 100-113 17911647-0 2007 IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. Amphotericin B 118-132 interleukin 10 Homo sapiens 0-5 17911647-2 2007 We address the role of the differential decline of IL-10 and TGF-beta in response to sodium antimony gluconate (SAG) and amphotericin B (AmB), the therapeutic success of SAG and AmB in Indian VL, and the significance of IL-10 and TGF-beta in the development and progression of post-kazla-azar dermal leishmaniasis (PKDL). Amphotericin B 121-135 interleukin 10 Homo sapiens 51-56 17389717-14 2007 Peritoneal amphotericin B level was inversely correlated with C-reactive protein level on the same day (r(2)=0.30). Amphotericin B 11-25 C-reactive protein Homo sapiens 62-80 17911647-2 2007 We address the role of the differential decline of IL-10 and TGF-beta in response to sodium antimony gluconate (SAG) and amphotericin B (AmB), the therapeutic success of SAG and AmB in Indian VL, and the significance of IL-10 and TGF-beta in the development and progression of post-kazla-azar dermal leishmaniasis (PKDL). Amphotericin B 121-135 transforming growth factor beta 1 Homo sapiens 61-69 17911647-2 2007 We address the role of the differential decline of IL-10 and TGF-beta in response to sodium antimony gluconate (SAG) and amphotericin B (AmB), the therapeutic success of SAG and AmB in Indian VL, and the significance of IL-10 and TGF-beta in the development and progression of post-kazla-azar dermal leishmaniasis (PKDL). Amphotericin B 137-140 interleukin 10 Homo sapiens 51-56 17911647-2 2007 We address the role of the differential decline of IL-10 and TGF-beta in response to sodium antimony gluconate (SAG) and amphotericin B (AmB), the therapeutic success of SAG and AmB in Indian VL, and the significance of IL-10 and TGF-beta in the development and progression of post-kazla-azar dermal leishmaniasis (PKDL). Amphotericin B 137-140 transforming growth factor beta 1 Homo sapiens 61-69 17646202-4 2007 Amphotericin B (AMB) concentrations in serum, CSF and tissue were determined by bioassay. Amphotericin B 0-14 amb Drosophila melanogaster 16-19 17293004-1 2007 Nanometer scale apolipoprotein A-I stabilized phospholipid disk complexes (nanodisks; ND) have been formulated with the polyene antibiotic amphotericin B (AMB). Amphotericin B 139-153 apolipoprotein A1 Homo sapiens 16-34 17293004-1 2007 Nanometer scale apolipoprotein A-I stabilized phospholipid disk complexes (nanodisks; ND) have been formulated with the polyene antibiotic amphotericin B (AMB). Amphotericin B 155-158 apolipoprotein A1 Homo sapiens 16-34 16966395-3 2006 Spectroscopic measurements demonstrated that HePC and AMB associate, leading to the formation of mixed aggregates in which AMB is solubilized as monomers. Amphotericin B 123-126 hepcidin antimicrobial peptide Homo sapiens 45-49 17641726-0 2007 Enhancement of a TH1 immune response in amphotericin B-treated mucocutaneous leishmaniasis. Amphotericin B 40-54 negative elongation factor complex member C/D Homo sapiens 17-20 16406402-4 2006 The aggregation state of amphotericin B was decreased by PEG-p(CL-co-TMC). Amphotericin B 25-39 STT3 oligosaccharyltransferase complex catalytic subunit A Homo sapiens 69-72 16483738-4 2006 The combination of K+ influx inhibition with 10 micromol/L bumetanide plus 10 micromol/L ouabain and K+ efflux stimulation with 3 mg/L amphotericin B or 5 micromol/L nigericin efficiently reduced the intracellular K+ content after 3 h. Manipulation of K+ fluxes with subsequent intracellular K+ depletion induced apoptosis of lung cancer cells, as detected by caspase-3 activity after 3 h K+ depletion followed by 24 h proliferation and TUNEL positive staining after 48 h proliferation. Amphotericin B 135-149 caspase 3 Homo sapiens 360-369 16901276-0 2006 Changes in MMP-2 and -9 activity and MMP-8 reactivity after amphotericin B induced synovitis and treatment with bufexamac. Amphotericin B 60-74 matrix metallopeptidase 2 Equus caballus 11-23 16901276-0 2006 Changes in MMP-2 and -9 activity and MMP-8 reactivity after amphotericin B induced synovitis and treatment with bufexamac. Amphotericin B 60-74 matrix metallopeptidase 8 Equus caballus 37-42 16901276-7 2006 IA injection of amphotericin B consistently resulted in significant increase in the immunoreactivity of MMP-8 and activity of both the latent and the active forms of MMP-2 and -9, among which the active form of MMP-2 increased the most. Amphotericin B 16-30 matrix metallopeptidase 8 Equus caballus 104-109 16901276-7 2006 IA injection of amphotericin B consistently resulted in significant increase in the immunoreactivity of MMP-8 and activity of both the latent and the active forms of MMP-2 and -9, among which the active form of MMP-2 increased the most. Amphotericin B 16-30 matrix metallopeptidase 2 Equus caballus 166-178 16901276-7 2006 IA injection of amphotericin B consistently resulted in significant increase in the immunoreactivity of MMP-8 and activity of both the latent and the active forms of MMP-2 and -9, among which the active form of MMP-2 increased the most. Amphotericin B 16-30 matrix metallopeptidase 2 Equus caballus 166-171 16759760-0 2006 Enhanced immune response by amphotericin B following NS1 protein prime-oral recombinant Salmonella vaccine boost vaccination protects mice from dengue virus challenge. Amphotericin B 28-42 influenza virus NS1A binding protein Mus musculus 53-56 16759760-5 2006 Addition of an antifungal antibiotic amphotericin B (AmB) to Salmonella vaccine further enhanced the synergic effects of prime-boost vaccine regimen on the elicited NS1-specific serum IgG response and the protective efficacy. Amphotericin B 37-51 influenza virus NS1A binding protein Mus musculus 165-168 16759760-5 2006 Addition of an antifungal antibiotic amphotericin B (AmB) to Salmonella vaccine further enhanced the synergic effects of prime-boost vaccine regimen on the elicited NS1-specific serum IgG response and the protective efficacy. Amphotericin B 53-56 influenza virus NS1A binding protein Mus musculus 165-168 16715392-1 2006 PURPOSE: The purpose of this study was to investigate the role of phospholipid transfer protein (PLTP) on the plasma distribution of amphotericin B (AmpB) following incubation with different AmpB formulations in human plasmas with varying lipid profiles. Amphotericin B 133-147 phospholipid transfer protein Homo sapiens 97-101 16715392-1 2006 PURPOSE: The purpose of this study was to investigate the role of phospholipid transfer protein (PLTP) on the plasma distribution of amphotericin B (AmpB) following incubation with different AmpB formulations in human plasmas with varying lipid profiles. Amphotericin B 149-153 phospholipid transfer protein Homo sapiens 97-101 16715392-1 2006 PURPOSE: The purpose of this study was to investigate the role of phospholipid transfer protein (PLTP) on the plasma distribution of amphotericin B (AmpB) following incubation with different AmpB formulations in human plasmas with varying lipid profiles. Amphotericin B 191-195 phospholipid transfer protein Homo sapiens 97-101 16715392-6 2006 The presence of the PLTP antibody resulted in a 20% decrease in the percentage AmpB recovered in the HDL fraction following the incubation of Abelcet. Amphotericin B 79-83 phospholipid transfer protein Homo sapiens 20-24 16715392-8 2006 CONCLUSIONS: Taken together, these findings suggest indirect evidence that PLTP may play an important role in the plasma distribution profile of AmpB following the incubation of Abelcet and may be one of the factors responsible for the preferential association of AmpB with HDL when administered as Abelcet. Amphotericin B 145-149 phospholipid transfer protein Homo sapiens 75-79 16715392-8 2006 CONCLUSIONS: Taken together, these findings suggest indirect evidence that PLTP may play an important role in the plasma distribution profile of AmpB following the incubation of Abelcet and may be one of the factors responsible for the preferential association of AmpB with HDL when administered as Abelcet. Amphotericin B 264-268 phospholipid transfer protein Homo sapiens 75-79 16406402-7 2006 PEG-p(CL-co-TMC) micelles could be an easy method for amphotericin B encapsulation. Amphotericin B 54-68 STT3 oligosaccharyltransferase complex catalytic subunit A Homo sapiens 12-15 16189267-0 2006 Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1. Amphotericin B 0-14 erythropoietin Homo sapiens 22-36 16189267-0 2006 Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1. Amphotericin B 0-14 hypoxia inducible factor 1 subunit alpha inhibitor Homo sapiens 72-75 16189267-0 2006 Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1. Amphotericin B 0-14 hypoxia inducible factor 1 subunit alpha Homo sapiens 99-104 16189267-6 2006 EPO mRNA levels were markedly attenuated by AmB treatment both in rat kidneys and in Hep3B cells. Amphotericin B 44-47 erythropoietin Rattus norvegicus 0-3 16189267-8 2006 Moreover, AmB was found to specifically repress the C-terminal transactivation domain (CAD) of HIF-1alpha, and this repression by AmB required Asn803, a target site of the factor-inhibiting HIF-1 (FIH); moreover, this repressive effect was reversed by FIH inhibitors. Amphotericin B 10-13 hypoxia inducible factor 1 subunit alpha Homo sapiens 95-105 16189267-8 2006 Moreover, AmB was found to specifically repress the C-terminal transactivation domain (CAD) of HIF-1alpha, and this repression by AmB required Asn803, a target site of the factor-inhibiting HIF-1 (FIH); moreover, this repressive effect was reversed by FIH inhibitors. Amphotericin B 10-13 hypoxia inducible factor 1 subunit alpha inhibitor Homo sapiens 172-195 16189267-8 2006 Moreover, AmB was found to specifically repress the C-terminal transactivation domain (CAD) of HIF-1alpha, and this repression by AmB required Asn803, a target site of the factor-inhibiting HIF-1 (FIH); moreover, this repressive effect was reversed by FIH inhibitors. Amphotericin B 10-13 hypoxia inducible factor 1 subunit alpha inhibitor Homo sapiens 197-200 16189267-8 2006 Moreover, AmB was found to specifically repress the C-terminal transactivation domain (CAD) of HIF-1alpha, and this repression by AmB required Asn803, a target site of the factor-inhibiting HIF-1 (FIH); moreover, this repressive effect was reversed by FIH inhibitors. Amphotericin B 10-13 hypoxia inducible factor 1 subunit alpha inhibitor Homo sapiens 252-255 16314670-2 2006 Addition of apolipoprotein A-I to a multilamellar phospholipid vesicle dispersion containing 20% (w/w) AMB induces the formation of reconstituted high density lipoprotein (rHDL), with solubilization of the antibiotic. Amphotericin B 103-106 apolipoprotein A-I Mus musculus 12-30 16491469-2 2006 Furthermore, the pet20-delta strain has a greatly reduced level of cytochrome c, especially at 37 degrees C. The pet20-delta strain was sensitive to high NaCl and CaCl2 concentrations, hydrogen peroxide, oligomycin, polymixin B, amphotericin B and fluconazole. Amphotericin B 229-243 Pet20p Saccharomyces cerevisiae S288C 17-22 16491469-2 2006 Furthermore, the pet20-delta strain has a greatly reduced level of cytochrome c, especially at 37 degrees C. The pet20-delta strain was sensitive to high NaCl and CaCl2 concentrations, hydrogen peroxide, oligomycin, polymixin B, amphotericin B and fluconazole. Amphotericin B 229-243 Pet20p Saccharomyces cerevisiae S288C 113-118 16625056-7 2006 Finally, U-73122 partially suppressed in vivo production of TNF-alpha and IL-6 induced by AmB administration in BALB/c mice. Amphotericin B 90-93 interleukin 6 Mus musculus 74-78 16615848-5 2005 RESULTS: The patient with CD4 above 200 did well with nephrectomy followed by amphotericin therapy for 14 days. Amphotericin B 78-90 CD4 molecule Homo sapiens 26-29 16000698-6 2005 In addition, increased intracellular [Na+] after selective plasma membrane permeabilization by a low concentration of the Na+ ionophore amphotericin B (1 microg/ml) induced dissociation of the PKA catalytic subunit from p65-NF-kappaB and IkappaBalpha. Amphotericin B 136-150 v-rel reticuloendotheliosis viral oncogene homolog A (avian) Mus musculus 220-233 16625056-5 2006 U-73122 and Go6976 reduced AmB-mediated induction of proinflammatory cytokines (tumor necrosis factor (TNF)-alpha and interleukin (IL)-6) in RAW264.7 cells. Amphotericin B 27-30 tumor necrosis factor Mus musculus 80-113 16625056-5 2006 U-73122 and Go6976 reduced AmB-mediated induction of proinflammatory cytokines (tumor necrosis factor (TNF)-alpha and interleukin (IL)-6) in RAW264.7 cells. Amphotericin B 27-30 interleukin 6 Mus musculus 118-136 16625056-6 2006 Furthermore, AmB-induced activation of NF-kappaB was observed in toll-like receptor (TLR) 2-expressed cells, and the activation of NF-kappaB was inhibited by U-73122, whereas peptidoglycan-induced NF-kappaB activation, which was also dependent on TLR2, was not inhibited by U-73122. Amphotericin B 13-16 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 39-48 16625056-6 2006 Furthermore, AmB-induced activation of NF-kappaB was observed in toll-like receptor (TLR) 2-expressed cells, and the activation of NF-kappaB was inhibited by U-73122, whereas peptidoglycan-induced NF-kappaB activation, which was also dependent on TLR2, was not inhibited by U-73122. Amphotericin B 13-16 toll-like receptor 2 Mus musculus 85-88 16625056-6 2006 Furthermore, AmB-induced activation of NF-kappaB was observed in toll-like receptor (TLR) 2-expressed cells, and the activation of NF-kappaB was inhibited by U-73122, whereas peptidoglycan-induced NF-kappaB activation, which was also dependent on TLR2, was not inhibited by U-73122. Amphotericin B 13-16 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 131-140 16625056-6 2006 Furthermore, AmB-induced activation of NF-kappaB was observed in toll-like receptor (TLR) 2-expressed cells, and the activation of NF-kappaB was inhibited by U-73122, whereas peptidoglycan-induced NF-kappaB activation, which was also dependent on TLR2, was not inhibited by U-73122. Amphotericin B 13-16 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 131-140 16625056-6 2006 Furthermore, AmB-induced activation of NF-kappaB was observed in toll-like receptor (TLR) 2-expressed cells, and the activation of NF-kappaB was inhibited by U-73122, whereas peptidoglycan-induced NF-kappaB activation, which was also dependent on TLR2, was not inhibited by U-73122. Amphotericin B 13-16 toll-like receptor 2 Mus musculus 247-251 16625056-7 2006 Finally, U-73122 partially suppressed in vivo production of TNF-alpha and IL-6 induced by AmB administration in BALB/c mice. Amphotericin B 90-93 tumor necrosis factor Mus musculus 60-69 16273336-0 2005 Release of TNF-alpha and IL-1beta from porcine brain endothelium corresponds to the pyrogenic potential of three marketed formulations of amphotericin. Amphotericin B 138-150 tumor necrosis factor Homo sapiens 11-20 16273336-3 2005 OBJECTIVE: To determine if the release of tumor necrosis factor-alpha (TNF-alpha) and interleukin-1-beta (IL-1) from brain endothelium corresponds to the incidence of amphotericin fever. Amphotericin B 167-179 tumor necrosis factor Homo sapiens 42-69 16273336-3 2005 OBJECTIVE: To determine if the release of tumor necrosis factor-alpha (TNF-alpha) and interleukin-1-beta (IL-1) from brain endothelium corresponds to the incidence of amphotericin fever. Amphotericin B 167-179 tumor necrosis factor Homo sapiens 71-80 16273336-3 2005 OBJECTIVE: To determine if the release of tumor necrosis factor-alpha (TNF-alpha) and interleukin-1-beta (IL-1) from brain endothelium corresponds to the incidence of amphotericin fever. Amphotericin B 167-179 interleukin 1 beta Homo sapiens 86-104 16273336-3 2005 OBJECTIVE: To determine if the release of tumor necrosis factor-alpha (TNF-alpha) and interleukin-1-beta (IL-1) from brain endothelium corresponds to the incidence of amphotericin fever. Amphotericin B 167-179 interleukin 1 beta Homo sapiens 106-110 16273336-8 2005 These experiments also suggest that amphotericin fever is initially mediated by TNF-alpha. Amphotericin B 36-48 tumor necrosis factor Homo sapiens 80-89 16358096-0 2005 Continuous infusion of amphotericin B: preliminary experience at Faculdade de Medicina da Fundacao ABC. Amphotericin B 23-37 ATP binding cassette subfamily B member 6 (Langereis blood group) Homo sapiens 99-102 16000698-6 2005 In addition, increased intracellular [Na+] after selective plasma membrane permeabilization by a low concentration of the Na+ ionophore amphotericin B (1 microg/ml) induced dissociation of the PKA catalytic subunit from p65-NF-kappaB and IkappaBalpha. Amphotericin B 136-150 nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha Mus musculus 238-250 16006446-7 2005 RESULTS: Combination of caspofungin + G-CSF or addition of G-CSF to the combination of caspofungin + amphotericin-B-intralipid increased the survival rate of infected mice up to 78.9% and prolonged their mean survival time to 25 days. Amphotericin B 101-115 colony stimulating factor 3 (granulocyte) Mus musculus 59-64 15814605-11 2005 CONCLUSIONS: AMB-related toxicity is associated with induction of IL-1beta, TNF-alpha and apoptosis in organs. Amphotericin B 13-16 interleukin 1 beta Mus musculus 66-74 15814605-11 2005 CONCLUSIONS: AMB-related toxicity is associated with induction of IL-1beta, TNF-alpha and apoptosis in organs. Amphotericin B 13-16 tumor necrosis factor Mus musculus 76-85 15843289-4 2005 Measures to prevent confusion and aid in understanding the differences between lipid and nonlipid formulations of amphotericin B should be implemented. Amphotericin B 114-128 activation induced cytidine deaminase Homo sapiens 34-37 15814605-0 2005 Induction of interleukin-1beta, tumour necrosis factor-alpha and apoptosis in mouse organs by amphotericin B is neutralized by conjugation with arabinogalactan. Amphotericin B 94-108 interleukin 1 beta Mus musculus 13-30 15814605-1 2005 OBJECTIVES: To investigate the possibilities that: (i) organ toxicity of amphotericin B-deoxycholate (AMB-DOC) is related to induction of interleukin-1beta (IL-1beta), tumour necrosis factor-alpha (TNF-alpha) and apoptosis in target organs; and (ii) the reduced toxicity resulting from the conjugation of AMB with water-soluble arabinogalactan (AMB-AG), is related to modulation of these parameters. Amphotericin B 102-105 interleukin 1 beta Mus musculus 138-155 15814605-1 2005 OBJECTIVES: To investigate the possibilities that: (i) organ toxicity of amphotericin B-deoxycholate (AMB-DOC) is related to induction of interleukin-1beta (IL-1beta), tumour necrosis factor-alpha (TNF-alpha) and apoptosis in target organs; and (ii) the reduced toxicity resulting from the conjugation of AMB with water-soluble arabinogalactan (AMB-AG), is related to modulation of these parameters. Amphotericin B 102-105 interleukin 1 beta Mus musculus 157-165 15814605-1 2005 OBJECTIVES: To investigate the possibilities that: (i) organ toxicity of amphotericin B-deoxycholate (AMB-DOC) is related to induction of interleukin-1beta (IL-1beta), tumour necrosis factor-alpha (TNF-alpha) and apoptosis in target organs; and (ii) the reduced toxicity resulting from the conjugation of AMB with water-soluble arabinogalactan (AMB-AG), is related to modulation of these parameters. Amphotericin B 102-105 tumor necrosis factor Mus musculus 198-207 15793154-0 2005 Secretion of proinflammatory cytokines and chemokines during amphotericin B exposure is mediated by coactivation of toll-like receptors 1 and 2. Amphotericin B 61-75 toll like receptor 1 Homo sapiens 116-143 15793154-1 2005 Amphotericin B (AmB) is a ligand of toll-like receptor 2 (TLR2). Amphotericin B 0-14 toll like receptor 2 Homo sapiens 36-56 15793154-1 2005 Amphotericin B (AmB) is a ligand of toll-like receptor 2 (TLR2). Amphotericin B 0-14 toll like receptor 2 Homo sapiens 58-62 15793154-1 2005 Amphotericin B (AmB) is a ligand of toll-like receptor 2 (TLR2). Amphotericin B 16-19 toll like receptor 2 Homo sapiens 36-56 15793154-1 2005 Amphotericin B (AmB) is a ligand of toll-like receptor 2 (TLR2). Amphotericin B 16-19 toll like receptor 2 Homo sapiens 58-62 15649994-0 2005 Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. Amphotericin B 10-24 toll-like receptor 2 Mus musculus 127-132 15856892-4 2005 A commercial preparation of nonconjugated AmB (Fungizone) also increased TNF-alpha production, but to a lesser extent than AmB-AG. Amphotericin B 42-45 tumor necrosis factor Homo sapiens 73-82 15856892-4 2005 A commercial preparation of nonconjugated AmB (Fungizone) also increased TNF-alpha production, but to a lesser extent than AmB-AG. Amphotericin B 47-56 tumor necrosis factor Homo sapiens 73-82 15649994-0 2005 Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. Amphotericin B 10-24 toll-like receptor 4 Mus musculus 136-141 15637558-11 2005 Between-group comparisons of the changes in the intranasal mucus levels of eosinophil-derived neurotoxin showed a reduction in the amphotericin B group and an increase in the placebo group ( P = .046); levels of IL-5 showed similar tendencies ( P = .082). Amphotericin B 131-145 ribonuclease A family member 2 Homo sapiens 75-104 15277314-11 2004 The increase in short circuit current (I(sc)) by 1.0 and 2.5 micrograms ml(-1) amphotericin B was markedly attenuated in IFN-gamma-treated cells. Amphotericin B 79-93 interferon gamma Homo sapiens 121-130 15803862-1 2005 Amphotericin B(AmB) formulations, Fungizone, and Amphotec caused substantially greater proinflammatory cytokine release than AmBisome (L-AMB) and Abelcet in TPA differentiated THP-1 macrophages as determined by antibody based protein arrays. Amphotericin B 0-14 GLI family zinc finger 2 Homo sapiens 176-181 15803862-1 2005 Amphotericin B(AmB) formulations, Fungizone, and Amphotec caused substantially greater proinflammatory cytokine release than AmBisome (L-AMB) and Abelcet in TPA differentiated THP-1 macrophages as determined by antibody based protein arrays. Amphotericin B 49-57 GLI family zinc finger 2 Homo sapiens 176-181 15539515-0 2004 Regulation of fungal infection by a combination of amphotericin B and peptide 2, a lactoferrin peptide that activates neutrophils. Amphotericin B 51-65 lactotransferrin Mus musculus 83-94 15648266-0 2004 Unidirectional inhibition of lipid transfer protein I-mediated transfer of cholesteryl esters between high-density and low-density lipoproteins by amphotericin B lipid complex. Amphotericin B 147-161 cholesteryl ester transfer protein Homo sapiens 29-53 15648266-1 2004 PURPOSE: The purpose of this study was to determine whether Fungizone or amphotericin B lipid complex (ABLC; ABELCET) affects the transfer of cholesteryl ester (CE) by lipid transfer protein I (LTP I; also known as cholesteryl ester transfer protein) between HDL and LDL (bidirectional transfer HDL to LDL and LDL to HDL). Amphotericin B 60-69 cholesteryl ester transfer protein Homo sapiens 168-192 15648266-1 2004 PURPOSE: The purpose of this study was to determine whether Fungizone or amphotericin B lipid complex (ABLC; ABELCET) affects the transfer of cholesteryl ester (CE) by lipid transfer protein I (LTP I; also known as cholesteryl ester transfer protein) between HDL and LDL (bidirectional transfer HDL to LDL and LDL to HDL). Amphotericin B 60-69 cholesteryl ester transfer protein Homo sapiens 194-199 15648266-1 2004 PURPOSE: The purpose of this study was to determine whether Fungizone or amphotericin B lipid complex (ABLC; ABELCET) affects the transfer of cholesteryl ester (CE) by lipid transfer protein I (LTP I; also known as cholesteryl ester transfer protein) between HDL and LDL (bidirectional transfer HDL to LDL and LDL to HDL). Amphotericin B 60-69 cholesteryl ester transfer protein Homo sapiens 215-249 15648266-1 2004 PURPOSE: The purpose of this study was to determine whether Fungizone or amphotericin B lipid complex (ABLC; ABELCET) affects the transfer of cholesteryl ester (CE) by lipid transfer protein I (LTP I; also known as cholesteryl ester transfer protein) between HDL and LDL (bidirectional transfer HDL to LDL and LDL to HDL). Amphotericin B 73-87 cholesteryl ester transfer protein Homo sapiens 168-192 15648266-1 2004 PURPOSE: The purpose of this study was to determine whether Fungizone or amphotericin B lipid complex (ABLC; ABELCET) affects the transfer of cholesteryl ester (CE) by lipid transfer protein I (LTP I; also known as cholesteryl ester transfer protein) between HDL and LDL (bidirectional transfer HDL to LDL and LDL to HDL). Amphotericin B 73-87 cholesteryl ester transfer protein Homo sapiens 194-199 15648266-1 2004 PURPOSE: The purpose of this study was to determine whether Fungizone or amphotericin B lipid complex (ABLC; ABELCET) affects the transfer of cholesteryl ester (CE) by lipid transfer protein I (LTP I; also known as cholesteryl ester transfer protein) between HDL and LDL (bidirectional transfer HDL to LDL and LDL to HDL). Amphotericin B 73-87 cholesteryl ester transfer protein Homo sapiens 215-249 15295712-3 2004 Measurement of the resulting prostanoids indicated that amphotericin B and IL-1 beta acted synergistically to increase the ability of endothelial cells to synthesize prostanoids from endogenous and exogenous substrate and to increase expression of cyclooxygenase-2. Amphotericin B 56-70 prostaglandin-endoperoxide synthase 2 Homo sapiens 248-264 15295712-6 2004 The synergistic effect with IL-1 beta was observed with free-form amphotericin B and, to a lesser extent, with lipid-complexed amphotericin B (Abelcet). Amphotericin B 66-80 interleukin 1 beta Homo sapiens 28-37 15295712-6 2004 The synergistic effect with IL-1 beta was observed with free-form amphotericin B and, to a lesser extent, with lipid-complexed amphotericin B (Abelcet). Amphotericin B 127-141 interleukin 1 beta Homo sapiens 28-37 15277314-12 2004 However, the inhibitory effect of PDBu on the amphotericin B-induced increase in I(sc) was of similar magnitude in vehicle- and IFN-gamma-treated cells. Amphotericin B 46-60 interferon gamma Homo sapiens 128-137 15491054-2 2004 Based on preliminary studies, our working hypothesis was that incorporation of AmpB into mixed micelles composed of Peceol would significantly enhance gastro-intestinal (GI) tract absorption by increasing lymphatic drug transport and decreasing P-glycoprotein (PGP)-mediated drug efflux. Amphotericin B 79-83 ATP binding cassette subfamily B member 1 Homo sapiens 245-259 15491054-2 2004 Based on preliminary studies, our working hypothesis was that incorporation of AmpB into mixed micelles composed of Peceol would significantly enhance gastro-intestinal (GI) tract absorption by increasing lymphatic drug transport and decreasing P-glycoprotein (PGP)-mediated drug efflux. Amphotericin B 79-83 ATP binding cassette subfamily B member 1 Homo sapiens 261-264 15491054-17 2004 CONCLUSIONS: Taken together, these findings suggest that Peceol increases the gastrointestinal absorption of AmpB by increasing the amount of drug that is transported through the mesenteric lymph duct and by decreasing mdr-1 mRNA and PGP protein expression, resulting in lower PGP-mediated AmpB efflux. Amphotericin B 109-113 ATP binding cassette subfamily B member 1 Homo sapiens 219-224 15491054-17 2004 CONCLUSIONS: Taken together, these findings suggest that Peceol increases the gastrointestinal absorption of AmpB by increasing the amount of drug that is transported through the mesenteric lymph duct and by decreasing mdr-1 mRNA and PGP protein expression, resulting in lower PGP-mediated AmpB efflux. Amphotericin B 109-113 ATP binding cassette subfamily B member 1 Homo sapiens 234-237 15491054-17 2004 CONCLUSIONS: Taken together, these findings suggest that Peceol increases the gastrointestinal absorption of AmpB by increasing the amount of drug that is transported through the mesenteric lymph duct and by decreasing mdr-1 mRNA and PGP protein expression, resulting in lower PGP-mediated AmpB efflux. Amphotericin B 109-113 ATP binding cassette subfamily B member 1 Homo sapiens 277-280 15025631-0 2004 The influence of amphotericin B and neomycin on the effect of human relaxin-2 on foetal membranes and isolated myometrium. Amphotericin B 17-31 relaxin 2 Homo sapiens 68-77 15361111-7 2004 Lymphocyte proliferation was restored together with an increase in CD4(+) subsets in animals treated with encapsulated amphotericin B, but not in those treated with the non-encapsulated compound. Amphotericin B 119-133 T-cell surface glycoprotein CD4 Mesocricetus auratus 67-70 15215088-0 2004 Cloning of S-adenosyl-L-methionine:C-24-Delta-sterol-methyltransferase (ERG6) from Leishmania donovani and characterization of mRNAs in wild-type and amphotericin B-Resistant promastigotes. Amphotericin B 150-164 sterol 24-C-methyltransferase Saccharomyces cerevisiae S288C 72-76 15025631-2 2004 Previously unpublished experiments indicate that neomycin and amphotericin B in vitro influences the effect of human relaxin-2 on the strength of human foetal membranes. Amphotericin B 62-76 relaxin 2 Homo sapiens 117-126 15025631-6 2004 Human relaxin-2 (hrlx-2, 10(-9) M) induced a decreased strength in human foetal membranes, although this effect of hrlx-2 was inhibited after co-incubation with neomycin and amphotericin B. Amphotericin B 174-188 relaxin 2 Homo sapiens 6-15 15040939-5 2004 Analysis of the antibody response which occurs in patients with invasive candidiasis, being treated with amphotericin B, showed a close correlation between recovery and antibody to the immunodominant heat shock protein 90 (hsp90). Amphotericin B 105-119 heat shock protein 90 alpha family class A member 1 Homo sapiens 200-221 14694143-5 2004 An ouabain-sensitive current carried by exogenous pumps could be detected in apically amphotericin B-permeabilized epithelia expressing human alpha1 and alpha2 subunits, but not the alpha3 subunit. Amphotericin B 86-100 adrenoceptor alpha 1D Homo sapiens 142-159 15040939-5 2004 Analysis of the antibody response which occurs in patients with invasive candidiasis, being treated with amphotericin B, showed a close correlation between recovery and antibody to the immunodominant heat shock protein 90 (hsp90). Amphotericin B 105-119 heat shock protein 90 alpha family class A member 1 Homo sapiens 223-228 15040939-7 2004 Mycograb is a human recombinant antibody to hsp90 which shows intrinsic antifungal activity and synergy with amphotericin B both in vitro and in vivo. Amphotericin B 109-123 heat shock protein 90 alpha family class A member 1 Homo sapiens 44-49 12801357-3 2003 Application of amphotericin B induced a significant higher daily urinary enzyme activity of the renal tubular enzymes N-acetyl-beta-glucosaminidase (NAG), beta-glucuronidase (GRS), alanine-aminopeptidase (AAP) and gamma-glutamyltransferase (GGT) in comparison with controls and sodium deoxycholate treated animals as well. Amphotericin B 15-29 O-GlcNAcase Rattus norvegicus 118-147 14742187-1 2004 Cytokine antibody arrays were used to establish the profiles of cytokine release from THP-1 monocytes exposed to different amphotericin B (AMB) drug delivery systems. Amphotericin B 123-137 GLI family zinc finger 2 Homo sapiens 86-91 15043394-3 2004 Orally administered cochleates containing amphotericin B (CAMB) showed broad-spectrum activity in murine infection models of candidiasis, aspergillosis and cryptococcosis. Amphotericin B 42-56 annexin A6 Mus musculus 58-62 14657087-5 2004 RESULTS: LC-AmB reduced both the haemolytic activity of amphotericin B and its toxicity towards mouse peritoneal macrophages. Amphotericin B 56-70 integrin beta 2 Mus musculus 9-15 14657087-7 2004 The relative liver weight increased slightly in mice treated daily with a dose of 20 mg/kg LC-AmB, as did the kidney weight in this group and the group treated with Fungizone. Amphotericin B 165-174 integrin beta 2 Mus musculus 91-97 12917249-8 2003 In addition, amphotericin B treatment resulted in a significant decrease in levels of left lung IL-6 (at 72 and 120 h), MIP-2 (at 120 h) and MCP-1 (at 120 h). Amphotericin B 13-27 interleukin 6 Rattus norvegicus 96-100 12917249-8 2003 In addition, amphotericin B treatment resulted in a significant decrease in levels of left lung IL-6 (at 72 and 120 h), MIP-2 (at 120 h) and MCP-1 (at 120 h). Amphotericin B 13-27 C-X-C motif chemokine ligand 2 Rattus norvegicus 120-125 12917249-8 2003 In addition, amphotericin B treatment resulted in a significant decrease in levels of left lung IL-6 (at 72 and 120 h), MIP-2 (at 120 h) and MCP-1 (at 120 h). Amphotericin B 13-27 C-C motif chemokine ligand 2 Rattus norvegicus 141-146 14521794-7 2003 Amphotericin B was selected to treat the PDH patients. Amphotericin B 0-14 pyruvate dehydrogenase phosphatase catalytic subunit 1 Homo sapiens 41-44 12821470-2 2003 Antibody to HSP90 is closely associated with recovery in patients with invasive candidiasis who are receiving amphotericin B (AMB). Amphotericin B 110-124 heat shock protein 90 alpha family class A member 1 Homo sapiens 12-17 12821470-2 2003 Antibody to HSP90 is closely associated with recovery in patients with invasive candidiasis who are receiving amphotericin B (AMB). Amphotericin B 126-129 heat shock protein 90 alpha family class A member 1 Homo sapiens 12-17 15124865-5 2004 We found that both in naive and compromised mice, AMB treatment caused significantly greater production of the pro-inflammatory cytokines tumour necrosis factor alpha (TNF-alpha) and interleukin 1 beta (IL-1beta) than was seen in animals treated with AMB-IL or with another lipid AMB formulation, AmBisome. Amphotericin B 50-53 tumor necrosis factor Mus musculus 168-177 15124865-5 2004 We found that both in naive and compromised mice, AMB treatment caused significantly greater production of the pro-inflammatory cytokines tumour necrosis factor alpha (TNF-alpha) and interleukin 1 beta (IL-1beta) than was seen in animals treated with AMB-IL or with another lipid AMB formulation, AmBisome. Amphotericin B 50-53 interleukin 1 beta Mus musculus 183-201 15124865-5 2004 We found that both in naive and compromised mice, AMB treatment caused significantly greater production of the pro-inflammatory cytokines tumour necrosis factor alpha (TNF-alpha) and interleukin 1 beta (IL-1beta) than was seen in animals treated with AMB-IL or with another lipid AMB formulation, AmBisome. Amphotericin B 50-53 interleukin 1 beta Mus musculus 203-211 14692429-6 2003 RESULTS: Amphotericin B has been shown to increase tumor necrosis factor alpha (TNF-alpha) concentrations in macrophages. Amphotericin B 9-23 tumor necrosis factor Homo sapiens 51-78 14692429-6 2003 RESULTS: Amphotericin B has been shown to increase tumor necrosis factor alpha (TNF-alpha) concentrations in macrophages. Amphotericin B 9-23 tumor necrosis factor Homo sapiens 80-89 14692429-8 2003 The immunoregulatory effects of amphotericin B include increases in apoptosis, production of monocyte chemoattractant protein 1, superoxide anion, nitric oxide, and intercellular adhesion molecule 1 expression. Amphotericin B 32-46 C-C motif chemokine ligand 2 Homo sapiens 93-127 14692429-8 2003 The immunoregulatory effects of amphotericin B include increases in apoptosis, production of monocyte chemoattractant protein 1, superoxide anion, nitric oxide, and intercellular adhesion molecule 1 expression. Amphotericin B 32-46 intercellular adhesion molecule 1 Homo sapiens 165-198 14692429-9 2003 CONCLUSIONS: Amphotericin B induces the production of TNF-alpha, interferon-gamma, and IL-1beta, which may potentiate its toxic effects. Amphotericin B 13-27 tumor necrosis factor Homo sapiens 54-63 14692429-9 2003 CONCLUSIONS: Amphotericin B induces the production of TNF-alpha, interferon-gamma, and IL-1beta, which may potentiate its toxic effects. Amphotericin B 13-27 interferon gamma Homo sapiens 65-81 14692429-9 2003 CONCLUSIONS: Amphotericin B induces the production of TNF-alpha, interferon-gamma, and IL-1beta, which may potentiate its toxic effects. Amphotericin B 13-27 interleukin 1 beta Homo sapiens 87-95 12860979-0 2003 The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. Amphotericin B 20-34 CD14 molecule Homo sapiens 103-107 12860979-3 2003 Because amphotericin B is a microbial product, we hypothesized that it stimulates immune cells via Toll-like receptors (TLRs) and CD14. Amphotericin B 8-22 CD14 molecule Homo sapiens 130-134 12860979-4 2003 We show here that amphotericin B induces signal transduction and inflammatory cytokine release from cells expressing TLR2 and CD14. Amphotericin B 18-32 toll like receptor 2 Homo sapiens 117-121 12860979-4 2003 We show here that amphotericin B induces signal transduction and inflammatory cytokine release from cells expressing TLR2 and CD14. Amphotericin B 18-32 CD14 molecule Homo sapiens 126-130 12860979-5 2003 Primary murine macrophages and human cell lines expressing TLR2, CD14, and the adapter protein MyD88 responded to amphotericin B with NF-kappaB-dependent reporter activity and cytokine release, whereas cells deficient in any of these failed to respond. Amphotericin B 114-128 toll like receptor 2 Homo sapiens 59-63 12860979-5 2003 Primary murine macrophages and human cell lines expressing TLR2, CD14, and the adapter protein MyD88 responded to amphotericin B with NF-kappaB-dependent reporter activity and cytokine release, whereas cells deficient in any of these failed to respond. Amphotericin B 114-128 CD14 molecule Homo sapiens 65-69 12860979-5 2003 Primary murine macrophages and human cell lines expressing TLR2, CD14, and the adapter protein MyD88 responded to amphotericin B with NF-kappaB-dependent reporter activity and cytokine release, whereas cells deficient in any of these failed to respond. Amphotericin B 114-128 MYD88 innate immune signal transduction adaptor Homo sapiens 95-100 12860979-6 2003 Cells mutated in TLR4 were less responsive to amphotericin B stimulation than cells expressing normal TLR4. Amphotericin B 46-60 toll like receptor 4 Homo sapiens 17-21 12860979-7 2003 These data demonstrate that TLR2 and CD14 are required for amphotericin B-dependent inflammatory stimulation of innate immune cells and that TLR4 may also provide stimulation of these cells. Amphotericin B 59-73 toll like receptor 2 Homo sapiens 28-32 12860979-7 2003 These data demonstrate that TLR2 and CD14 are required for amphotericin B-dependent inflammatory stimulation of innate immune cells and that TLR4 may also provide stimulation of these cells. Amphotericin B 59-73 CD14 molecule Homo sapiens 37-41 12801357-4 2003 A significant increase in the renal excretion of NAG, GRS, AAP and GGT occurred after the first day of amphotericin B treatment and continued until the fourth day. Amphotericin B 103-117 O-GlcNAcase Rattus norvegicus 49-52 12801357-4 2003 A significant increase in the renal excretion of NAG, GRS, AAP and GGT occurred after the first day of amphotericin B treatment and continued until the fourth day. Amphotericin B 103-117 glucuronidase, beta Rattus norvegicus 54-57 12801357-4 2003 A significant increase in the renal excretion of NAG, GRS, AAP and GGT occurred after the first day of amphotericin B treatment and continued until the fourth day. Amphotericin B 103-117 gamma-glutamyltransferase 1 Rattus norvegicus 67-70 12801357-3 2003 Application of amphotericin B induced a significant higher daily urinary enzyme activity of the renal tubular enzymes N-acetyl-beta-glucosaminidase (NAG), beta-glucuronidase (GRS), alanine-aminopeptidase (AAP) and gamma-glutamyltransferase (GGT) in comparison with controls and sodium deoxycholate treated animals as well. Amphotericin B 15-29 O-GlcNAcase Rattus norvegicus 149-152 12801357-3 2003 Application of amphotericin B induced a significant higher daily urinary enzyme activity of the renal tubular enzymes N-acetyl-beta-glucosaminidase (NAG), beta-glucuronidase (GRS), alanine-aminopeptidase (AAP) and gamma-glutamyltransferase (GGT) in comparison with controls and sodium deoxycholate treated animals as well. Amphotericin B 15-29 glucuronidase, beta Rattus norvegicus 155-173 12801357-3 2003 Application of amphotericin B induced a significant higher daily urinary enzyme activity of the renal tubular enzymes N-acetyl-beta-glucosaminidase (NAG), beta-glucuronidase (GRS), alanine-aminopeptidase (AAP) and gamma-glutamyltransferase (GGT) in comparison with controls and sodium deoxycholate treated animals as well. Amphotericin B 15-29 glucuronidase, beta Rattus norvegicus 175-178 12801357-3 2003 Application of amphotericin B induced a significant higher daily urinary enzyme activity of the renal tubular enzymes N-acetyl-beta-glucosaminidase (NAG), beta-glucuronidase (GRS), alanine-aminopeptidase (AAP) and gamma-glutamyltransferase (GGT) in comparison with controls and sodium deoxycholate treated animals as well. Amphotericin B 15-29 gamma-glutamyltransferase 1 Rattus norvegicus 214-239 12801357-3 2003 Application of amphotericin B induced a significant higher daily urinary enzyme activity of the renal tubular enzymes N-acetyl-beta-glucosaminidase (NAG), beta-glucuronidase (GRS), alanine-aminopeptidase (AAP) and gamma-glutamyltransferase (GGT) in comparison with controls and sodium deoxycholate treated animals as well. Amphotericin B 15-29 gamma-glutamyltransferase 1 Rattus norvegicus 241-244 12741430-6 2003 MEASUREMENTS AND MAIN RESULTS: Toxicity of the amphotericin B formulations were assessed by measuring interleukin (IL)-1beta expression in an in vitro model. Amphotericin B 47-61 interleukin 1 beta Homo sapiens 102-124 12741430-10 2003 Amphotericin B content of Sigma, Pharmacia, Pharma-Tek, and Gensia formulations, as measured by ELISA, was increased approximately 450%, 200%, 200%, and 100%, respectively, compared with Apothecon. Amphotericin B 0-14 TEK receptor tyrosine kinase Homo sapiens 51-54 12672504-3 2003 In the present study, we measured the activation of cyclooxygenase-2 (COX-2) and subsequent release of prostaglandin E-2 (PgE-2) from brain microvessel endothelium treated with these three formulations of amphotericin-B. Amphotericin B 205-219 prostaglandin-endoperoxide synthase 2 Bos taurus 52-68 12672504-10 2003 Furthermore, PgE-2 release following exposure of BBMEC monolayers to either LPS or the various amphotericin-B formulations was reduced by the addition of the selective COX-2 inhibitor, NS-398. Amphotericin B 95-109 prostaglandin-endoperoxide synthase 2 Bos taurus 168-173 12672504-11 2003 These studies indicate that amphotericin-B induces COX-2 expression in brain microvessel endothelium resulting in release of fever producing PgE-2. Amphotericin B 28-42 prostaglandin-endoperoxide synthase 2 Bos taurus 51-56 12672504-12 2003 The magnitude of PgE-2 release from BBMEC following exposure to various amphotericin-B formulations mirrors the clinical observations regarding amphotericin-B induced fever and serves as initial support for the clinical use of COX-2 inhibitors to reduce amphotericin-B fever. Amphotericin B 72-86 prostaglandin-endoperoxide synthase 2 Bos taurus 227-232 12503936-1 2003 OBJECTIVE: To report the development of nephrogenic diabetes insipidus (NDI) associated with the use of high-dose liposomal amphotericin B. Amphotericin B 124-138 arginine vasopressin receptor 2 Homo sapiens 72-75 12935435-1 2003 PURPOSE: The objective of this study was to evaluate therapeutic and haemolytic effects of liposomal preparation derived from proliposome entrapping inclusion complex of amphotericin B (AmB) with the chemically modified beta-cyclodextrin (beta-CD). Amphotericin B 170-184 beta-carotene oxygenase 1 Mus musculus 239-246 12935435-1 2003 PURPOSE: The objective of this study was to evaluate therapeutic and haemolytic effects of liposomal preparation derived from proliposome entrapping inclusion complex of amphotericin B (AmB) with the chemically modified beta-cyclodextrin (beta-CD). Amphotericin B 186-189 beta-carotene oxygenase 1 Mus musculus 239-246 12935435-9 2003 CONCLUSIONS: the results of these experiments permitted us to conclude that the stabilization of liposome derived from proliposome entrapping inclusion complex of amphotericin B (AmB) with beta-CD could serve an alternative approach to enhance the therapeutic window of AmB in clinical medicine. Amphotericin B 163-177 beta-carotene oxygenase 1 Mus musculus 189-196 12935435-9 2003 CONCLUSIONS: the results of these experiments permitted us to conclude that the stabilization of liposome derived from proliposome entrapping inclusion complex of amphotericin B (AmB) with beta-CD could serve an alternative approach to enhance the therapeutic window of AmB in clinical medicine. Amphotericin B 179-182 beta-carotene oxygenase 1 Mus musculus 189-196 12935435-9 2003 CONCLUSIONS: the results of these experiments permitted us to conclude that the stabilization of liposome derived from proliposome entrapping inclusion complex of amphotericin B (AmB) with beta-CD could serve an alternative approach to enhance the therapeutic window of AmB in clinical medicine. Amphotericin B 270-273 beta-carotene oxygenase 1 Mus musculus 189-196 12562711-0 2003 Heat-induced superaggregation of amphotericin B attenuates its ability to induce cytokine and chemokine production in the human monocytic cell line THP-1. Amphotericin B 33-47 GLI family zinc finger 2 Homo sapiens 148-153 12562711-2 2003 AmB-DOC produced dose-dependent increases in interleukin (IL)-1beta, IL-1alpha, tumour necrosis factor-alpha, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta at 2 h. HT-AmB induced cytokine and chemokine production at a lower level than those observed with corresponding concentrations of AmB-DOC, while retaining antifungal activity. Amphotericin B 0-3 interleukin 1 alpha Homo sapiens 69-78 12562711-2 2003 AmB-DOC produced dose-dependent increases in interleukin (IL)-1beta, IL-1alpha, tumour necrosis factor-alpha, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta at 2 h. HT-AmB induced cytokine and chemokine production at a lower level than those observed with corresponding concentrations of AmB-DOC, while retaining antifungal activity. Amphotericin B 0-3 C-C motif chemokine ligand 3 Homo sapiens 110-154 12562711-2 2003 AmB-DOC produced dose-dependent increases in interleukin (IL)-1beta, IL-1alpha, tumour necrosis factor-alpha, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta at 2 h. HT-AmB induced cytokine and chemokine production at a lower level than those observed with corresponding concentrations of AmB-DOC, while retaining antifungal activity. Amphotericin B 0-3 C-C motif chemokine ligand 4 Homo sapiens 159-168 12505158-2 2003 Functional characterization of chicken P2X1 receptors was performed using the amphotericin B perforated patch configuration to avoid the current run-down observed under whole-cell patch-clamp conditions. Amphotericin B 78-92 purinergic receptor P2X 1 Gallus gallus 39-43 12503936-8 2003 The most likely etiology for the NDI was liposomal amphotericin B and its associated hypokalemia. Amphotericin B 51-65 arginine vasopressin receptor 2 Homo sapiens 33-36 12503936-11 2003 The Naranjo probability scale classified this as a possible adverse reaction because of the temporal sequence of NDI after high-dose liposomal amphotericin B and previously reported cases of NDI associated with amphotericin B desoxycholate. Amphotericin B 143-157 arginine vasopressin receptor 2 Homo sapiens 113-116 12445856-8 2002 This review examines the current understanding of the relationship between CETP activity and the lipoprotein distribution of a number of compounds (e.g. amphotericin B and cyclosporine A). Amphotericin B 153-167 cholesteryl ester transfer protein Homo sapiens 75-79 12460998-3 2002 In an effort to identify additional AMB-responsive genes, the gene expression profiles of both THP-1 cells and human peripheral blood mononuclear cells (hPBMCs) on exposure to AMB were assessed using cDNA microarray analysis. Amphotericin B 36-39 GLI family zinc finger 2 Homo sapiens 95-100 12460998-5 2002 Increases in MIP-1 alpha and MIP-1 beta were also observed in the supernatants of hPBMCs exposed to AMB. Amphotericin B 100-103 C-C motif chemokine ligand 3 Homo sapiens 13-24 12460998-5 2002 Increases in MIP-1 alpha and MIP-1 beta were also observed in the supernatants of hPBMCs exposed to AMB. Amphotericin B 100-103 C-C motif chemokine ligand 4 Homo sapiens 29-39 12237341-0 2002 Revisiting an old antimicrobial drug: amphotericin B induces interleukin-1-converting enzyme as the main factor for inducible nitric-oxide synthase expression in activated endothelia. Amphotericin B 38-52 nitric oxide synthase 2 Homo sapiens 116-147 12364555-4 2002 We have developed and implemented an amphotericin B-mediated cytotoxicity assay to screen for potential therapeutic drugs that induce cholesterol movement in cultured NPC cells. Amphotericin B 37-51 NPC intracellular cholesterol transporter 1 Homo sapiens 167-170 12455841-13 2002 Our results demonstrate that amphotericin B-induced arthritis in a single joint gives rise to a systemic acute phase response measurable as increased concentrations in serum SAA, haptoglobin, fibrinogen and alpha2-globulins during the first 2 weeks of the condition and, thereby, that such an increase need not be indicative of infectious arthritis. Amphotericin B 29-43 serum amyloid A protein Equus caballus 174-177 12455841-13 2002 Our results demonstrate that amphotericin B-induced arthritis in a single joint gives rise to a systemic acute phase response measurable as increased concentrations in serum SAA, haptoglobin, fibrinogen and alpha2-globulins during the first 2 weeks of the condition and, thereby, that such an increase need not be indicative of infectious arthritis. Amphotericin B 29-43 haptoglobin Equus caballus 179-190 12364555-5 2002 NPC cells are relatively resistant to amphotericin B killing due to intracellular sequestration of cellular cholesterol. Amphotericin B 38-52 NPC intracellular cholesterol transporter 1 Homo sapiens 0-3 12237341-1 2002 We have investigated the impact of the widely used antifungal agent Amphotericin B (AmB) on cytokine activated aortic endothelial cells (AEC) and their inflammatory response as monitored by cytokine and inducible nitric-oxide synthase (iNOS) expression as well as high-output nitric oxide synthesis. Amphotericin B 68-82 nitric oxide synthase 2 Homo sapiens 203-234 12364555-7 2002 A library of 44240 compounds was screened and 55 compounds were identified that promote amphotericin B-mediated killing of NPC cells. Amphotericin B 88-102 NPC intracellular cholesterol transporter 1 Homo sapiens 123-126 12237341-1 2002 We have investigated the impact of the widely used antifungal agent Amphotericin B (AmB) on cytokine activated aortic endothelial cells (AEC) and their inflammatory response as monitored by cytokine and inducible nitric-oxide synthase (iNOS) expression as well as high-output nitric oxide synthesis. Amphotericin B 68-82 nitric oxide synthase 2 Homo sapiens 236-240 12237341-1 2002 We have investigated the impact of the widely used antifungal agent Amphotericin B (AmB) on cytokine activated aortic endothelial cells (AEC) and their inflammatory response as monitored by cytokine and inducible nitric-oxide synthase (iNOS) expression as well as high-output nitric oxide synthesis. Amphotericin B 84-87 nitric oxide synthase 2 Homo sapiens 203-234 12237341-1 2002 We have investigated the impact of the widely used antifungal agent Amphotericin B (AmB) on cytokine activated aortic endothelial cells (AEC) and their inflammatory response as monitored by cytokine and inducible nitric-oxide synthase (iNOS) expression as well as high-output nitric oxide synthesis. Amphotericin B 84-87 nitric oxide synthase 2 Homo sapiens 236-240 11796331-3 2002 Against the infection in CDF(1) mice, treatment with 10 mg of TAK-457 and 1 mg of amphotericin B/kg reduced the fungal burden in lungs and rescued all mice. Amphotericin B 82-96 mitogen-activated protein kinase kinase kinase 7 Mus musculus 62-75 12003965-0 2002 A sub-inhibitory concentration of amphotericin B enhances candidastatic activity of interferon-gamma- and interleukin-13-treated murine peritoneal macrophages. Amphotericin B 34-48 interferon gamma Mus musculus 84-100 12003965-0 2002 A sub-inhibitory concentration of amphotericin B enhances candidastatic activity of interferon-gamma- and interleukin-13-treated murine peritoneal macrophages. Amphotericin B 34-48 interleukin 13 Mus musculus 106-120 12003965-9 2002 Amphotericin B associated with IL-13 or IFN-gamma, but not with IL-4, enhanced the yeast growth inhibition activity of macrophages. Amphotericin B 0-14 interleukin 13 Mus musculus 31-36 12003965-9 2002 Amphotericin B associated with IL-13 or IFN-gamma, but not with IL-4, enhanced the yeast growth inhibition activity of macrophages. Amphotericin B 0-14 interferon gamma Mus musculus 40-49 12003965-10 2002 The ROIs were involved in the additive effect of IFN-gamma with amphotericin B, whereas another mechanism was implicated in the increase of candidastatic activity of macrophages treated with IL-13 in association with amphotericin B. Amphotericin B 64-78 interferon gamma Mus musculus 49-58 12003965-10 2002 The ROIs were involved in the additive effect of IFN-gamma with amphotericin B, whereas another mechanism was implicated in the increase of candidastatic activity of macrophages treated with IL-13 in association with amphotericin B. Amphotericin B 217-231 interleukin 13 Mus musculus 191-196 12014897-16 2002 There are several specific risk factors for particular NAC species: C. parapsilosis is related to foreign body insertion, neonates and hyperalimentation; C. krusei to azole prophylaxis and along with C. tropicalis to neutropenia and BMT; C. glabrata to azole prophylaxis, surgery and urinary or vascular catheters; C. lusitaniae and C. guilliermondii to previous polyene (amphotericin B or nystatin) use; and C. rugosa to burns. Amphotericin B 372-386 synuclein alpha Homo sapiens 55-58 12005097-2 2002 The diagnosis was confirmed as a gp91phox defect by genetic analysis, and the patient was managed with broad spectrum antibacterial agents, gamma-interferon and later amphotericin B. Amphotericin B 167-181 cytochrome b-245 beta chain Homo sapiens 33-41 11585052-7 2001 Finally, amphotericin B, which is widely used as an antifungal drug, was shown to form a complex with LTP1, although no affinity could be determined. Amphotericin B 9-23 non-specific lipid-transfer protein 4.1 Triticum aestivum 102-106 11861661-6 2002 Finally, the resistance of NPC cells to lysis by amphotericin B was shown not to reflect a reduction in plasma membrane cholesterol arising from a block in lysosomal cholesterol export but rather the diversion of the amphotericin B to cholesterol-rich endolysosomes. Amphotericin B 49-63 NPC intracellular cholesterol transporter 1 Homo sapiens 27-30 11714599-2 2001 In vitro bioassay studies have shown that these fungicidal lipidic derivatives possess strong antifungal activity against Candida spp resistant strains to amphotericin B, 5-fluorocytosine and azoles. Amphotericin B 155-169 histocompatibility minor 13 Homo sapiens 130-133 11751145-0 2002 In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Amphotericin B 36-50 histocompatibility minor 13 Homo sapiens 84-87 11756198-0 2002 Liposomal amphotericin B (AmBisome) compared with amphotericin B +/- FMLP induces significantly less in vitro neutrophil aggregation with granulocyte-colony-stimulating factor/dexamethasone-mobilized allogeneic donor neutrophils. Amphotericin B 10-24 colony stimulating factor 3 Homo sapiens 138-175 11574818-0 2001 Amphotericin B decreases adenylyl cyclase activity and aquaporin-2 expression in rat kidney. Amphotericin B 0-14 aquaporin 2 Rattus norvegicus 55-66 11574818-11 2001 These findings indicate that the amphotericin-induced urinary concentration defect may in part be causally related to a reduced abundance of AQP2 channels in the kidney. Amphotericin B 33-45 aquaporin 2 Rattus norvegicus 141-145 11683244-0 2001 The effect of serum albumin on amphotericin B aggregate structure and activity. Amphotericin B 31-45 albumin Homo sapiens 14-27 11494409-2 2001 AMB caused a dose-dependent increase of NO generation in interferon-gamma (IFN-gamma)-stimulated rat and mouse astrocytes, as well as in IFN-gamma + tumor necrosis factor-alpha (TNF-alpha)-activated rat astrocytoma cell line C6. Amphotericin B 0-3 interferon gamma Rattus norvegicus 57-73 11494409-2 2001 AMB caused a dose-dependent increase of NO generation in interferon-gamma (IFN-gamma)-stimulated rat and mouse astrocytes, as well as in IFN-gamma + tumor necrosis factor-alpha (TNF-alpha)-activated rat astrocytoma cell line C6. Amphotericin B 0-3 interferon gamma Rattus norvegicus 75-84 11494409-2 2001 AMB caused a dose-dependent increase of NO generation in interferon-gamma (IFN-gamma)-stimulated rat and mouse astrocytes, as well as in IFN-gamma + tumor necrosis factor-alpha (TNF-alpha)-activated rat astrocytoma cell line C6. Amphotericin B 0-3 interferon gamma Mus musculus 137-176 11494409-2 2001 AMB caused a dose-dependent increase of NO generation in interferon-gamma (IFN-gamma)-stimulated rat and mouse astrocytes, as well as in IFN-gamma + tumor necrosis factor-alpha (TNF-alpha)-activated rat astrocytoma cell line C6. Amphotericin B 0-3 tumor necrosis factor Mus musculus 178-187 11494409-7 2001 AMB toxicity toward IFN-gamma-stimulated astrocytes was dependent on both AMB and NO action, since AMB and NO-releasing substance SNP synergized in inducing astrocyte mitochondrial dysfunction. Amphotericin B 0-3 interferon gamma Rattus norvegicus 20-29 11477563-7 2001 Amphotericin B (3.2 micromol/L) combined with bumetanide (100 micromol/L) potentiated cisplatin-induced free nucleosome and caspase-3 activity. Amphotericin B 0-14 caspase 3 Homo sapiens 124-133 11477563-9 2001 The caspase inhibitor Boc-D-FMK, but unexpectedly also bumetanide, markedly reduced cisplatin cytotoxicity and annihilated the augmented cytotoxicity of cisplatin in the presence of amphotericin B. Amphotericin B 182-196 BOC cell adhesion associated, oncogene regulated Homo sapiens 22-25 11451704-0 2001 Influence of liposomal amphotericin B on CD8 T-cell function. Amphotericin B 23-37 CD8a molecule Homo sapiens 41-44 11451704-1 2001 Liposomal amphotericin B was immunosuppressive on target cell lysis in vitro and on protection mediated by cytotoxic CD8 T cells in murine listeriosis. Amphotericin B 10-24 CD8a molecule Homo sapiens 117-120 11465810-6 2001 The authors propose that in amphotericin B-induced partial nephrogenic diabetes insipidus, pharmacological doses of antidiuretic hormone may offer an additional benefit to commonly used diuretic therapy. Amphotericin B 28-42 arginine vasopressin Homo sapiens 116-136 11545558-5 2001 With amphotericin B treatment, the patient is well with normalization of erythrocyte sedimentation rate and C-reactive protein. Amphotericin B 5-19 C-reactive protein Homo sapiens 108-126 11181343-13 2001 These results indicate that IFN-gamma has therapeutic efficacy in severely immunodeficient animals, especially in combination with AmB. Amphotericin B 131-134 interferon gamma Mus musculus 28-37 11158754-0 2001 Reduction of no synthase expression and tumor necrosis factor alpha production in macrophages by amphotericin B lipid carriers. Amphotericin B 97-111 tumor necrosis factor Mus musculus 40-67 11158754-1 2001 The present study compared the abilities of different lipid carriers of amphotericin B (AMB) to activate murine peritoneal macrophages, as assessed by their capacities to produce nitric oxide (NO) and tumor necrosis factor alpha (TNF-alpha). Amphotericin B 72-86 tumor necrosis factor Mus musculus 201-228 11158754-1 2001 The present study compared the abilities of different lipid carriers of amphotericin B (AMB) to activate murine peritoneal macrophages, as assessed by their capacities to produce nitric oxide (NO) and tumor necrosis factor alpha (TNF-alpha). Amphotericin B 72-86 tumor necrosis factor Mus musculus 230-239 11158754-1 2001 The present study compared the abilities of different lipid carriers of amphotericin B (AMB) to activate murine peritoneal macrophages, as assessed by their capacities to produce nitric oxide (NO) and tumor necrosis factor alpha (TNF-alpha). Amphotericin B 88-91 tumor necrosis factor Mus musculus 201-228 11158754-6 2001 The incorporation of AMB into lipid carriers reduced NO and TNF-alpha production with all formulations but more so with liposomes than with lipid complexes. Amphotericin B 21-24 tumor necrosis factor Mus musculus 60-69 11349055-0 2001 Lactoferrin peptide increases the survival of Candida albicans-inoculated mice by upregulating neutrophil and macrophage functions, especially in combination with amphotericin B and granulocyte-macrophage colony-stimulating factor. Amphotericin B 163-177 lactotransferrin Mus musculus 0-11 11157903-6 2001 The efficacy of SPA-S-753 is between equivalent and <10-fold as potent as amphotericin B. Amphotericin B 77-91 surfactant associated protein A1 Mus musculus 16-19 11169461-6 2001 Experiments using amphotericin B-permeabilized monolayers demonstrated that EGF inhibited Na transport by decreasing apical membrane Na conductance without affecting insulin-dependent stimulation of the Na+-K+ ATPase. Amphotericin B 18-32 epidermal growth factor Homo sapiens 76-79 11160513-12 2001 In amphotericin-perforated patches bradykinin (1 microM) activated TEA-sensitive currents that were abolished by preincubation with bis-(o-aminophenoxy)-N,N,N",N"-tetraacetic acid-AM (BAPTA-AM). Amphotericin B 3-15 kininogen 1 Homo sapiens 35-45 11254642-3 2001 Treatment with AmB, SP-D, and rSP-D increased the survival rate to 80, 60, and 80%, respectively, suggesting that SP-D (and rSP-D) can protect immunosuppressed mice from an otherwise fatal challenge with Aspergillus fumigatus conidia. Amphotericin B 15-18 surfactant protein D Rattus norvegicus 124-129 11083636-7 2000 When combined with a suboptimal amount of amphotericin B, GM-CSF enhanced survival of normal or T-cell-depleted mice given a lethal challenge. Amphotericin B 42-56 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 58-64 11015297-3 2000 AmB used at concentrations of 0.6 to 1.25 microg ml(-1) led to increases in ecNOS mRNA and protein expression as well as NO production. Amphotericin B 0-3 nitric oxide synthase 3 Homo sapiens 76-81 11169529-0 2001 Heat-induced superaggregation of amphotericin B modifies its interaction with serum proteins and lipoproteins and stimulation of TNF-alpha. Amphotericin B 33-47 tumor necrosis factor Homo sapiens 129-138 11035737-5 2000 These results for a model of visceral infection indicate that endogenous TNF is required early on to control intracellular L. donovani, support granuloma development, and mediate optimal initial effects of Sb and prevent relapse after ordinarily curative AmB treatment. Amphotericin B 255-258 tumor necrosis factor Mus musculus 73-76 11015297-5 2000 In contrast, incubation of cells with higher albeit subtoxic concentrations of AmB (2.5 - 5.0 microg ml(-1)) resulted in a decrease or respectively in completely abolished ecNOS mRNA and protein expression with a strongly reduced or inhibited ecNOS activity, due to a decrease of ecNOS mRNA half-life. Amphotericin B 79-82 nitric oxide synthase 3 Homo sapiens 172-177 11015297-5 2000 In contrast, incubation of cells with higher albeit subtoxic concentrations of AmB (2.5 - 5.0 microg ml(-1)) resulted in a decrease or respectively in completely abolished ecNOS mRNA and protein expression with a strongly reduced or inhibited ecNOS activity, due to a decrease of ecNOS mRNA half-life. Amphotericin B 79-82 nitric oxide synthase 3 Homo sapiens 243-248 11015297-5 2000 In contrast, incubation of cells with higher albeit subtoxic concentrations of AmB (2.5 - 5.0 microg ml(-1)) resulted in a decrease or respectively in completely abolished ecNOS mRNA and protein expression with a strongly reduced or inhibited ecNOS activity, due to a decrease of ecNOS mRNA half-life. Amphotericin B 79-82 nitric oxide synthase 3 Homo sapiens 243-248 10979935-0 2000 Amphotericin B induces expression of genes encoding chemokines and cell adhesion molecules in the human monocytic cell line THP-1. Amphotericin B 0-14 GLI family zinc finger 2 Homo sapiens 124-129 10979935-4 2000 The present study demonstrates that amphotericin B increases mRNA for the chemokines interleukin (IL)-8, monocyte chemoattractant protein (MCP)-1, and macrophage inflammatory protein (MIP)-1beta, as well as the cell adhesion molecules intercellular adhesion molecule (ICAM)-1 and CD44 in the human monocytic cell line THP-1. Amphotericin B 36-50 C-X-C motif chemokine ligand 8 Homo sapiens 85-103 10979935-4 2000 The present study demonstrates that amphotericin B increases mRNA for the chemokines interleukin (IL)-8, monocyte chemoattractant protein (MCP)-1, and macrophage inflammatory protein (MIP)-1beta, as well as the cell adhesion molecules intercellular adhesion molecule (ICAM)-1 and CD44 in the human monocytic cell line THP-1. Amphotericin B 36-50 C-C motif chemokine ligand 2 Homo sapiens 105-145 10979935-4 2000 The present study demonstrates that amphotericin B increases mRNA for the chemokines interleukin (IL)-8, monocyte chemoattractant protein (MCP)-1, and macrophage inflammatory protein (MIP)-1beta, as well as the cell adhesion molecules intercellular adhesion molecule (ICAM)-1 and CD44 in the human monocytic cell line THP-1. Amphotericin B 36-50 C-C motif chemokine ligand 4 Homo sapiens 151-194 10979935-4 2000 The present study demonstrates that amphotericin B increases mRNA for the chemokines interleukin (IL)-8, monocyte chemoattractant protein (MCP)-1, and macrophage inflammatory protein (MIP)-1beta, as well as the cell adhesion molecules intercellular adhesion molecule (ICAM)-1 and CD44 in the human monocytic cell line THP-1. Amphotericin B 36-50 CD44 molecule (Indian blood group) Homo sapiens 280-284 10979935-4 2000 The present study demonstrates that amphotericin B increases mRNA for the chemokines interleukin (IL)-8, monocyte chemoattractant protein (MCP)-1, and macrophage inflammatory protein (MIP)-1beta, as well as the cell adhesion molecules intercellular adhesion molecule (ICAM)-1 and CD44 in the human monocytic cell line THP-1. Amphotericin B 36-50 GLI family zinc finger 2 Homo sapiens 318-323 10979935-5 2000 Amphotericin B increased the concentrations of IL-8, MCP-1, and MIP-1beta in a dose-dependent fashion. Amphotericin B 0-14 C-X-C motif chemokine ligand 8 Homo sapiens 47-51 10979935-5 2000 Amphotericin B increased the concentrations of IL-8, MCP-1, and MIP-1beta in a dose-dependent fashion. Amphotericin B 0-14 C-C motif chemokine ligand 2 Homo sapiens 53-58 10979935-5 2000 Amphotericin B increased the concentrations of IL-8, MCP-1, and MIP-1beta in a dose-dependent fashion. Amphotericin B 0-14 C-C motif chemokine ligand 4 Homo sapiens 64-73 10979935-6 2000 Amphotericin B also induced expression of ICAM-1 but not CD44 in these cells. Amphotericin B 0-14 intercellular adhesion molecule 1 Homo sapiens 42-48 10708429-4 2000 Polyene antibiotics such as amphotericin B have been shown to delay the accumulation of PrP(Sc) and to increase the incubation time of the disease after experimental transmission in laboratory animals. Amphotericin B 28-42 prion protein Mus musculus 88-91 10980171-4 2000 IFN-gamma alone was modestly effective, but impressively and significantly potentiated amphotericin in reducing infection in the most important site of infection, the brain. Amphotericin B 87-99 interferon gamma Mus musculus 0-9 11204768-0 2000 Synergistic effects of low doses of histatin 5 and its analogues on amphotericin B anti-mycotic activity. Amphotericin B 68-82 histatin 3 Homo sapiens 36-46 11204768-5 2000 In contrast, strong synergism of amphotericin B with the peptides was found against several Aspergillus, Candida, and Cryptococcus strains, and against an amphotericin B-resistant C. albicans laboratory mutant in the standardised broth microdilution assays according to the NCCLS standard method M27-T. Amphotericin B showed synergism with dhvar5, another designed analogue of histatin 5, and with magainin 2 against all seven tested strains. Amphotericin B 33-47 histatin 3 Homo sapiens 377-387 10817741-2 2000 The MIC of FK463 was lower than those of azoles and amphotericin B against CDR1-expressing C26 and CaMDR-expressing C40 strains. Amphotericin B 52-66 cerebellar degeneration related antigen 1 Mus musculus 75-79 10905554-2 2000 AMA, a derivative of the polyene antibiotic amphotericin B, formed a stable complex when mixed with phosphodiester oligodeoxynucleotides and enhanced the intracellular uptake of a 5" fluoresceinated anti-mdr1 20-mer into NIH-MDR-G185 cells. Amphotericin B 44-58 ATP binding cassette subfamily B member 1 Homo sapiens 204-208 10708429-6 2000 We show here for the first time that amphotericin B can inhibit PrP(Sc) generation in scrapie-infected GT1-7 and N2a cells. Amphotericin B 37-51 prion protein Mus musculus 64-67 11208118-3 2000 Treatment of MDCK epithelial cells with acute high doses or chronic low doses of AmphB caused a loss of surface caveolae and the rapid redistribution of cav-1, and exogenously expressed cav-3, from the cell surface into modified endosomes. Amphotericin B 81-86 caveolin 1 Canis lupus familiaris 153-158 11208118-3 2000 Treatment of MDCK epithelial cells with acute high doses or chronic low doses of AmphB caused a loss of surface caveolae and the rapid redistribution of cav-1, and exogenously expressed cav-3, from the cell surface into modified endosomes. Amphotericin B 81-86 caveolin 3 Canis lupus familiaris 186-191 11208118-5 2000 In differentiating C2C12 mouse myotubes, AmphB also caused a complete redistribution of cav-3 from precursor T-tubule elements into enlarged endosomes, morphologically very similar to those seen in MDCK cells. Amphotericin B 41-46 caveolin 3 Mus musculus 88-93 10662479-13 1999 Sensitivity analyses demonstrated that the addition of G-CSF to conventional amphotericin B in the treatment of a presumed deep-seated fungal infection offers not only clinical benefits, but cost benefits which are robust to changes in clinical and economic parameters. Amphotericin B 77-91 colony stimulating factor 3 Homo sapiens 55-60 10602717-4 2000 The activities of peritoneal macrophages and neutrophils from mice administered hM-CSF plus AMPH-B in combination for inhibition of hyphal growth of C. albicans cells and intracellular phagocytosis and killing of the cells were greater than those of comparable phagocytic cells from control mice to which hM-CSF plus AMPH-B was not administered. Amphotericin B 92-98 colony stimulating factor 1 Homo sapiens 305-311 10602717-5 2000 These results suggest that intravenous administration of hM-CSF augments the efficacy of AMPH-B by enhancing the antifungal activities of macrophages and neutrophils. Amphotericin B 89-95 colony stimulating factor 1 Homo sapiens 57-63 10602717-6 2000 Therefore, it is expected that therapy with the combination AMPH-B and hM-CSF could improve the efficacy of AMPH-B and reduce the therapeutic dose of the antifungal drug that is required. Amphotericin B 108-114 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 74-77 10602733-8 2000 Sodium deoxycholate (the vehicle of AmB) by itself induced a significant decline of 5-hydroxy-propafenone and N-desalkyl-propafenone production, while microsomal cytochrome P-450 concentrations remained unchanged. Amphotericin B 36-39 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 162-178 10564063-8 1999 However, the majority of AmpB was recovered in the HDL3 fraction following the incubation of ABLC. Amphotericin B 25-29 HDL3 Homo sapiens 51-55 10646527-4 2000 Polyene antibiotics, such as amphotericin B, have been shown to delay the accumulation of PrP(Sc) and to increase the incubation time of the disease after experimental transmission in laboratory animals. Amphotericin B 29-43 prion protein Mus musculus 90-93 10646527-5 2000 Unlike agents such as Congo red, the inhibitory effect of amphotericin B on PrP(Sc) generation has not been observed in infected cultures. Amphotericin B 58-72 prion protein Mus musculus 76-79 10646527-6 2000 Using transfected cells expressing wild-type or mutated mouse PrPs, we show here that amphotericin B is able to interfere with the generation of abnormal PrP isoforms in culture. Amphotericin B 86-100 prion protein Mus musculus 62-65 10602717-3 2000 Furthermore, the therapeutic efficacy of amphotericin B (AMPH-B) in infected mice was enhanced by its combined use with hM-CSF, while that of fluconazole (FLCZ) was not. Amphotericin B 41-55 colony stimulating factor 1 Homo sapiens 120-126 10602717-3 2000 Furthermore, the therapeutic efficacy of amphotericin B (AMPH-B) in infected mice was enhanced by its combined use with hM-CSF, while that of fluconazole (FLCZ) was not. Amphotericin B 57-63 colony stimulating factor 1 Homo sapiens 120-126 10603400-6 2000 In contrast to Sb, amphotericin B (AmB) induced high-level killing in GKO mice; AmB was also fully active in iNOS KO and X-CGD animals. Amphotericin B 80-83 nitric oxide synthase 2, inducible Mus musculus 109-113 10603400-7 2000 Although resolution of L. donovani infection requires iNOS, residual visceral infection remained largely suppressed in iNOS KO mice treated with Sb or AmB. Amphotericin B 151-154 nitric oxide synthase 2, inducible Mus musculus 119-123 10603400-10 2000 Treatment with either Sb or AmB permits an iNOS-independent mechanism to emerge and control residual intracellular L. donovani infection. Amphotericin B 28-31 nitric oxide synthase 2, inducible Mus musculus 43-47 11200380-1 2000 Twelve immunocompetent adults with Mediterranean visceral leishmaniasis (VL) were treated with amphotericin B colloidal dispersion (ABCD; 2 mg/kg/d for 7 d). Amphotericin B 95-109 ATP binding cassette subfamily D member 2 Homo sapiens 132-139 10479156-0 1999 Amphotericin B-induced interleukin-1beta expression in human monocytic cells is calcium and calmodulin dependent. Amphotericin B 0-14 interleukin 1 beta Homo sapiens 23-40 10479156-0 1999 Amphotericin B-induced interleukin-1beta expression in human monocytic cells is calcium and calmodulin dependent. Amphotericin B 0-14 calmodulin 1 Homo sapiens 92-102 10479156-3 1999 Amphotericin B-induced transcription and expression of interleukin (IL)-1beta by human monocytes is believed to be involved in mediating infusion-related adverse effects. Amphotericin B 0-14 interleukin 1 beta Homo sapiens 55-77 10479156-5 1999 Furthermore, amphotericin B-induced IL-1beta expression is attenuated by the calmodulin antagonist calmidazolium. Amphotericin B 13-27 interleukin 1 beta Homo sapiens 36-44 10479156-5 1999 Furthermore, amphotericin B-induced IL-1beta expression is attenuated by the calmodulin antagonist calmidazolium. Amphotericin B 13-27 calmodulin 1 Homo sapiens 77-87 10479156-6 1999 Amphotericin B 5.41 microM increases [Ca++]i by up to 300 nM in these cells. Amphotericin B 0-14 carbonic anhydrase 1 Homo sapiens 38-44 10479156-7 1999 In the presence of a nominal calcium buffer or EGTA, amphotericin B-induced IL-1beta expression is attenuated. Amphotericin B 53-67 interleukin 1 beta Homo sapiens 76-84 10479156-8 1999 Thus, amphotericin B acts as an ionophore to increase [Ca++]i and activates calmodulin-mediated expression of IL-1beta in human monocytes. Amphotericin B 6-20 carbonic anhydrase 1 Homo sapiens 55-61 10479156-8 1999 Thus, amphotericin B acts as an ionophore to increase [Ca++]i and activates calmodulin-mediated expression of IL-1beta in human monocytes. Amphotericin B 6-20 calmodulin 1 Homo sapiens 76-86 10479156-8 1999 Thus, amphotericin B acts as an ionophore to increase [Ca++]i and activates calmodulin-mediated expression of IL-1beta in human monocytes. Amphotericin B 6-20 interleukin 1 beta Homo sapiens 110-118 10440258-6 1999 The inhibitory effect of thrombin on ouabain-sensitive potassium (86Rb) uptake was suppressed in the presence of hirudin (an antagonist for thrombin receptors) but persisted in the presence of amphotericin B (a pseudo ionophore that effectively clamps plasma membrane sodium permeability at a high value). Amphotericin B 193-207 coagulation factor II, thrombin Homo sapiens 25-33 9815226-1 1998 Amphotericin B has been shown to cause release of cytokines, including interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha), from monocytes and macrophages. Amphotericin B 0-14 interleukin 1 beta Homo sapiens 71-88 10443532-5 1999 When present only during initial infection, AMB (3-20 microg/ml) reduced p24 levels by 70-80% after 7 and 10 days post-infection, while CD-AMB inhibited p24 production by approximately 30-40% at day 7 and 50-60% at day 10. Amphotericin B 44-47 transmembrane p24 trafficking protein 2 Homo sapiens 73-76 10074211-5 1999 The AmB effect against strain 263K was more prominent in mice whose endogenous PrP gene had been inactivated by homologous recombination. Amphotericin B 4-7 prion protein Mus musculus 79-82 10049295-1 1999 The present study shows that a number of basic antifungal peptides, including human salivary histatin 5, a designed histatin analog designated dhvar4, and a peptide from frog skin, PGLa, are active against amphotericin B-resistant Candida albicans, Candida krusei, and Aspergillus fumigatus strains and against a fluconazole-resistant Candida glabrata isolate. Amphotericin B 206-220 histatin 3 Homo sapiens 93-103 11399571-0 1999 Malignancy: Granulocyte Colony Stimulating Factor Increases the Efficacy of Conventional Amphotericin in the Treatment of Presumed Deep-Seated Fungal Infection in Neutropenic Patients following Intensive Chemotherapy or Bone Marrow Transplantation for Haematological Malignancies. Amphotericin B 89-101 colony stimulating factor 3 Homo sapiens 12-49 11399571-7 1999 Addition of granulocyte colony stimulating factor to empiric amphotericin B significantly reduced the number of patients requiring salvage therapy with lipid-associated or liposomal formulations of amphotericin B addition of granulocyte colony stimulating factor to empiric intravenous amphotericin B improves the response rate and thereby reduces the number of patients requiring salvage therapy with liposomal or lipid-associated preparations of amphotericin B. Amphotericin B 198-212 colony stimulating factor 3 Homo sapiens 12-49 11399571-7 1999 Addition of granulocyte colony stimulating factor to empiric amphotericin B significantly reduced the number of patients requiring salvage therapy with lipid-associated or liposomal formulations of amphotericin B addition of granulocyte colony stimulating factor to empiric intravenous amphotericin B improves the response rate and thereby reduces the number of patients requiring salvage therapy with liposomal or lipid-associated preparations of amphotericin B. Amphotericin B 198-212 colony stimulating factor 3 Homo sapiens 12-49 11399571-7 1999 Addition of granulocyte colony stimulating factor to empiric amphotericin B significantly reduced the number of patients requiring salvage therapy with lipid-associated or liposomal formulations of amphotericin B addition of granulocyte colony stimulating factor to empiric intravenous amphotericin B improves the response rate and thereby reduces the number of patients requiring salvage therapy with liposomal or lipid-associated preparations of amphotericin B. Amphotericin B 198-212 colony stimulating factor 3 Homo sapiens 12-49 10394017-2 1999 Amphotericin B Colloidal Dispersion (ABCD, AmphocilTM), a noncovalent complex of amphotericin B and cholesteryl sulfate, is active in vitro and in vivo against a wide variety of fungal species; its activity is broadly comparable to the range of activity of conventionally formulated amphotericin B (CAB). Amphotericin B 0-14 neural proliferation, differentiation and control 1 Homo sapiens 299-302 10394017-2 1999 Amphotericin B Colloidal Dispersion (ABCD, AmphocilTM), a noncovalent complex of amphotericin B and cholesteryl sulfate, is active in vitro and in vivo against a wide variety of fungal species; its activity is broadly comparable to the range of activity of conventionally formulated amphotericin B (CAB). Amphotericin B 81-95 neural proliferation, differentiation and control 1 Homo sapiens 299-302 9815226-1 1998 Amphotericin B has been shown to cause release of cytokines, including interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha), from monocytes and macrophages. Amphotericin B 0-14 interleukin 1 beta Homo sapiens 90-98 9815226-1 1998 Amphotericin B has been shown to cause release of cytokines, including interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha), from monocytes and macrophages. Amphotericin B 0-14 tumor necrosis factor Homo sapiens 104-131 9815226-1 1998 Amphotericin B has been shown to cause release of cytokines, including interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha), from monocytes and macrophages. Amphotericin B 0-14 tumor necrosis factor Homo sapiens 133-142 9815226-2 1998 Human and murine monocytic cell lines were used to evaluate the effects of amphotericin B on the transcription of IL-1alpha, IL-1beta, and TNF-alpha and the transcription and production of soluble IL-1 receptor antagonist (sIL-1Ra). Amphotericin B 75-89 interleukin 1 alpha Mus musculus 114-123 9815226-2 1998 Human and murine monocytic cell lines were used to evaluate the effects of amphotericin B on the transcription of IL-1alpha, IL-1beta, and TNF-alpha and the transcription and production of soluble IL-1 receptor antagonist (sIL-1Ra). Amphotericin B 75-89 tumor necrosis factor Mus musculus 139-148 9815226-3 1998 The effects of inhibitors of transcription and translation on amphotericin B-induced IL-1beta expression in a human monocytic cell line were also evaluated. Amphotericin B 62-76 interleukin 1 beta Homo sapiens 85-93 9593022-5 1998 In addition, antibody titers to rK39 in HIV-negative patients infected with L. infantum or L. chagasi declined during treatment with meglumine antimoniate or liposomal amphotericin B. Amphotericin B 168-182 keratin 39 Rattus norvegicus 32-36 9833996-2 1998 METHODS: AmB was encapsulated in dipalmitoylphosphatidylcholine/ cholesterol (DPPC/CH, 2:1) liposomes after complex formation with distearoyl-N-(monomethoxy poly(ethylene glycol)succinyl) phosphatidylethanolamine (DSPE-PEG). Amphotericin B 9-12 SUN domain containing ossification factor Homo sapiens 78-90 9818745-1 1998 Amphotericin B is an antifungal drug associated with side effects such as fever and chills, symptoms which may be mediated by pro-inflammatory cytokines such as interleukin-1beta (IL-1beta) and tumour necrosis factor-alpha (TNFalpha). Amphotericin B 0-14 interleukin 1 beta Homo sapiens 161-178 9818745-1 1998 Amphotericin B is an antifungal drug associated with side effects such as fever and chills, symptoms which may be mediated by pro-inflammatory cytokines such as interleukin-1beta (IL-1beta) and tumour necrosis factor-alpha (TNFalpha). Amphotericin B 0-14 interleukin 1 beta Homo sapiens 180-188 9818745-1 1998 Amphotericin B is an antifungal drug associated with side effects such as fever and chills, symptoms which may be mediated by pro-inflammatory cytokines such as interleukin-1beta (IL-1beta) and tumour necrosis factor-alpha (TNFalpha). Amphotericin B 0-14 tumor necrosis factor Homo sapiens 224-232 9818745-3 1998 The results of the present study show that amphotericin B slightly increased the production of pro-inflammatory cytokines by human mononuclear cells (PBMC), whereas the production of the anti-inflammatory cytokine IL-1ra was significantly inhibited. Amphotericin B 43-57 interleukin 1 receptor antagonist Homo sapiens 214-220 9716711-2 1998 Using amphotericin B perforated-patch recording of whole-cell currents, the Ca2+ channel current was inhibited by 28.4+/-6.4% by 400 nM ET-1, but was unaffected when experiments were repeated using the whole-cell, ruptured-patch configuration. Amphotericin B 6-20 endothelin 1 Rattus norvegicus 136-140 9556221-1 1998 The alteration in the fluorescence spectra observed for the polyene antibiotics: nystatin and amphotericin B in the presence of human serum albumin is due to a decrease in the polar character of the antibiotic environment when these are bound to the protein. Amphotericin B 94-108 albumin Homo sapiens 140-147 9490813-13 1998 Experiments with amphotericin B-permeabilized monolayers revealed that the apical PGE2-activated, NPPB- and glibenclamide-sensitive conductance was Cl- dependent and that the current-voltage relationship and anion permeation properties (SCN->Br- > Cl- > I-) were characteristic of the cystic fibrosis transmembrane conductance regulator (CFTR). Amphotericin B 17-31 CF transmembrane conductance regulator Homo sapiens 294-345 9490813-13 1998 Experiments with amphotericin B-permeabilized monolayers revealed that the apical PGE2-activated, NPPB- and glibenclamide-sensitive conductance was Cl- dependent and that the current-voltage relationship and anion permeation properties (SCN->Br- > Cl- > I-) were characteristic of the cystic fibrosis transmembrane conductance regulator (CFTR). Amphotericin B 17-31 CF transmembrane conductance regulator Homo sapiens 347-351 9338137-0 1997 Amphotericin B augments interleukin-6 production by human gingival fibroblasts in vitro. Amphotericin B 0-14 interleukin 6 Homo sapiens 24-37 9570555-7 1998 The ability of animals to survive a secondary infection in the absence of IFN-gamma was verified by showing that IFN-gamma(-/-) mice previously immunized with H. capsulatum and treated with amphotericin B at the time of primary infection had prolonged survival following reinfection with a normally lethal dose. Amphotericin B 190-204 interferon gamma Mus musculus 113-122 9323308-3 1997 Following amphotericin B plus deoxycholate application for day 1, ethoxycoumarin-O-deethylase activity decrease significantly whereas microsomal cytochrome P450 concentration, cytochrome c reductase activity, antipyrine clearance and glucose-6-phosphatase activity did not change significantly. Amphotericin B 10-24 glucose-6-phosphatase catalytic subunit 1 Rattus norvegicus 234-255 9323308-4 1997 In contrast, following application of amphotericin B plus deoxycholate for 4 days the cytochrome P450 concentration was reduced by 50% (p < 0.05) as well as ethoxycoumarin-O-deethylase activity, antipyrine clearance and glucose-6-phosphatase activity: ethoxycoumarin-O-deethylase 232 +/- 68 pmol/mg/min, control 442 +/- 99 pmol/mg/min (p < 0.01); antipyrine clearance 0.56 +/- 0.21 ml/min, control 0.96 +/- 0.18 ml/min (p < 0.01), and glucose-6-phosphatase 193 +/- 28 mU/mg, control 351 +/- 95 mU/mg (p < 0.05). Amphotericin B 38-52 glucose-6-phosphatase catalytic subunit 1 Rattus norvegicus 223-244 9323308-4 1997 In contrast, following application of amphotericin B plus deoxycholate for 4 days the cytochrome P450 concentration was reduced by 50% (p < 0.05) as well as ethoxycoumarin-O-deethylase activity, antipyrine clearance and glucose-6-phosphatase activity: ethoxycoumarin-O-deethylase 232 +/- 68 pmol/mg/min, control 442 +/- 99 pmol/mg/min (p < 0.01); antipyrine clearance 0.56 +/- 0.21 ml/min, control 0.96 +/- 0.18 ml/min (p < 0.01), and glucose-6-phosphatase 193 +/- 28 mU/mg, control 351 +/- 95 mU/mg (p < 0.05). Amphotericin B 38-52 glucose-6-phosphatase catalytic subunit 1 Rattus norvegicus 444-465 9466531-9 1998 A resistant break point for amphotericin B of > 1 microg/mL for MLC and > or = 1 microg/mL for MIC could be inferred from this study. Amphotericin B 28-42 modulator of VRAC current 1 Homo sapiens 67-70 9578147-3 1998 The IC50 of amphotericin B for LTA4 hydrolase activity was 0.72 microM. Amphotericin B 12-26 leukotriene A4 hydrolase Homo sapiens 31-45 10064206-1 1998 Liposomal amphotericin B (L-Amp B), a novel formulation of amphotericin B, is effective for the treatment of invasive fungal infections in children and adults and is associated with less toxicity than the conventional preparation. Amphotericin B 10-24 lysosomal associated membrane protein 2 Homo sapiens 26-33 9354704-4 1997 Amphotericin B (70 microM) was added to the luminal solution to permeabilize the apical membrane and determine the current-voltage relationship of the basolateral K conductance after activation by 100 microM CPT-cAMP. Amphotericin B 0-14 cathelicidin antimicrobial peptide Homo sapiens 212-216 16696093-9 1996 Amphotericin B increased platelet adherence to PMN and the number of platelets bound per PMN.Conclusions-In vitro, amphotericin B induces P-selectin expression on the surface of unactivated platelets and increases platelet adhesion to PMN, which is exacerbated by storage. Amphotericin B 0-14 selectin P Homo sapiens 138-148 8892962-0 1996 Possible role of the V3 domain of gp120 in resistance to an amphotericin B derivative (MS8209) blocking human immunodeficiency virus entry. Amphotericin B 60-74 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 34-39 9252443-10 1997 Experiments with amphotericin B-permeabilized tissues showed that GRP, SP, ionomycin, and thapsigargin increased current through an outwardly rectifying K conductance located on the apical membrane of the cells. Amphotericin B 17-31 gastrin releasing peptide Homo sapiens 66-69 9252443-10 1997 Experiments with amphotericin B-permeabilized tissues showed that GRP, SP, ionomycin, and thapsigargin increased current through an outwardly rectifying K conductance located on the apical membrane of the cells. Amphotericin B 17-31 tachykinin precursor 1 Homo sapiens 71-73 9056019-1 1997 A new member of the polyene family, N-dimethylaminoacetyl-partricin A 2-dimethylaminoethylamide diaspartate (SPA), was investigated and was found to be more effective than amphotericin B (i) in vivo by enhancing mouse resistance to cryptococcal meningoencephalitis and (ii) in vitro by potentiating the anticryptococcal activity of murine microglial cells. Amphotericin B 172-186 surfactant associated protein A1 Mus musculus 109-112 9184176-0 1997 Augmentation of production of TNF-alpha and anti-tumour activity by an amphotericin B preparation for clinical use in mice. Amphotericin B 71-85 tumor necrosis factor Mus musculus 30-39 9184176-1 1997 Effects of amphotericin B on production of endogenous tumour necrosis factor alpha (TNF-alpha) and anti-tumour activity in mice was examined. Amphotericin B 11-25 tumor necrosis factor Mus musculus 84-93 9184176-2 1997 Intravenous administration of Fungizone, an amphotericin B preparation complexed with deoxycholate, augmented the induction of endogenous TNF in response to a second stimulus with intravenous doses of FK23 (heat-killed Enterococcus faecalis). Amphotericin B 30-39 tumor necrosis factor Mus musculus 138-141 9184176-2 1997 Intravenous administration of Fungizone, an amphotericin B preparation complexed with deoxycholate, augmented the induction of endogenous TNF in response to a second stimulus with intravenous doses of FK23 (heat-killed Enterococcus faecalis). Amphotericin B 44-58 tumor necrosis factor Mus musculus 138-141 9184176-4 1997 The time interval between priming injection of Fungizone and secondary injection of FK23 for the maximal effect was 3 h. Similar augmentation of TNF production was also observed in amphotericin B-primed and FK23-injected mice. Amphotericin B 47-56 tumor necrosis factor Mus musculus 145-148 9184176-4 1997 The time interval between priming injection of Fungizone and secondary injection of FK23 for the maximal effect was 3 h. Similar augmentation of TNF production was also observed in amphotericin B-primed and FK23-injected mice. Amphotericin B 181-195 tumor necrosis factor Mus musculus 145-148 9184176-7 1997 These results suggest that amphotericin B is able to elicit anti-tumour activity, perhaps through activation of the immune system, and in particular augmentation of the induction of endogenous TNF. Amphotericin B 27-41 tumor necrosis factor Mus musculus 193-196 16696093-9 1996 Amphotericin B increased platelet adherence to PMN and the number of platelets bound per PMN.Conclusions-In vitro, amphotericin B induces P-selectin expression on the surface of unactivated platelets and increases platelet adhesion to PMN, which is exacerbated by storage. Amphotericin B 115-129 selectin P Homo sapiens 138-148 8843304-6 1996 These effects were partially mediated by either tumor necrosis factor alpha or interleukin-1, because AmB enhanced IFN-gamma-induced production of these cytokines by macrophages and their specific antibodies partially inhibited the AmB-induced enhancement of NO generation when they were used separately. Amphotericin B 102-105 tumor necrosis factor Mus musculus 48-75 8772132-10 1996 Similar results were obtained using the amphotericin B perforated-patch whole-cell-recording technique, suggesting that the variable response to VIP does not reflect the loss of a pivotal intracellular regulator. Amphotericin B 40-54 vasoactive intestinal peptide Rattus norvegicus 145-148 8837228-0 1996 Differential effects of a new amphotericin B derivative, MS-8209, on mouse BSE and scrapie: implications for the mechanism of action of polyene antibiotics. Amphotericin B 30-44 BSE Bos taurus 75-78 8837228-2 1996 The results show that (i) the treatment prolonged the incubation period of both BSE-infected and scrapie-infected mice, (ii) MS-8209 and AmB were much more efficient in delaying the onset of scrapie than that of BSE, and (iii) a delay in Prp-res (proteinase K-resistant prion protein) and GFAP (glial fibrillary acidic protein) accumulation was observed in the brains of scrapie-infected mice, but was not significant in BSE-infected mice. Amphotericin B 137-140 BSE Bos taurus 80-83 8837228-2 1996 The results show that (i) the treatment prolonged the incubation period of both BSE-infected and scrapie-infected mice, (ii) MS-8209 and AmB were much more efficient in delaying the onset of scrapie than that of BSE, and (iii) a delay in Prp-res (proteinase K-resistant prion protein) and GFAP (glial fibrillary acidic protein) accumulation was observed in the brains of scrapie-infected mice, but was not significant in BSE-infected mice. Amphotericin B 137-140 prion protein Mus musculus 238-241 8691629-3 1996 For example, verapamil or cyclosporin A may be useful for p-glycoprotein related multidrug resistance, and amphotericin B, docosahexaenoic acid or 8-chloro cAMP can be used for the modification of cisplatin-resistance. Amphotericin B 107-121 ATP binding cassette subfamily B member 1 Homo sapiens 58-72 8843304-6 1996 These effects were partially mediated by either tumor necrosis factor alpha or interleukin-1, because AmB enhanced IFN-gamma-induced production of these cytokines by macrophages and their specific antibodies partially inhibited the AmB-induced enhancement of NO generation when they were used separately. Amphotericin B 102-105 interferon gamma Mus musculus 115-124 8843304-6 1996 These effects were partially mediated by either tumor necrosis factor alpha or interleukin-1, because AmB enhanced IFN-gamma-induced production of these cytokines by macrophages and their specific antibodies partially inhibited the AmB-induced enhancement of NO generation when they were used separately. Amphotericin B 232-235 tumor necrosis factor Mus musculus 48-75 8843304-6 1996 These effects were partially mediated by either tumor necrosis factor alpha or interleukin-1, because AmB enhanced IFN-gamma-induced production of these cytokines by macrophages and their specific antibodies partially inhibited the AmB-induced enhancement of NO generation when they were used separately. Amphotericin B 232-235 interferon gamma Mus musculus 115-124 8740098-1 1996 To evaluate the safety, tolerance and pharmacokinetics of a new formulation of amphotericin B (AmB; CAS 1397-89-3) 18 AIDS patients treated for different kinds of mycoses were studied: oropharingeal and/or esophageal azole-resistant candidiasis (9), CNS cryptococcosis (7) or aspergillosis (2). Amphotericin B 79-93 BCAR1 scaffold protein, Cas family member Homo sapiens 100-103 8821599-1 1995 BRL 49594A (BRL) is a water soluble analogue of amphotericin B which has been developed as a polyene with efficacy similar to amphotericin B but with much reduced toxicity. Amphotericin B 48-62 von Willebrand factor C domain-containing protein 2-like Mus musculus 0-3 8720196-5 1995 Clinical toxicity was associated with increases in TNF-alpha plasma levels during two of four infusions of AmB and three of four infusions of AmB/lipid. Amphotericin B 107-110 tumor necrosis factor Homo sapiens 51-60 8720196-5 1995 Clinical toxicity was associated with increases in TNF-alpha plasma levels during two of four infusions of AmB and three of four infusions of AmB/lipid. Amphotericin B 142-145 tumor necrosis factor Homo sapiens 51-60 8720196-7 1995 Three of four AmB infusions and all four AmB/lipid infusions accompanied by clinical toxicity were associated with major increases in IL-1-RA plasma concentrations. Amphotericin B 14-17 interleukin 1 receptor antagonist Homo sapiens 134-141 8720196-7 1995 Three of four AmB infusions and all four AmB/lipid infusions accompanied by clinical toxicity were associated with major increases in IL-1-RA plasma concentrations. Amphotericin B 41-44 interleukin 1 receptor antagonist Homo sapiens 134-141 8720196-11 1995 The findings provide further evidence that expression of TNF-alpha, IL-6 and IL-1-RA plays an important role in mediating AmB-related acute toxicity in vivo. Amphotericin B 122-125 tumor necrosis factor Homo sapiens 57-66 8720196-11 1995 The findings provide further evidence that expression of TNF-alpha, IL-6 and IL-1-RA plays an important role in mediating AmB-related acute toxicity in vivo. Amphotericin B 122-125 interleukin 6 Homo sapiens 68-72 8720196-11 1995 The findings provide further evidence that expression of TNF-alpha, IL-6 and IL-1-RA plays an important role in mediating AmB-related acute toxicity in vivo. Amphotericin B 122-125 interleukin 1 receptor antagonist Homo sapiens 77-84 8821599-1 1995 BRL 49594A (BRL) is a water soluble analogue of amphotericin B which has been developed as a polyene with efficacy similar to amphotericin B but with much reduced toxicity. Amphotericin B 48-62 von Willebrand factor C domain-containing protein 2-like Mus musculus 12-15 8821599-1 1995 BRL 49594A (BRL) is a water soluble analogue of amphotericin B which has been developed as a polyene with efficacy similar to amphotericin B but with much reduced toxicity. Amphotericin B 126-140 von Willebrand factor C domain-containing protein 2-like Mus musculus 0-3 8821599-1 1995 BRL 49594A (BRL) is a water soluble analogue of amphotericin B which has been developed as a polyene with efficacy similar to amphotericin B but with much reduced toxicity. Amphotericin B 126-140 von Willebrand factor C domain-containing protein 2-like Mus musculus 12-15 8821599-3 1995 In the models in which BRL and amphotericin B were compared, BRL was well tolerated but was less effective than a similar regimen of amphotericin B. Amphotericin B 31-45 von Willebrand factor C domain-containing protein 2-like Mus musculus 61-64 7844378-4 1995 For both fluconazole and amphotericin B recipients, colony counts in organs were significantly higher in animals that also received anti-TNF-alpha antibody. Amphotericin B 25-39 tumor necrosis factor Mus musculus 137-146 7581092-8 1995 Of the marrow-positive patients, there was a slightly shortened granulocyte recovery, shortened hospital stays and lessened amphotericin usage in the patients who received CY/G-CSF-mobilized PBPC compared with the CY-mobilized patients. Amphotericin B 124-136 colony stimulating factor 3 Homo sapiens 175-180 7602192-5 1995 Combination therapy with M-CSF and amphotericin-B (AMPH-B) showed the therapy with either M-CSF or AMPH-B alone. Amphotericin B 35-49 colony stimulating factor 1 Homo sapiens 90-95 7602192-5 1995 Combination therapy with M-CSF and amphotericin-B (AMPH-B) showed the therapy with either M-CSF or AMPH-B alone. Amphotericin B 51-57 colony stimulating factor 1 Homo sapiens 25-30 7602192-5 1995 Combination therapy with M-CSF and amphotericin-B (AMPH-B) showed the therapy with either M-CSF or AMPH-B alone. Amphotericin B 51-57 colony stimulating factor 1 Homo sapiens 90-95 7602192-5 1995 Combination therapy with M-CSF and amphotericin-B (AMPH-B) showed the therapy with either M-CSF or AMPH-B alone. Amphotericin B 99-105 colony stimulating factor 1 Homo sapiens 25-30 7828276-3 1995 CA3 and CK2 cells were sensitive to amphotericin B, and resistant to cyclosporin A and aphidicolin, compared with their parental cells. Amphotericin B 36-50 carbonic anhydrase 3 Homo sapiens 0-3 7828276-4 1995 Amphotericin B increased cisplatin toxicity 2-fold in CA3 cells and 2.7-fold in CK2 cells, while it had no effect in parental HEp2 cells. Amphotericin B 0-14 carbonic anhydrase 3 Homo sapiens 54-57 7828276-8 1995 Therefore, the resistance to cisplatin in human larynx carcinoma CA3 and CK2 cells can be partially reversed by amphotericin B and aphidicolin. Amphotericin B 112-126 carbonic anhydrase 3 Homo sapiens 65-68 7529537-0 1994 Protective effect of granulocyte-colony stimulating factor against amphotericin B-induced myelosuppression in vitro. Amphotericin B 67-81 colony stimulating factor 3 Homo sapiens 21-58 7529537-3 1994 The present study defines the role of G-CSF in preventing amphotericin B-induced myelosuppression. Amphotericin B 58-72 colony stimulating factor 3 Homo sapiens 38-43 7529537-7 1994 These data suggest that G-CSF prevents the amphotericin B-induced myelosuppression by antagonizing the suppressive effects of TNF and IFN and by enhancing the proliferative activity of BM. Amphotericin B 43-57 colony stimulating factor 3 Homo sapiens 24-29 7529537-7 1994 These data suggest that G-CSF prevents the amphotericin B-induced myelosuppression by antagonizing the suppressive effects of TNF and IFN and by enhancing the proliferative activity of BM. Amphotericin B 43-57 tumor necrosis factor Homo sapiens 126-129 7529537-7 1994 These data suggest that G-CSF prevents the amphotericin B-induced myelosuppression by antagonizing the suppressive effects of TNF and IFN and by enhancing the proliferative activity of BM. Amphotericin B 43-57 interferon alpha 1 Homo sapiens 134-137 7730240-4 1994 However, AmB (0.25-10 mg/L) elicited TNF alpha production by macrophages. Amphotericin B 9-12 tumor necrosis factor Mus musculus 37-46 7730240-5 1994 This response was concentration-dependent, and peak TNF alpha levels were detected between 3 and 6 h. This effect was attenuated by incorporation of AmB into liposomal vesicles and by pretreating macrophages with pentoxifylline or dexamethasone. Amphotericin B 149-152 tumor necrosis factor Mus musculus 52-61 7844378-6 1995 This study suggests that exogenous TNF-alpha and drugs that increase the endogenous production of TNF-alpha by the host may be useful adjuncts to fluconazole and amphotericin B for the treatment of systemic candidiasis. Amphotericin B 162-176 tumor necrosis factor Mus musculus 35-44 7963740-4 1994 rIFN-gamma association significantly enhanced the effect of a single dose of amphotericin B (0.25 mg/kg 24 h after infection) to prolong mouse survival and to reduce colony counts in the brain. Amphotericin B 77-91 interferon gamma Rattus norvegicus 0-10 7915757-2 1994 Recently it has been reported that amphotericin B (AmB) treatment of hamsters infected with scrapie strain 263K prolongs the incubation period of the disease, and dissociates in vivo replication of the scrapie agent from PrPSc accumulation. Amphotericin B 35-49 prion protein Mus musculus 221-226 7915757-2 1994 Recently it has been reported that amphotericin B (AmB) treatment of hamsters infected with scrapie strain 263K prolongs the incubation period of the disease, and dissociates in vivo replication of the scrapie agent from PrPSc accumulation. Amphotericin B 51-54 prion protein Mus musculus 221-226 7915757-6 1994 Results indicate that MS-8209 was as efficient as AmB in prolonging the incubation time and decreasing PrPSc accumulation in the hamster scrapie model. Amphotericin B 50-53 prion protein Mus musculus 103-108 7915757-9 1994 In long-term treatment of mice, MS-8209 and AmB markedly reduced PrPSc levels in the preclinical stage of the disease. Amphotericin B 44-47 prion protein Mus musculus 65-70 8040121-5 1994 Tissue distribution analysis of L-Amp B revealed that in macrophage/PMN-depleted mice there was a decrease in the concentration of Amp B in the liver, with concomitant increases in the circulation, spleen and lung, both in the uninfected and in the infected conditions. Amphotericin B 34-39 tubulin-specific chaperone E Mus musculus 68-71 8178492-3 1994 CD4+ rat and mouse cells are only sensitive to HIV-2 and SIV fusion in the presence of active amphotericin B. Amphotericin B 94-108 Cd4 molecule Rattus norvegicus 0-3 8178492-6 1994 CD4+ rat cells are sensitive to entry by HIV-2 (HTLV-1) pseudotypes and also to HIV-2 if amphotericin B is present. Amphotericin B 89-103 Cd4 molecule Rattus norvegicus 0-3 7948785-3 1994 The chief objective of this research was to analyze directly the effect of AMP-B on arginine-vasopressin (AVP)- or dibutyrl cAMP (DcAMP)-stimulated water and urea transport of the inner medullary collecting duct (IMCD) obtained from rats by the in vitro microperfusion technique. Amphotericin B 75-80 arginine vasopressin Rattus norvegicus 106-109 7948785-5 1994 AMP-B (10(-5) M) added to the bath fluid decreased the AVP-stimulated Lp (x 10(-6) cm/s.atm) of rat IMCD from 19.41 +/- 2.19 to 10.00 +/- 1.39 (P < 0.001), and the reversibility of its action was observed during a third period when Lp increased to 19.80 +/- 2.19 (P < 0.001) after the initial conditions were restored. Amphotericin B 0-5 arginine vasopressin Rattus norvegicus 55-58 7948785-7 1994 AMP-B also decreased AVP-stimulated Pu (x 10(-5) cm/s) when added to the bath fluid from 36.60 +/- 2.05 to 29.88 +/- 1.36 (P < 0.001), and this effect was reversible after AMP-B was withdrawn from the bath (37.40 +/- 1.36; P < 0.001). Amphotericin B 0-5 arginine vasopressin Rattus norvegicus 21-24 8191567-6 1994 RESULTS: Amphotericin B produced a concentration-dependent decrease in the surface binding of CD42b MoAb with no consistent changes in the binding of CD41a, CD63, or CD62 MoAbs after a 3-day exposure. Amphotericin B 9-23 glycoprotein Ib platelet subunit alpha Homo sapiens 94-99 8191567-7 1994 Stored but not fresh PCs showed decreased binding of MoAb CD42b after a 6-hour exposure to amphotericin B (4 micrograms/mL). Amphotericin B 91-105 glycoprotein Ib platelet subunit alpha Homo sapiens 58-63 8191567-9 1994 When the binding of MoAb CD42b to permeabilized platelets was used to measure total platelet content, amphotericin B (4 micrograms/mL) decreased MoAb CD42b binding to a similar degree in fresh and stored platelets. Amphotericin B 102-116 glycoprotein Ib platelet subunit alpha Homo sapiens 25-30 8191567-9 1994 When the binding of MoAb CD42b to permeabilized platelets was used to measure total platelet content, amphotericin B (4 micrograms/mL) decreased MoAb CD42b binding to a similar degree in fresh and stored platelets. Amphotericin B 102-116 glycoprotein Ib platelet subunit alpha Homo sapiens 150-155 8146894-6 1994 GM-CSF patients received significantly more platelets that were ABO incompatible, that were given during a febrile period, or that were given while the patient was on amphotericin. Amphotericin B 167-179 colony stimulating factor 2 Homo sapiens 0-6 1348570-0 1992 Amphotericin B treatment dissociates in vivo replication of the scrapie agent from PrP accumulation. Amphotericin B 0-14 prion protein Homo sapiens 83-86 8013489-8 1994 Amphotericin B treatment was given in 55 cases, often combined with other antifungal agents, leukocyte transfusions or granulocyte-macrophage-colony stimulating factor. Amphotericin B 0-14 colony stimulating factor 2 Homo sapiens 119-167 8391922-2 1993 In PC-9/CDDP but not PC-9 cells, augmentation of cytotoxicity was observed when a nontoxic concentration (10 micrograms/ml) of AmB was combined with cisplatin, cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II), and cis-diammine(glycolato)platinum(II). Amphotericin B 127-130 proprotein convertase subtilisin/kexin type 9 Homo sapiens 3-7 8352556-1 1993 We have determined an effect of amphotericin B (AMB), an antifungal drug, on the cytotoxicity of cis-diamminedichloro-platinum (II) (CDDP) and 4 CDDP analogues in a human ovarian carcinoma cell line (NOS2). Amphotericin B 32-46 nitric oxide synthase 2 Homo sapiens 200-204 8352556-1 1993 We have determined an effect of amphotericin B (AMB), an antifungal drug, on the cytotoxicity of cis-diamminedichloro-platinum (II) (CDDP) and 4 CDDP analogues in a human ovarian carcinoma cell line (NOS2). Amphotericin B 48-51 nitric oxide synthase 2 Homo sapiens 200-204 8352556-4 1993 AMB also increased the intracellular CDDP accumulation in CDDP resistant cells (NOS2CR), derived from NOS2. Amphotericin B 0-3 nitric oxide synthase 2 Homo sapiens 80-84 8406644-6 1993 Six (8%) and 9(12%) patients of SAG group showed primary (with no response to SAG during treatment) and secondary unresponsiveness (with no response to SAG after relapse) respectively and they were cured with amphotericin B. Amphotericin B 209-223 S-antigen visual arrestin Homo sapiens 32-35 8483118-0 1993 Recombinant human erythropoietin in the treatment of anemia in AIDS patients receiving concomitant amphotericin B and zidovudine. Amphotericin B 99-113 erythropoietin Homo sapiens 18-32 8492751-9 1993 The overall rate of success with modifications (Amphotericin B, Vancomycin, Clindamycin, Metronidazole) was higher in Reg. Amphotericin B 48-62 regenerating family member 1 alpha Homo sapiens 118-121 1492075-0 1992 Effect of amphotericin B on dopachrome tautomerase activity and other melanogenic parameters in cultured B16/F10 melanoma cells. Amphotericin B 10-24 dopachrome tautomerase Mus musculus 28-50 1492075-1 1992 The antifungal reagent Fungizone (amphotericin B and deoxycholate) caused an activation in dopachrome tautomerase and dopa oxidase activities of B16/F10 melanoma cells at the routine concentration (2.5 micrograms/ml) used for preventing molds and yeast growth in cultures of animal cells. Amphotericin B 23-32 dopachrome tautomerase Mus musculus 91-113 1492075-1 1992 The antifungal reagent Fungizone (amphotericin B and deoxycholate) caused an activation in dopachrome tautomerase and dopa oxidase activities of B16/F10 melanoma cells at the routine concentration (2.5 micrograms/ml) used for preventing molds and yeast growth in cultures of animal cells. Amphotericin B 34-48 dopachrome tautomerase Mus musculus 91-113 8089051-0 1994 The release of TNF-alpha and IL-6 from human monocytes stimulated by filtrates of Candida albicans after treatment with amphotericin B. Amphotericin B 120-134 tumor necrosis factor Homo sapiens 15-24 8089051-0 1994 The release of TNF-alpha and IL-6 from human monocytes stimulated by filtrates of Candida albicans after treatment with amphotericin B. Amphotericin B 120-134 interleukin 6 Homo sapiens 29-33 8257149-0 1993 Augmentation of murine tumor necrosis factor production by amphotericin B in vitro and in vivo. Amphotericin B 59-73 tumor necrosis factor Mus musculus 23-44 8257149-3 1993 When administered to mice, the priming activity of amphotericin B for tumor necrosis factor production in vivo was also observed. Amphotericin B 51-65 tumor necrosis factor Mus musculus 70-91 8239612-0 1993 Preincubation of Candida albicans strains with amphotericin B reduces tumor necrosis factor alpha and interleukin-6 release by human monocytes. Amphotericin B 47-61 tumor necrosis factor Homo sapiens 70-97 8239612-0 1993 Preincubation of Candida albicans strains with amphotericin B reduces tumor necrosis factor alpha and interleukin-6 release by human monocytes. Amphotericin B 47-61 interleukin 6 Homo sapiens 102-115 8424133-0 1993 The effect of thromboxane A2 receptor antagonism on amphotericin B-induced renal vasoconstriction in the rat. Amphotericin B 52-66 thromboxane A2 receptor Rattus norvegicus 14-37 1384722-5 1992 A second allo BMT, accelerating granulocyte recovery by recombinant human granulocyte colony-stimulating factor (rhG-CSF), was successfully performed and the fungal liver abscess resolved with a combination therapy of fluconazole and amphotericin B. Amphotericin B 234-248 colony stimulating factor 3 Homo sapiens 74-111 1510450-4 1992 After 6 days of daily intraperitoneal injections of AmB-DC, decreased body weight and glomerular filtration rate as well as increased degree of diuresis, uremia, microalbuminuria, and N-acetyl-beta-D-glucosaminidase excretion in urine were noted. Amphotericin B 52-55 O-GlcNAcase Rattus norvegicus 184-215 1348570-3 1992 Here we report that treatment of scrapie-infected hamsters with amphotericin B delays the accumulation in the brain of the proteinase-resistant portion of PrPSc by about 30 days without affecting scrapie replication. Amphotericin B 64-78 prion protein Homo sapiens 155-160 2029076-4 1991 His post-transplantation course was complicated by a transient autoimmune hemolytic anemia related to an ABO blood group incompatibility and hepatic fungal microabscesses which responded to Amphotericin therapy. Amphotericin B 190-202 ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase Homo sapiens 105-108 1510423-0 1992 Pharmacologic modulation of interleukin-1 expression by amphotericin B-stimulated human mononuclear cells. Amphotericin B 56-70 interleukin 1 alpha Homo sapiens 28-41 1805684-1 1991 To reduce the toxicity of amphotericin B methyl ester (AME), which shows some anti-HIV-1 activity, sulfated amphotericin B (SAB) was prepared from amphotericin B (AB), and its anti-HIV-1 activity was examined in vitro. Amphotericin B 26-40 SH3 domain binding protein 5 Homo sapiens 99-122 1805684-1 1991 To reduce the toxicity of amphotericin B methyl ester (AME), which shows some anti-HIV-1 activity, sulfated amphotericin B (SAB) was prepared from amphotericin B (AB), and its anti-HIV-1 activity was examined in vitro. Amphotericin B 26-40 SH3 domain binding protein 5 Homo sapiens 124-127 1834060-0 1991 Amphotericin B stimulates secretion of beta-hexosaminidase from mouse adherent spleen cells. Amphotericin B 0-14 O-GlcNAcase Mus musculus 39-58 1323600-0 1992 Effect of amphotericin B on hepatic cytochrome P-450 and glucose-6-phosphatase in the rat. Amphotericin B 10-24 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 36-52 1323600-0 1992 Effect of amphotericin B on hepatic cytochrome P-450 and glucose-6-phosphatase in the rat. Amphotericin B 10-24 glucose-6-phosphatase catalytic subunit 1 Rattus norvegicus 57-78 1323600-1 1992 The effect of amphotericin B on hepatic microsomal cytochrome P-450 (P-450) concentration was measured in vitro, in vivo and ex vivo in the rat. Amphotericin B 14-28 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 51-67 1323600-2 1992 In vitro, both amphotericin B (0-500 micrograms/ml) and its vehicle, sodium deoxycholate (0-410 micrograms/ml), caused similar dose-dependent decreases of P-450 concentrations and glucose-6-phosphatase activity. Amphotericin B 15-29 glucose-6-phosphatase catalytic subunit 1 Rattus norvegicus 180-201 1323600-9 1992 These results show that amphotericin B decreases hepatic cytochrome P-450 content and function in the rat. Amphotericin B 24-38 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 57-73 1647195-0 1991 Intravenous administration of amphotericin B entrapped in liposomes: induction of high serum levels of TNF alpha. Amphotericin B 30-44 tumor necrosis factor Homo sapiens 103-112 2014979-1 1991 The effects of four monoesters of sucrose with different acyl chain lengths (palmitate, C16; myristate, C14; laurate, C12; and caprate, C10) on the aggregation state of amphotericin B (AmB), its binding to cholesterol and ergosterol, its toxicity to cells, and its lethality to mice were determined. Amphotericin B 169-183 gene rich cluster, C10 gene Mus musculus 136-139 2165609-5 1990 Amphotericin B, a Na+ ionophore, and monensin were able to mimick the effect of Na(+)-channel activators, while a KCl depolarization failed to do this. Amphotericin B 0-14 sodium voltage-gated channel alpha subunit 8 Rattus norvegicus 80-93 2213553-4 1990 Although AMB concentrations of 20 microM or less did not increase lactic dehydrogenase release, P1 and MGP uptakes were significantly reduced (50% inhibition) by 2.5 and 5 microM AMB, respectively. Amphotericin B 179-182 matrix Gla protein Oryctolagus cuniculus 96-106 2213553-6 1990 Analysis of P1 and MGP uptake kinetics, after treatment of the cells with 10 microM AMB, showed that inhibition occurred through a decrease in Vmax (66 and 57% inhibition for P1 and MGP, respectively) without affecting Km value. Amphotericin B 84-87 matrix Gla protein Oryctolagus cuniculus 19-22 2213553-6 1990 Analysis of P1 and MGP uptake kinetics, after treatment of the cells with 10 microM AMB, showed that inhibition occurred through a decrease in Vmax (66 and 57% inhibition for P1 and MGP, respectively) without affecting Km value. Amphotericin B 84-87 matrix Gla protein Oryctolagus cuniculus 182-185 2360827-1 1990 Amphotericin B can stimulate macrophages to produce tumor necrosis factor alpha (TNF alpha), one of the inflammatory mediators that may be responsible for the febrile toxicity associated with drug administration. Amphotericin B 0-14 tumor necrosis factor Homo sapiens 52-79 2090936-4 1990 Because fibrin fibres of a spider web coagulum in the CSF resembled Aspergillus mycelium, the patient was then treated with amphotericin B + flucytosine. Amphotericin B 124-138 colony stimulating factor 2 Homo sapiens 54-57 2360827-1 1990 Amphotericin B can stimulate macrophages to produce tumor necrosis factor alpha (TNF alpha), one of the inflammatory mediators that may be responsible for the febrile toxicity associated with drug administration. Amphotericin B 0-14 tumor necrosis factor Homo sapiens 81-90 2360827-2 1990 The purpose of this study was to compare the in vitro TNF-inducing activity of one recalled lot of an amphotericin B preparation which was associated with more frequent febrile reactions in patients with a preparation not associated with a greater incidence of febrile reaction. Amphotericin B 102-116 tumor necrosis factor Homo sapiens 54-57 2360827-4 1990 The in vitro TNF induction assay may serve as a screening tool for the selection of the least pyrogenic lots of amphotericin B preparation. Amphotericin B 112-126 tumor necrosis factor Homo sapiens 13-16 2299214-0 1990 Amphotericin B blunts erythropoietin response to anemia. Amphotericin B 0-14 erythropoietin Homo sapiens 22-36 2299214-1 1990 Amphotericin B causes a normochromic, normocytic anemia thought to be mediated by direct marrow toxicity or suppression of erythropoietin production. Amphotericin B 0-14 erythropoietin Homo sapiens 123-137 2299214-5 1990 Despite anemia in all amphotericin B-treated patients, erythropoietin levels declined or remained relatively constant during therapy while erythropoietin levels in controls were appropriate for the degree of anemia. Amphotericin B 22-36 erythropoietin Homo sapiens 55-69 2299214-6 1990 Within 2 weeks of completion of amphotericin B treatment, two patients had increasing erythropoietin levels in response to anemia. Amphotericin B 32-46 erythropoietin Homo sapiens 86-100 34952645-0 2021 DC-SIGN targets amphotericin B-loaded liposomes to diverse pathogenic fungi. Amphotericin B 16-30 CD209a antigen Mus musculus 0-7 22727066-13 2012 We found that the ARL1 COS-resistant over-expression strain was as sensitive to Amphotericin B, Fluconazole and Terbinafine as the wild type cells and that when COS and Fluconazole are used in combination they act in a synergistic fashion. Amphotericin B 80-94 Arf family GTPase ARL1 Saccharomyces cerevisiae S288C 18-22 2101864-7 1990 In 21 patients treated with amphotericin B, four fungemias were found: two by both hemagglutination (HAT) and immunofluorescence (IFT), one by IFT and one by antigen detection (Ramco Cand-Tec) alone. Amphotericin B 28-42 tec protein tyrosine kinase Homo sapiens 188-191 34952645-2 2021 Our goal herein was to show that targeting liposomal AmB to fungal cells with the C-type lectin pathogen recognition receptor DC-SIGN improves antifungal activity. Amphotericin B 53-56 CD209a antigen Mus musculus 126-133 34952645-11 2021 CONCLUSIONS: DC-SIGN"s CRD specifically targeted antifungal liposomes to three highly evolutionarily diverse pathogenic fungi and enhanced the antifungal efficacy of liposomal AmB both in vitro and in vivo. Amphotericin B 176-179 CD209a antigen Mus musculus 13-20 34482605-2 2021 Our previous studies showed that BSC2 is involved in resistance to amphotericin B (AMB) through anti-oxidation in Saccharomyces cerevisiae. Amphotericin B 67-81 Bsc2p Saccharomyces cerevisiae S288C 33-37 34482605-2 2021 Our previous studies showed that BSC2 is involved in resistance to amphotericin B (AMB) through anti-oxidation in Saccharomyces cerevisiae. Amphotericin B 83-86 Bsc2p Saccharomyces cerevisiae S288C 33-37 34482605-8 2021 Although BSC2-overexpression increased the level of mannose in the cell wall, DPM1-overexpression in both BY4741 and bsc2 could confer resistance to CAS and AMB. Amphotericin B 158-161 dolichyl-phosphate beta-D-mannosyltransferase Saccharomyces cerevisiae S288C 78-82 34482605-8 2021 Although BSC2-overexpression increased the level of mannose in the cell wall, DPM1-overexpression in both BY4741 and bsc2 could confer resistance to CAS and AMB. Amphotericin B 158-161 Bsc2p Saccharomyces cerevisiae S288C 117-121 34773853-10 2021 Amphotericin B treatment restored production of pro-inflammatory cytokines IL-17 and IL-22. Amphotericin B 0-14 interleukin 17A Mus musculus 75-80 34688150-5 2021 6-Gingerol combined with amphotericin B represented a safe mixture, extremely leishmanicidal, a potent antioxidant, induced a remarkable apoptotic index, significantly increased the expression of the Th1-related cytokines (IL-12p40, IFN-gamma, and TNF- alpha), iNOS, and transcription factors (STAT1, c-Fos, and Elk-1). Amphotericin B 25-39 negative elongation factor complex member C/D, Th1l Mus musculus 200-203 34688150-5 2021 6-Gingerol combined with amphotericin B represented a safe mixture, extremely leishmanicidal, a potent antioxidant, induced a remarkable apoptotic index, significantly increased the expression of the Th1-related cytokines (IL-12p40, IFN-gamma, and TNF- alpha), iNOS, and transcription factors (STAT1, c-Fos, and Elk-1). Amphotericin B 25-39 interleukin 12b Mus musculus 223-231 34688150-5 2021 6-Gingerol combined with amphotericin B represented a safe mixture, extremely leishmanicidal, a potent antioxidant, induced a remarkable apoptotic index, significantly increased the expression of the Th1-related cytokines (IL-12p40, IFN-gamma, and TNF- alpha), iNOS, and transcription factors (STAT1, c-Fos, and Elk-1). Amphotericin B 25-39 interferon gamma Mus musculus 233-242 34688150-5 2021 6-Gingerol combined with amphotericin B represented a safe mixture, extremely leishmanicidal, a potent antioxidant, induced a remarkable apoptotic index, significantly increased the expression of the Th1-related cytokines (IL-12p40, IFN-gamma, and TNF- alpha), iNOS, and transcription factors (STAT1, c-Fos, and Elk-1). Amphotericin B 25-39 tumor necrosis factor Mus musculus 248-258 34688150-5 2021 6-Gingerol combined with amphotericin B represented a safe mixture, extremely leishmanicidal, a potent antioxidant, induced a remarkable apoptotic index, significantly increased the expression of the Th1-related cytokines (IL-12p40, IFN-gamma, and TNF- alpha), iNOS, and transcription factors (STAT1, c-Fos, and Elk-1). Amphotericin B 25-39 nitric oxide synthase 2, inducible Mus musculus 261-265 34688150-5 2021 6-Gingerol combined with amphotericin B represented a safe mixture, extremely leishmanicidal, a potent antioxidant, induced a remarkable apoptotic index, significantly increased the expression of the Th1-related cytokines (IL-12p40, IFN-gamma, and TNF- alpha), iNOS, and transcription factors (STAT1, c-Fos, and Elk-1). Amphotericin B 25-39 signal transducer and activator of transcription 1 Mus musculus 294-299 34688150-5 2021 6-Gingerol combined with amphotericin B represented a safe mixture, extremely leishmanicidal, a potent antioxidant, induced a remarkable apoptotic index, significantly increased the expression of the Th1-related cytokines (IL-12p40, IFN-gamma, and TNF- alpha), iNOS, and transcription factors (STAT1, c-Fos, and Elk-1). Amphotericin B 25-39 FBJ osteosarcoma oncogene Mus musculus 301-306 34688150-5 2021 6-Gingerol combined with amphotericin B represented a safe mixture, extremely leishmanicidal, a potent antioxidant, induced a remarkable apoptotic index, significantly increased the expression of the Th1-related cytokines (IL-12p40, IFN-gamma, and TNF- alpha), iNOS, and transcription factors (STAT1, c-Fos, and Elk-1). Amphotericin B 25-39 ELK1, member of ETS oncogene family Mus musculus 312-317 34688150-10 2021 In conclusion, 6-gingerol with amphotericin B synergistically exerted anti-leishmanial activity in vitro and in vivo and potentiated macrophages" leishmanicidal activity, modulated Th1- and Th2-related phenotypes improved the histopathological changes in the BALB/c mice infected with L. major. Amphotericin B 31-45 negative elongation factor complex member C/D, Th1l Mus musculus 181-184 34912784-7 2021 AmB was quantified in two CSF samples collected throughout the treatment with concentrations of 12.26 and 18.45 ng ml-1 on the 8th and 15th days of the treatment, respectively. Amphotericin B 0-3 interleukin 17F Homo sapiens 115-119 34543091-2 2021 isolates to 5 antifungal drugs (amphotericin B, voriconazole, posaconazole, isavuconazole, terbinafine) by EUCAST method. Amphotericin B 32-46 calpastatin Homo sapiens 107-113 34988292-1 2021 Objective: To study the in vitro killing efficacy of Kerasave (AL.CHI.MI.A Srl), a medium provided with amphotericin B tablet for hypothermic storage of human donor corneas, against relevant contaminants associated with postkeratoplasty infections. Amphotericin B 104-118 sarcalumenin Homo sapiens 75-78 34773853-10 2021 Amphotericin B treatment restored production of pro-inflammatory cytokines IL-17 and IL-22. Amphotericin B 0-14 interleukin 22 Mus musculus 85-90 34744538-15 2021 Overall, VRC has been shown to be an effective antifungal agent and is an alternative to amphotericin B to fight Aspergillus spp. Amphotericin B 89-103 histocompatibility minor 13 Homo sapiens 125-128 34060984-8 2021 Anti-Leishmanial effect of different concentrations of liposomal curcumin (0.05-30 mug mL-1) and amphotericin B (25 mug mL-1) were studied on Leishmania major (MRHO/IR/75/ER) at various hours (24, 48, and 72) using hemocytometer technique. Amphotericin B 97-111 L1 cell adhesion molecule Mus musculus 120-124